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ABSTRACT
Diethyltoluenediamine (CAS 68479-98-1) is a ring-ethylated analog of 
toluenediamine (TDA) and like TDA, consists of the 2,4- and 2,6-diamine 
isomers. DETDA was developed by Albermarle Corporation as a substitute for 
TDA in some applications. To determine the uptake and distribution of 2,4- 
and 2,6-DETDA, 5 groups of 4 adult male Sprague Dawley rats were gavaged 
at 179 pmol/kg body weight with [3H]-2,4- or [3H]-2,6-DETDA. Multiple tissues 
were collected at 1, 4, 8, 24 and 48 hours. Very high levels of label occurred in 
the gastrointestinal system and bladder during the first 8 hours while liver and 
kidney exhibited moderate levels. The concentration of radioactivity in most 
tissues except the stomach, duodenum, caecum, colon, bladder and thyroid 
was greatest at the 4 hour time point. Thyroid levels, at the 24 and 48 hour 
time points, were the highest of all tissues examined. By 8 hours, urinary 
excretion became the primary route of elimination. By 24 hours, over 60% of 
the labeled compound had been excreted and by 6 days less than 4% of label 
remained in the tissues. Low levels of residual label was found in all tissues 
examined at day 6. To determine urinary and fecal excretion pattens of 2,4- 
and 2,6-DETDA, 5 adult male Sprague Dawley rats were gavaged at 179 
pmol/kg body weight of [3H]-2,4- or [3H]-2,6-DETDA. Urine and feces were 
collected for 6 days then blood and tissues were collected at euthanasia on 
day 6. Excretion data revealed that the primary route of elimination of DETDA 
was the urinary system with the majority of label being excreted in the first 24 
hours. Compared to the 2,4-isomer, 2,6-DETDA exhibited a higher rate of
xvi
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urinary excretion. Both 2,4- and 2,6-DETDA demonstrated covalent binding to 
rat liver DNA and liver protein.
xvii
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INTRODUCTION
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is an industrial 
compound utilized as a polyurethane chain extender in reaction injection 
molded applications. DETDA is commercially supplied as a mixture of isomers 
with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4-diamine (2,4- 
DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA) and 0.5-3% 
dialkylated m-phenylenediamine. DETDA has been manufactured by 
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years 
under the name Ethacure®100 (1.1). DETDA also has uses as curing agents 
for polyurethanes and epoxies, antioxidants, lubrication, wire coatings and 
replacements for more toxic industrial compounds, such as 4,4'-methylenebis- 
2-chloroaniline (MOCA) and toluenediamine (TDA). Ethacure has been 
analyzed using standard laboratory studies including acute and subchronic 
toxicity tests as well as a battery of mutagenicity and carcinogenicity in vitro 
tests. Results from a two-year feeding study in rats showed DETDA related 
effects on the pancreas, liver, thyroid and eyes as well as increased tumors in 
the liver and thyroid glands of male rats (I.2). These findings along with the 
structural similarity to the known mutagenic noncarcinogen:carcinogen pair-
2,6- and 2,4-toluenediamine (TDA) dictated the need for a metabolic study of 
the DETDA mixture (I.3-I.5).
Through a proprietary process, Ethacure is synthesized from 
toluenediamine, an intermediate compound widely used in industry. TDA is
1
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used primary in the synthesis of toluene diisocyanate, a cross-linking agent in 
the production of polyurethane foam. It is also used as an intermediate in the 
synthesis of dyes used in textiles, wood stains and pigments (1.4,1.6-1.8).
Because of the proprietary nature of DETDA, a review of existing 
industrial information and literature on this compound was not possible. 
However, it is known that studies into its metabolism, absorption, distribution, 
and excretion have not been conducted. In an attempt to understand the 
characteristics and biotransformation of DETDA, a critical review of the closely 
related compound toluenediamine was undertaken. The metabolism, 
absorption, distribution, and excretion of two isomers of toluenediamine, 2,4- 
TDA and 2,6-TDA, have been studied. In addition, 2,4-TDA has been found to 
be carcinogenic in rats (1.3,1.4,1.9) while 2,6-TDA is a known mutagen (1.5,1.10).
Because of the inherent dangers associated with the mass production 
of chemical compounds, worker exposures must be kept to a minimum, but the 
inherent risks of exposure must also be defined. Methods of detecting both 
acute and chronic exposure to humans is desirable and in most instances is 
dictated by governmental agencies. Therefore, understanding how the DETDA 
compound is absorbed, distributed, metabolized and excreted in a mammalian 
system is important and must be explored in order to accurately establish 
safety guidelines for workers and the general population.
In this study, the absorption, distribution and excretion of both 2,4- 
DETDA and 2,6-DETDA was evaluated in young adult male Sprague Dawley
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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rats. In order to perform these studies, analytical methods of detection and 
quantitation (HPLC, GC, Liquid Scintillation Counting), extraction protocols, 
and certain physical characteristics (pK, values, extinction coefficients, 
wavelength characteristics) of DETDA needed to be known and were explored.
Ethacure was tritiated then separated into the 2,4- and 2,6-DETDA 
isomers. Acetylated DETDA metabolites were synthesized and used in a 
preliminary metabolism study in male Sprague Dawley rats.
Forty-eight hour distribution studies on both the 2,4- and 2,6-DETDA 
isomers were earned out using the tritiated DETDA. A 6 day urinary and fecal 
excretion study, including a day 6 distribution point, was also conducted on 
both isomers. Lastly, covalent binding of DETDA to rat liver DNA and liver 
protein was also evaluated.
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CHAPTER 1 
LITERATURE REVIEW 
Historical Overview of Chemical Carcinogenesis
Excessive exposure to chemical agents suspected of causing cancer 
was first noted in 1761 when Hill found that usage of tobacco snuff was related 
to development of nasal cancer (1.1). A few years later, Dr. Percivall Pott 
found a correlation in men between chronic exposure to chimney soot and 
development of scrotal cancer (1.2). A few years after Pott's findings, the 
Danish chimney sweepers's guild recommended that chimney sweeps take a 
daily bath to remove the soot (1.3). The success of these recommendations 
became apparent a century later when Butlin found a decreased incidence of 
scrotal cancer in northern European sweeps compared to English workers, who 
did not regularly bathe (1.4).
By the middle of the 1800's, German factories were using aromatic 
amines as precursors in the synthesis of dyes, requiring synthesis of large 
quantities of these chemicals (1.5). Within 50 years, Rehn demonstrated that 
chronic exposure to aromatic amines in an aniline-dye factory resulted in 
urinary bladder cancer (1.6). In 1892, Butlin and others, found skin cancer to 
be correlated with exposure of tars and paraffin oils in northern European 
workers (1.4,1.7,1.8). These findings were noted in the British Workmen's 
Compensation Act in 1907 when epitheliomas and skin ulcerations from 
handling pitch and tars were added to the document (1.9). From that point on,
5
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aromatic amines such as 2-naphthylamine, benzidine, and 4-aminobiphenyl 
became increasingly implicated in the carcinogenic process (1.5,1.10-1.14).
In the early 1940's research on the carcinogenesis of aromatic amines 
began in earnest and provided a solid foundation for the present day discipline 
of chemical carcinogenesis (1.5,1.10,1.11,1.14-1.16).
Toluenediamine Characteristics 
DETDA is a proprietary compound, thus there is little information in the 
open literature on this material except for patents dealing with synthesis and 
industrial use. Because of structural similarities to TDA (Fig. 1.1), DETDA is 
expected to be absorbed, distributed, metabolized and excreted like TDA.
Each of these points as well as the carcinogenic and mutagenic properties of
2,4- and/or 2,6-TDA must be explored in order to gain insight into the potential 
metabolism of DETDA.
Industrial uses of 2,4-TDA are primarily as an intermediate in the 
synthesis of toluene diisocyanate, a cross-linking agent in the production of 
polyurethane foam, as well as dyes used in textiles, wood stains and pigments 
(1.17-1.19). As early as 1913, 2,4-TDA was the object of study by researchers 
because of its widespread use and extensive worker exposure. In 1976, the 
production of 2,4-TDA in the United States alone was 233 million pounds 
(1.20,1.21). TDA was a component of oxidation activated hair dyes sold over- 
the-counter until 1971 and was used at concentrations as high at 1 mg/kg 
(1.22). These hair dyes were removed from the market after Ito reported TDA
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Figure 1.1 Chemical structures of DETDA and TDA isomers.
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to be carcinogenic in rodents (1.17,1.23,1.24). Later it was also found to be 
mutagenic, with S-9, in the Ames test (1.22,1.25).
Pharmacokinetic aspects of chemical toxicants 
Absorption
Absorption is the process whereby a substance moves across biological 
membranes to gain access to the bloodstream of an organism. Pulmonary, 
gastrointestinal, and dermal absorption are the three basic routes by which 
xenobiotics enter the body. Other routes such as subcutaneous, intra- 
peritoneal, and intramuscular are important in the administration of medicinal 
compounds and as a route for medical research, but are generally not 
applicable to TDA or DETDA.
Pulmonary absorption of 2,4-TDA
2,4-TDA is a dark brown solid material with particles ranging from sub- 
microscopic to millimeter in size. Because much of TDA is present as a dust, it 
can act as both an aerosol and particulate matter (1.25). As with all par­
ticulates and aerosols, the limiting absorption parameters of the compound are 
particle size and water solubility. Particles larger than 5 pm tend to be 
deposited in the nasopharyngeal area. These particles are usually removed by 
sneezing, coughing or swallowing. Soluble particles may be dissolved into the 
mucous blanket and be absorbed into the bloodstream before it can be 
removed. Particles 2-5 pm are generally deposited into the tracheobronchiolar 
regions. These particle can be removed by the ciliated cells of the respiratory
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tract by generating a retrograde movement of the mucous layer. Reflex 
coughing and sneezing increases the rate of removal of these particles. 
Particles 1 pm or smaller migrate down to the alveolar sacs where they are 
absorbed into the bloodstream or removed by macrophages and cleared by the 
lymphatic system (1.26). Therefore, it is the smallest particles that generally 
pose the most risk from exposure. The use of filters or respirators in high 
exposure areas significantly reduces this risk. Pulmonary absorption studies of 
particulate TDA have not been conducted.
DETDA is a clear amber liquid with a vapor pressure of less than 0.001 
mm Hg @ 20°C (1.27). The low volatility of DETDA means that very little 
compound should be present in the air of the workers environment. In the case 
of DETDA as an aerosol, it would be treated as with TDA according to particle 
size. Again, under normal situations, this scenario would be unlikely but could 
arise during equipment or reactor malfunction. Generally this may be insig­
nificant as a route of absorption.
Gastrointestinal absorption of 2,4-TDA
The movement of most toxic substances across cellular membranes 
occurs by simple diffusion. This diffusion will occur primarily in the part of the 
intestinal tract where the compound can exist in the non-ionized, or lipid- 
soluble form (1.26,1.28).
Both TDA and DETDA can be used to illustrate how the pIC, of a 
compound and the pH of the organ involved can effect the absorption of that
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compound. The pK„ of the two ionizable amine groups has been empirically 
determined in our lab by the titration method to be 2.6 and 5.3 for TDA and 2.5 
and 4.6 for DETDA.1 In rats, the average stomach and small intestine pH was 
found to be 4.4 and 6.8 respectively2 (1.29). Using the Henderson-Hasselbalch 
equation (Figure 1.2), the ratio of ionized to non-ionized TDA can be 
approximately determined in both the stomach and small intestine (1.26,1.28).
In the rat stomach (pH 4.4), the amine group with a pK„ of 2.6 will be 62 
times as likely to be in the nonionized state, while the second amine group (pK, 
of 5.3), will be 8 times as likely to be ionized. In the small intestine (pH 6.8), 
the amine group with a pK, of 2.6 will be 16,667 times as likely to be in the 
nonionized absorbable state, while the second amine group (pK, of 5.3), will be 
31 times as likely to be nonionized. Therefore, if no other factors are involved, 
TDA will be moderately absorbed from the stomach and highly absorbed from 
the small intestine.
In man, gastric secretion pH levels range from 1.0-3.5 while small 
intestine pH varies from 7.5-8.0 (1.30). Taking the average gastric pH from the 
above values and again applying the Henderson-Hasselbalch equation, it can 
be seen that differences in pH produce profound differences in theoretical 
absorption (Table 1.1).
See Chapter 2 for details on titration method of determining pK, for both TDA and DETDA.
pH of both gastric and small intestinal contents will vary. Diet, stress, feeding habits and 
coprophagy can greatly affect pH levels. Values used are an average from a study done 
on bacterial flora of the alimentary tract.




Figure 1.2 Henderson Hasselbalch equation used to determine ratio of 
ionized to non-ionized TDA and DETDA.

















Table 1.1 Analysis of the relationship between the pK of amin$ groups and organ content pH to the differences
in theoretical absorption of TDA and DETDA.
Com pound Species Organ pKa of am ine  
group
pH of organ 
contents




TD A R at Stom ach 2.6 4.40 0 .016 Yes
TD A R at Stom ach 5.3 4.40 7 .9 No
TD A R at Intestine 2 .6 6.80 0 .0 000 6 Yes
TD A R at Intestine 5.3 6 .80 0 .032 Yes
TD A Hum an Stom ach 2 .6 2.25 2.24 No
TD A Hum an Stomach 5.3 2 .25 1122 No
TD A Hum an Intestine 2 .6 7.75 0 .0 00007 Yes
TD A Hum an Intestine 5.3 7.75 0 .0035 Yes
D E TD A R at Stom ach 2.5 4 .40 0 .013 Yes
D E TD A R at Stomach 4 .6 4 .40 1.59 No
D E TD A R at Intestine 2 .5 6 .60 0 .0 0005 Yes
D E TD A R at Intestine 4 .6 6 .80 0 .006 Yes
D E TD A H um an Stomach 2 .5 2.25 1.78 No
D E TD A Hum an Stom ach 4.6 2.25 224 No
D E TD A Hum an Intestine 2 .5 7.75 0 .0 00006 Yes
D E TD A Hum an Intestine 4 .6 7.75 0 .0007 Yes
ro
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There are however, numerous other factors involved in the absorption of 
TDA firom the gastrointestinal tract. Surface area, blood flow to the area, 
solubility, concentration at the site of absorption, intestinal contents, gastric 
emptying time and biotransformation by gut bacteria all affect absorption to 
some degree (1.31-1.33). Within these factors, however, considerable 
interspecies differences can be found. For example the rat, unlike the human, 
tends to have considerable bacterial flora in the forestomach and upper small 
intestine with the capacity of metabolizing a compound and altering the 
absorption process (1.34). Bacteria have the capability to metabolize some 
compounds before absorption takes place, with the possibility of altering the 
absorption process. At the same time, the absorption rate of the compound in 
the small intestine will be greater than the absorption rate in the stomach even 
when the compound is mostly ionized in the intestine and nonionized in the 
stomach (1.31). This can be attributed mainly to the villi and microvilli 
architecture of the mucosal surface of the small intestine which increases the 
surface area 600-fold compared to the gastric mucosa (1.26).
In the experimental environment, factors such as stomach contents, 
concentration of the compound and solubility can usually be controlled 
resulting in a more standardized absorption profile. In the uncontrolled 
situation, such as workers in a production facility, absorption would be 
expected to be inconsistent resulting in significant differences between
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individuals. Oral dosing of the TDA compound must be considered possible 
because of airborne TDA particles as well as contamination on workers hands 
which may not be washed prior to hand-mouth contact.
Timchalk et al. administered 60 mg/kg [14C]-2,4-TDA orally to male 
Fisher 344 rats and recovered 93% of the dose at 48 hours. Of that 93%, 
fractions from urine, tissues and cage washing comprised 76%. The remaining 
17% of the radioactivity was distributed in the feces (1.35). Since fecal 
distribution could be a mixture of non-absorbed compound as well as 
compound excreted into the bile, actual TDA absorption would be a minimum of 
76% of the administered dose. Because TDA has been shown to easily 
penetrate the gastrointestinal mucosa, the oral exposure was of concern as a 
potential route.
Dermal absorption of 2,4-TDA
In order to understand the dermal absorption of TDA, a review of the 
anatomy and physiology of skin should be undertaken (1.26,1.32,1.36,1.37). 
The properties of skin allow it to be both a barrier to environmental, biological, 
and chemical agents as well as a primary route for the administration of certain 
medicinal compounds. A compound may enter the systemic circulation through 
the skin, by first passing through the epidermis or appendages (hair follicles, 
sweat glands, sebaceous glands) which are more important for ions and large 
polar molecules. The skin is composed of two major divisions, the epidermis 
and the dermis. The epidermis is subdivided into the stratum comeum, stratum
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granulosum, stratum spinosum and stratum germinativium. The stratum 
comeum is the rate limiting barrier allowing transport only by passive diffusion. 
It is a comified layer, replaced every 3-4 weeks in humans, composed of 
densely packed inactive keratinized cells which have lost their nuclei. These 
exfoliated cells are continually being replaced by cells stemming from the basal 
layer of the epidermis. In man, the thickness of the stratum comeum varies 
from 0.07 to 0.12 mm over most of the body, but can be as thick as 1.4 mm on 
the soles of the feet. Polar substances probably diffuse through protein 
filaments in the stratum comeum while nonpolar compounds diffuse through 
the lipid matrix between the filaments, their rate limited by the lipid solubility 
and molecular weight of the compound.
Once a compound passes the stratum comeum, diffusion through the 
porous, aqueous lower layers of the epidermis occurs. The stratum 
granulosum, spinosum and germinativum make up this lower layer which is a 
very poor barrier against diffusion.
The dermis is the layer where compounds are able to enter the systemic 
circulation through the vascular and/or the lymphatic system. This layer 
consists of connective tissue, sebaceous glands, sweat glands and ducts, 
blood vessels, capillaries, lymphatics, fat and hair follicles. The rate of 
diffusion through the dermal layer depends not only on the physical 
characteristics of the compound in question but on factors such as blood flow, 
interstitial fluid flow, concentration gradient, area and thickness of the
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membranes involved, and the partitioning of the molecules between the 
membrane and aqueous phase (1.28).
There are also many biological factors which attribute to the absorption 
of a compound through the skin (1.38). Only intact skin can form an adequate 
barrier to the environment. Any agent that damages or denudes the stratum 
comeum (trauma, disease) will markedly increase absorption across the skin, 
often as much as 100-fold. Absorption will also vary with the body site 
involved, but this also depends on the type of compound in question.
The absorption of hydrocortisone has been shown to be greatest in the 
scrotum, followed by forehead, scalp, back, forearm, palm and plantar surface 
(1.39). With water, as the stratum comeum thickness increases, diffusivity also 
increases resulting in a fairly uniform permeability (1.38). Besides the stratum 
comeum thickness, the density of hair follicles, the concentration of sweat and 
sebaceous glands and the amount and depth of underlying capillaries in the 
skin will also modify the permeability. Species differences will also play a role 
in absorption. In general, for topically applied compounds, rabbit skin is 
usually the most permeable followed by rat, miniature swine, rhesus monkey 
and man. The skin of monkeys and pigs seem to have absorption qualities 
similar to human skin for many compounds whereas rat and rabbit skin is 
generally more permeable. Bartek et al. found that the caudal back skin of the 
rat was about 2-3 times as permeable as the forearm skin of man (1.40). A 
study by Feldmann etal. concluded that human scalp was about 3.5 times as
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permeable as the forearm (1.39). These two studies seem to indicate that at 
least, in terms of permeability, human scalp and rat skin (from the caudal back 
area) seem to be similar (1.41). However, most studies involving an animal 
model for human skin have followed the recommendations of the 1977 
publication “The Guidelines for Preclinical and Clinical Testing of New 
Medicinal Products” published by the Association of the British Pharmaceutical 
Industry, which encourages the use of piglets as a human model because of 
the similarities of skin structure (1.38).
Marzulli et al. found that [14C]-2,4-TDA in acetone applied topically to 
monkey abdomens and human forearms resulted in 54% and 24% skin 
penetration respectively (1.42). In contrast, two earlier studies involving the 
closely related compound 2,5-TDA in hair dye formulations, showed absorption 
rates of between 0.2% and 1 % (1.43,1.44). Although there is limited data on 
the dermal absorption of 2,4-TDA, these studies show that TDA can be 
absorbed dermally and as such, the public should be protected from exposure 
(1.24). Because of the structural similarity of DETDA to TDA, the expectation 
is that DETDA will also be absorbed through the dermal route.
The skin also has the ability to metabolize or biotransform many 
compounds into active or inactive metabolites. The rate and extent of 
biotransformation can alter the rate and amount of parent compound entering 
the systemic circulation. At the same time, blood flow through the skin affects 
the percutaneous absorption of xenobiotics that penetrate the stratum
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comeum. Blood flow is a dynamic process that changes rapidly depending on 
body temperature, stress, disease, and the ambient environment (1.38). 
Intraperitoneal absorption of 2,4-TDA
As mentioned before, the i.p. route is used by both researchers and the 
medical community for the quick administration of compounds into the 
circulatory system. This route results in the rapid absorption of the compound 
because of the vast surface area and rich blood supply of the peritoneal cavity. 
These compounds are absorbed primarily by uptake through the portal 
circulation and must therefore make a first pass through the liver before 
entering the systemic circulation. In some cases, this “first pass effect” can 
completely extract and metabolize a compound, precluding access to the 
general circulation and the other organ systems.
Intravenous administration of 2,4-TDA
The i.v. route of administration totally eliminates the absorption factor 
because the compound is introduced directly into the systemic circulation 
giving it almost instantaneous access to any body organ. This route is 
especially useful in research because it allows the elimination of absorption 
factors which can be difficult to quantify.
Pisftibntign
Once access to the systemic circulation occurs, either through 
absorption or i.v. administration, the compound is distributed throughout the 
body tissues. Distribution is generally a fairly rapid process but depends
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largely on tissue blood flow and the rate of diffusion of the compound from the 
capillary beds into the tissue cells. Other factors involved are mass of the 
target tissue relative to body weight, pH of the body fluids involved, lipid 
solubility and molecular weight of the compound, degree of ionization and 
binding affinity for plasma and tissue proteins.
There is a significant difference in the rate of blood flow to tissues 
(1.26,1.31,1.45). The heart, liver, kidneys, and brain receive large quantities of 
blood relative to their body weight. In contrast, muscle, fat, skin, and much of 
the viscera receive markedly less. Blood flow to each tissue, however, will vary 
depending on the body functions occurring at the time.
Each capillary bed is fed by an arteriole and drained by a venule. Blood 
flows intermittently through these capillaries by contractions of metarteriole and 
precapillary sphincters controlled primarily by oxygen concentration. For lipid- 
soluble substances, the compound can rapidly diffuse across the capillary 
membrane directly and mix with interstitial fluid and plasma. Small water- 
soluble substances and ions, on the other hand, are thought to pass through 
intercellular clefts or pores between adjacent capillary endothelial cells. Very 
polar molecules and larger ions, because they are surrounded by a hydration 
shell, utilize special transport mechanisms in order to traverse the membrane. 
These water soluble molecules are also excluded from the central nervous 
system by the blood-brain barrier. The actual rate of diffusion is proportional to 
the difference of the concentration of the compound on both sides of the 
capillary cell membrane (1.46).
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The concentration of a compound in the blood of an animal depends on 
the volume of distribution of that compound. Body water can be broken down 
into three groups: plasma water, interstitial water, and intracellular water. The 
distribution of a compound in the body is complex and usually associated with 
more than one compartment. Lipid soluble compounds, because of their 
nature, distribute easily into the interstitial and intracellular compartments. 
Lipid-insoluble compounds, on the other hand, have a very limited distribution 
pattern because of the associated problems with membrane permeability.
Tissue binding and tissue reservoirs can also dramatically affect 
distribution of a compound. The binding of certain compounds to plasma 
proteins, weak acids to albumin and weak bases to c^-acid glycoproteins, can 
significantly limit their distribution since only the unbound or free-fraction of a 
drug or compound is in equilibrium with the plasma membrane. The high 
molecular weight of a compound-protein complex prevents it from freely 
crossing the capillary cell membrane therefore preventing distribution into other 
compartments.
Tissues with a high percentage of body mass (muscle, fat, bone) can 
often act as a reservoir or storage depot. A compound in a tissue depot will be 
in equilibrium with the free-fraction of the compound located in the plasma. As 
the concentration of compound in plasma decreases, due to metabolism or 
excretion, more compound is released from the reservoir to restore the 
equilibrium. This same reservoir concept also occurs with plasma proteins 
since the ligand-protein complex is a reversible process (1.26,1.31).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
21
The binding of a compound to plasma proteins can be determined using 
a Scatchard plot (1.26,1.47). The bound to free-ligand ratio is plotted on the 
ordinate while the concentration of bound ligand is plotted on the abscissa. 
From this plot, the number of ligand binding sites per molecule of protein as 
well as the affinity constant (k,) for the ligand-protein complex can be 
determined. Non-linearity of the plot is indicative of more than one type of 
binding site each with different affinities.
Unger et al. evaluated 23 tissues plus blood and feces after i.p. dosing 
with 2,4-[14C]TDA (1.19). For the majority of tissues sampled, the greatest 
amount of radioactivity was recorded at the 1 hour time point. Exceptions were 
the gonads, kidney, lung, muscle, blood and epididymis which had highest 
levels at 0.5 hours while the large intestine and aorta showed highest levels at 
the 2 hour time point. As expected, high blood flow areas tend to have high 
concentrations per gram of tissue as seen with the liver, kidney and adrenal 
gland levels. High concentrations in the intestinal tract are probably indicative 
of biliary excretion into the small intestine. In the tissues evaluated, not 
counting the intestines and their contents, the liver had the greatest percentage 
of dose followed by the muscle and skin. These three tissues have all 
developed tumors upon exposure to 2,4-TDA.
At the same time, Grantham et al. were comparing the metabolism of 
rats and mice after administering an i.p. dose of [14C]-2,4-TDA (1.48). Although 
only a few tissues were evaluated in this study, the higher concentrations were
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again recorded in the liver and kidney. Interestingly, at 24 hours after dosing, 
the rats had significantly higher tissue concentrations of 2,4-TDA compared to 
mice, presumably because of the lower excretion rate in rats.
These two studies provide the only detailed information on the 
distribution of TDA in the mammalian system. Comparisons between oral, 
dermal, I.P. and I.V. dosing have not been undertaken. Because of the 
carcinogenic and mutagenic properties of 2,4-TDA, comparative studies in man 
are unavailable.
DETDA is expected to closely follow the distribution pattern of TDA 
because of similar structure and properties (pk,, solubility, molecular weight). 
The difference in TDA distribution between rats and mice may be an indication 
that DETDA distribution may also differ within animal models.
Metabolism
The animal kingdom is constantly being exposed to a wide array of 
chemical agents. The fate of these agents is either elimination or accumulation 
in the organism. Some compounds can be eliminated entirely unchanged in 
the urine, bile, feces, milk, expired air, perspiration and saliva. These are 
predominately water soluble substances. Lipophilic compounds, even if 
excreted, are able to readily cross cell membranes and be reabsorbed into the 
body. Over time, some lipophilic substances will accumulate in high 
concentrations in selected tissues often causing detrimental effects in the 
organism. Fortunately, the body has been provided with enzyme systems that
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
23
are capable of making lipophilic substances more hydrophilic, allowing them to 
be readily excreted. This process, termed biotransformation, often involves 
more than one enzymatic process chemically modifying the parent compound 
at one or more positions producing a chemically distinct compound, or 
metabolite, which is usually more water soluble and less likely to be 
reabsorbed.
There are basically two types of biotransformation reactions: phase I 
reactions and phase II reactions (1.49). Phase I generally involve oxidation, 
reduction or hydrolysis of the compound which adds or uncovers functional 
groups on the molecule. Phase II enzyme systems utilize these functional 
groups as sites for conjugation or synthesis reactions.
Biotransformation enzymes are located in multiple organ systems 
including the liver, lung, kidney, intestines, skin, adrenal glands, placenta and 
testes. The primary organ involved in metabolism is the liver since it is the first 
line of defense for compounds entering the body through the intestinal or 
intraperitoneal route of administration. Many compounds entering through the 
dermal or respiratory route will eventually also pass through the liver as they 
gain access to the general circulation.
It should be remembered that biotransformation of foreign compounds is 
an integrated process between phase I and phase II enzymes even though the 
discussion of each system and its components will be individualized for clarity.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
24
Phase I enzyme reaction
The biotransformation pathway which can add a functional group to a 
compound is carried out by either the mixed-function oxidase (MFO), flavin- 
monooxygenase (FMO) or peroxidase-based co-oxidation system. Numerous 
oxidation-reduction reactions are also carried out by enzymes as part of the 
phase I system.
Mixed-Function Oxidase Systems
The MFO system is composed of two enzymes: NADPH-cytochrome P- 
450 reductase and cytochrome P-450, a heme-containing enzyme, both 
contained within the phospholipid membrane of the endoplasmic reticulum.
With the exception of red blood cells and skeletal muscle, cytochrome P-450 
has been found in all body tissue cells. More than 40 cytochrome P450 genes 
expressing different protein enzymes have been isolated in the rat while more 
than 20 different proteins are encoded by the multi-gene family in humans 
(1.49-1.52). The most common isoform involved in aromatic amine metabolism 
is the PAH and isosafrole inducible CYP1A2 ( P-450 1A2, rat p-450d, mouse 
P3-450, rabbit LM4, human HLd or P450PA) enzyme which can catalyze, 
among others, the N-oxidation reaction (1.52-1.54). In some instances the 
CYP1A1( P-450 1A1, p-450c) isoform is also able to catalyze N-oxidation 
reactions on aromatic amines but probably is involved more in the oxidation 
reactions of polycyclic aromatic hydrocarbon compounds (1.55,1.56). This 
generality depends on the substrate or compound oxidized and the species
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involved in the reaction. In the past, the cytochrome P450 system was thought 
to be more involved in the N-hyroxylation of primary arylamines whereas the 
FMO system was more involved in secondary and tertiary arylamines (1.57). 
This should be taken only as a generality as the FMO system has been shown 
to catalyze all three classes of amines (1.49).
Concerning 2,4-TDA, Cunningham et al. found that the cytochrome P- 
450 enzyme produced an N-hydroxylated intermediate, probably at the 4 
position, which was subsequently acetylated resulting in a mutagenic 
metabolite. Because induction by (3-naphthoflavone caused an increased 
mutagenicity with 2,4-TDA in the TA98 Ames tester strain, the P4501A1 
enzyme isomer is thought to catalyze the hydroxylation reaction (1.17,1.58). 
Whether the P4501A2 isomer, generally thought to catalyze most primary 
arylamines, was also involved in the hydroxylation was not mentioned.
As with most aromatic amines, DETDA is expected to undergo some 
degree of N-hydroxylation reactions. However, it is unknown at this time what 
effect the ethyl groups will have on this reaction. With the 2,4-DETDA isomer, 
any N-hydroxylation reaction will probably favor the 2 amine over the 4 amine 
because of the ortho positioned ethyl groups.
In the 2,4-TDA compound, there are 3 ring positions (3, 5 and 6) 
capable of being hydroxylated. Waring et al. showed that orally administered 
2,4-TDA resulted in aromatic or ring hydroxylation occurring at all three of 
these positions (1.18,1.48). Similar results were seen with 2,6-TDA, where
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both ring hydroxylation (3 and 5 positions) and acetylated amino group 
metabolites were detected in urine samples following exposure in male F344 
rats (1.59). N-hydroxylation of the amine groups was probably a prerequisite to 
the acetylated metabolites produced (1.11,1.60).
In addition to aromatic ring and N-hydroxylation reactions, alkyl or C- 
oxidation can be a route of detoxification when alkyl groups are present on the 
compound. This can occur at the last or next-to-last carbon as an oxygen atom 
is inserted into the carbon-hydrogen bond (1.49).
In the mouse, Grantham et al. discovered that C-oxidation of the TDA 
methyl group forming benzoic acid metabolites was a major reaction pathway. 
These metabolites often formed glycine conjugates prior to excretion (1.48). In 
another study, the rat, guinea pig and rabbit produced no detectable amounts 
of benzoic acid metabolites.
With DETDA, both methyl and ethyl alkyl groups are present on the 
aromatic ring. C-hydroxylation on the benzylic carbon of the ethyl groups is 
expected to occur with probable conjugation reactions involving glucuronidation 
and/or sulfation following. Oxidation of the methyl group to a benzoic acid 
metabolite is also expected.
These studies suggest that the phase I cytochrome P450 enzyme 
system does play a significant role in the disposition of both 2,4- and 2,6-TDA. 
DETDA is expected to undergo phase I enzymatic reactions producing many of 
the same metabolites seen with TDA.
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Flavin Monooxvaenase System
The NADPH-dependent FMO system has been isolated from a number 
of species including the rat, mouse, pig, rabbit and human. The amount of 
enzyme is usually highest in the liver but does vary from species to species.
The mechanism of action differs considerably from the P450 enzyme in which 
there is an initial binding of the substrate to the enzyme forming a complex in 
which oxygen binds to a reduced iron molecule. With FMO, oxygen first binds 
to the hydroperoxyflavin then later transfers to the substrate. In this reaction 
there is no need for an activated substrate, therefore any electron-rich 
compound that can be oxidized by a hydroperoxide may possibly serve as a 
substrate (1.51,1.61). The FMO system is more likely to catalyze a secondary 
or tertiary amine compound but definitely has the capability to utilize a primary 
amine as a substrate (1.49). Therefore, both TDA and DETDA could possibly 
utilize this enzyme as an avenue to N-hydroxylation. No published data is 
available at this time concerning TDA or DETDA as a substrate for the MFO 
system.
Phase II enzyme reactions
The phase II biotransformation system involves a number of biosynthetic 
conjugation reactions requiring activated cofactors or substrates. These 
energy requiring reactions involve the linking of an endogenous moiety to the 
compound or metabolite of interest generally leading to detoxification and 
excretion. A wide range of functional groups are derivatized by these enzymes
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including: -OH, -COOH, -NH2, -NR2, -SH and epoxides (1.62). However, in 
some cases, these conjugation reactions can produce metabolically activated 
compounds capable of binding to DNA, RNA, proteins and other tissue 
nucleophiles. There are eight classical conjugation reactions: glucuronidation, 
glucose conjugation, sulfation, methylation, acetylation, cyanide detoxication, 
glutathione conjugation and amino acid conjugation (1.62,1.63). For the 
purpose of this project only four reactions will be reviewed: glucuronidation, 
sulfation, acetylation and glutathione conjugation.
UDP-Glucuronosvltransferase
Unlike most phase II cytosolic enzymes, UDPGT (uridine diphosphate 
glucuronosyltransferase) is localized in the endoplasmic reticulum. This 
enzyme catalyzes the reaction between a high-energy nucleotide, UDP- 
glucuronic acid, and the compound's functional group, usually -OH, -COOH, or 
-NH2. The resulting conjugate is a more polar, water-soluble compound 
capable of being excreted in the urine or bile. Highest activity is in the liver 
followed by kidney and intestinal mucosa. There are two gene superfamilies in 
the human enzyme, UGT1A and UGT2A/UGT2B, which catalyze phenols, 
arylamines, bilirubin and endogenous or exogenous steroids. Glucuronidation 
is considered to be a high-capacity but low affinity conjugation reaction 
(1.49,1.50,1.62).
N-hydroxylated arylamine metabolites produced by the P-450 enzyme 
system have been shown to be N-glucuronidated in the liver before being 
excreted in the urine. These N-glucuronides are slower to be hydrolyzed by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
29
3-glucuronidase than 0- or S-glucuronide species making them more stable 
metabolites(1.49). Although O-glucuronidation does occur with arylamines, 
Kadlubar et al. found this to be a minor pathway with compounds such as the 
hydroxylamines of napthylamine, aminobiphenyl, aminofluorene and 
aminoazobenzene (1.64). Differences between species and substrate 
specificities in the N-glucuronidation of arylamines were also pointed out. For 
most of the arylamines tested, the human enzymes had lower activity than 
those of dogs and rats. Some species appear to fail to glucuronidate 
xenobiotics (1.49). The domestic cat, lion, lynx, and Gunn rat are unable to 
form glucuronides of phenol, naphthol and other phenol derivatives.
Glucuronidation of TDA (molecular weight 140) produces a glucuronic 
acid conjugate with a molecular weight of 332. Glucuronides of molecular 
weight less than 250 are generally excreted in the urine while molecular 
weights greater than 350 are usually excreted in the bile. These weights are 
nominal and do vary among species. It is expected with TDA that most 
glucuronic acid conjugates would be excreted in the urine. With DETDA, this 
may not be the case because of the slightly higher molecular weight.
Grantham et al. compared urinary metabolites in the rat vs. mouse after 
the administration of an i.p. dose of [14C]-2,4-toluenediamine (1.1 pCi/mg, 
77mg/kg body wt). They found that metabolite conjugation with glucuronides 
was more than doubled in mice over rats (17.4% of the administered dose vs. 
7.5%) (1.48,1.65). Waring ef al. compared metabolites in rabbits, rats and 
guinea-pigs after oral dosing of 50mg/kg of 2,4-TDA. Glucuronides amounted
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to 46%, 34% and 65% respectively after 48 hour urine collection. There 
appears to be greater glucuronidation upon oral dosing compared to 
intraperitoneal injection (1.18). For TDA in rodents, glucuronidation plays a 
significant role in the detoxification of the compound (1.65). This is due to a 
plethora of functional groups made available by phenolic and N-hydroxylated 
metabolites produced by phase I reactions. With orally administered DETDA 
ring hydroxylated species should be minimal but C- and N-hydroxylation may 
occur resulting in glucuronide metabolites similar to TDA.
Sulfotransferase
This cytosolic enzyme has been isolated in a number of organs including 
the liver, kidney, intestines and lungs (1.66). Sulfotransferase is involved in 
the formation of sulfate monoesters with compounds having an available 
hydroxyl group. These compounds can be phenols or phenolic groups, 
alcohols, hydroxylamines, hydroxysteroids, bile salts, and arylamines. As with 
glucuronidation, a donor group is required. In this case, the sulfate donor is 
provided by the cofactor 3'-phosphoadenosine-5’-phosphosulfate (PAPS).
PAPS synthesis is a two-step process involving ATP sulfurylase and adenosine 
5'-phosphosulfate kinase. ATP sulfurylase first forms adenosine 5- 
phosphosulfate (APS) from inorganic sulfate (obtained from the oxidation of 
cysteine) and ATP. Next adenosine 5'-phosphosulfate kinase adds a 
phosphate group from ATP to the 3'-position of APS producing the needed 
cofactor.
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Detoxifying sulfotransferases have been classified into four groups: aryl 
sulfotransferase, hydroxysteroid sulfotransferase, estrone sulfotransferase, and 
bile salt sulfotransferase. Of these groups, aryl sulfotransferase is of interest 
because of its ability to conjugate phenols and hydroxylamines. This enzyme 
is a high-affinity, low capacity system. In low substrate concentrations, sulfate 
esters may be the predominant conjugate, but as the concentration of substrate 
increases, glucuronides would predominate due to the higher capacity of the 
glucuronidation enzyme system. The pig, opossum, and brachymorphic mice 
have been found to be deficient in sulfotransferase enzyme activity. The 
predominant route of excretion of sulfate esters appears to be urine 
(1.49,1.62,1.67).
Grantham et al. compared urinary metabolites in the rat and mouse after 
the administration of an i.p. dose of [14C]-2,4-toluenediamine (1.1 pCi/mg, 77 
mg/kg body wt). They found sulfate conjugation was almost the same in rats 
and mice (10.1% of the administered dose vs. 9.6%) (1.48). No other studies 
were found detailing sulfate conjugation with TDA. DETDA is expected to 
undergo sulfate conjugation in similar manner to TDA.
Acetyl Transferases
Acetylation is a major pathway for the biotransformation of many 
arylamine compounds earned out by a cytosolic acetyltransferase enzyme. 
Arylamine N-acetylation, arylhydroxylamine O-acetylation and N,0- 
acetyltransfer of arylhydroxamic acids has been shown to occur from a single 
32 kDa protein in rat liver cytosol (1.68).
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The N-acetylation of arylamines is a two-step process. First, the acetyl 
group from the needed cofactor, acetyl coenzyme A, transfers to the N-acetyl 
transferase enzyme forming an acetyl-N-acetyl transferase. Secondly, the 
amino group of the arylamine compound is acetylated with subsequent enzyme 
regeneration (1.49,1.69).
Both the dog and fox are deficient in the N-acetyl transferase enzyme, 
and therefore acetylate arylamine compounds poorly. Other species show 
differing levels of N-acetylation activity, for example, hamster liver cytosol has 
shown the greatest activity followed by guinea pig, rabbit, mouse and rat 
(1.62,1.70-1.73). Within species, extrahepatic N-acetyl transferase activity 
varies greatly among tissues. In rabbits, the highest levels have been found in 
duodenum and lung with decreasing levels in thymus, ovary, spleen, uterus, 
adrenals, leukocytes, kidney, bone marrow, salivary gland, pancreas, 
erythrocytes and brain (1.69).
Acetylation polymorphism has been reported in the human, mouse, 
rhesus monkey and hamster. This genetic based polymorphism is usually 
classified as “fast” or “slow" based on the enzymes ability to acetylate 
isoniazid, sulfamethazine and other compounds (1.49,1.69,1.74,1.75). In 
humans, hepatic N-acetyltransferase polymorphism has been linked to two 
alleles at a single autosomal gene locus (1.75,1.76).
With many compounds, biotransformation does not always lead to 
detoxification. In these situations, metabolism can produce a genotoxic
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compound. Human studies have demonstrated an association between rapid 
acetylators and colo-rectal cancer and slow acetyiators and urinary bladder 
cancer (1.64,1.68,1.74,1.77-1.82).
Dogs, which are very poor acetylators, are prone to bladder tumors upon 
administration of carcinogenic aromatic amines making them good animal 
models for slow acetylators in man (1.83). Lower et al. found that various 
arylamines administered to dogs produced urinary bladder tumors, suggesting 
that N-acetylation was not required in their formation (1.73). A later study 
involving administration of carcinogenic arylacetamides to dogs resulted in 
both bladder and liver tumors when the substrate was specific for 
arylacetamide deacetylase enzyme systems (1.84). This study seemed to 
indicate that the absense of the acetyl group was necessary for bladder tumor 
formation.
In humans, acetylation polymorphism has resulted in fairly predictable 
patterns of toxicity and tumor formation. In “slow acetylator” individuals, 
isoniazid exposure often resulted in peripheral neuropathies while the 
consequences for exposure in “rapid acetylators” was hepatitis 
(1.69,1.82,1.85-1.90). It now appears as though “slow acetylators” may be at 
higher risk for bladder cancer when exposed to carcinogenic arylamines (1.82). 
In contrast, llett et al. showed a correlation between “rapid acetylators” and 
colorectal carcinomas in 49 cancer patients (1.74).
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Multiple studies in rats have shown the relevance of N-acetylation in the 
metabolism of toluenediamine. In two separate studies in Fischer 344 male 
rats, Grantham et al. reported that 4-acetylamino-2-aminotoluene (5.7% and 
5.2% of dose) and the 2,4-diacetylaminotoluene (2.6% and 1.4% of dose) were 
significant urinary excretion products (1.48,1.65). Waring et al. found a high 
percentage of phenolic metabolites and less than 3% mono- and di-acetylated 
products in female Wistar rats (1.18). Timchalk et al. found comparable levels 
of free 2,4-TDA and acetylated metabolites when oral and i.v. 3 mg [14C]-2,4- 
TDA/kg were administered to Fischer 344 rats (1.35). Comparing the ratio 
between free plus acetylated 2,4-TDA to total acid-labile metabilites they found 
61% of detected metabolites as free or acetylated and 39% as other conjugates 
when administered a 60 mg/kg oral dose while a 3 mg/kg dose resulted in 
about 85% free and acetylated metabolites. From this study, lower in vivo 
exposure levels seem to result in acetylation as the primary conjugation 
reaction.
Using hamster liver cytosol, Glinsukon etal. found 2,4-TDA metabolized 
to 3 acetylaminotoluene products. The primary metabolite was 4-acetylamino- 
2-aminotoluene of which a small percentage was then metabolized to 2,4- 
diacetylaminotoluene. The 2-acetylamino-4-aminotoluene was also found to be 
further metabolized to 2,4-diacetylaminotoluene (1.91). From all indications, it 
appears that the monoacetyl metabolite, 2-acetylamino-4-aminotoluene is only 
a very minor metabolite and is probably further metabolized to the diacetyl- 
aminotoluene product.
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Kawakubo et al. studied the acetyltransferase activity of hamster skin in 
arylamine metabolism (1.92). In their study, arylamine N-acetylation, 0- 
acetylation of N-hydroxyarylamine and N,0-acetyltransfer of arylhydroxamic 
acids were all demonstrated using hamster skin cytosol. A later study showed 
human skin has a N-acetyltransferase activity comparable with hamster skin.
In the study, skin N-acetyltransferase activity was higher than liver activity and 
seemed to indicate that a polymorphic acetylation was occuring with an 
arylamine substrate (1.93).
At one time, skin was thought to be primarily a mechanical barrier 
against hazardous chemicals. Studies now show that skin is a very com­
plicated multifunctional organ with metabolic capabilities. Dermal exposure to 
Ethacure could allow skin N-acetyltransferase enzyme systems to play a role in 
biotransformation. This implies that the skin could either activate or inactivate 
DETDA before it has a chance to enter the systemic circulation. As with most 
arylamine compounds, skin exposure to Ethacure must be kept to a minimum. 
Exgretipn
When a chemical is eliminated from the body, it does so either 
unchanged or as a metabolite. The most important routes of excretion are 
urinary and fecal. However the lung, sweat, milk, saliva, and tears are capable 
of some excretion, generally in a minor capacity. In order for a compound to be 
efficiently excreted from the body, it must be relatively polar. Biotransformation 
reactions transform lipid soluble compounds into more polar substances 
allowing for excretion.
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Urinary excretion
The kidney is generally thought of as the major organ for the excretion of 
toxic compounds. Three processes are involved in renal excretion: glomerular 
filtration, active tubular secretion, and passive tubular reabsorption (1.31,1.94- 
1.96).
Glomerular filtration
Approximately one-fifth of the total cardiac output flows through the 
kidneys at any given time. As the blood flows through the glomerulus, plasma 
is filtered through the glomerular membrane into Bowman’s capsule forming the 
glomerular filtrate. Because of the glomerular membrane pore size, 
substances larger than a molecular weight of 69,000 are excluded from the 
filtrate. This molecular seive prevents virtually all plasma proteins from 
becoming part of the filtrate while many smaller peptides are allowed to pass 
through. The binding of xenobiotics to proteins greater than 69,000 can also 
alter the rate of filtration as they are prevented from passing through the 
glomerulus.
Active tubular secretion
Active tubular transport systems are located in the basolateral 
membranes of the proximal kidney tubules. There are separate transport 
systems for organic acids (anions) and organic bases (cations). As an active 
transport system, the degree of secretion is a function of the number of binding 
sites available to the xenobiotic. This means that other compounds capable of 
binding to those sites will compete with the xenobiotic thus inhibiting its
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secretion. Protein-bound xenobiotics can be actively transported across the 
tubular cells allowing them to be excreted into the renal tubules.
Passive Tubular Reabsorption
After glomerular filtration and secretion of the compound from the 
peritubular capillaries, the nonionized forms of weak acids and bases are 
passively reabsorbed, primarily in the distal tubules. The xenobiotic in the 
lumen becomes more concentrated because of the efficient reabsorption of 
water in the tubules. As a result, a concentration gradient is established 
between the compound in the tubule lumen and the free compound in the 
plasma. The pH of the tubular fluid directly affects the absorption. In an 
alkaline urine, weak acids are rapidly excreted and poorly re-absorbed 
because of ionization. In an acidic urine, weak acids are rapidly re-absorbed 
and poorly excreted. The opposite effects occur when weak bases are 
subjected to the same conditions. Strong acids and bases are ionized at 
urinary pH and are almost totally excreted. As would be expected, 
reabsorption also increases with lipid solubility.
The end result of these excretion mechanisms is the removal of a 
constant fraction of the compound as blood flows through the kidneys.
Fecal excretion
Excretion in the feces is the other major pathway used by the body to 
eliminate xenobiotics. Fecal excretion is comprised of three main components: 
nonabsorbed compound, biliary excretion, and intestinal excretion (1.26,1.31, 
1.97,1.98).
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Nonabsorbed compound
The absorption of a compound from the gastrointestinal tract is related 
to the lipophilicity of that compound. Most drugs and chemicals have at least 
some degree of lipophilicity, and are capable of being absorbed to some 
extent. It is unlikely that any compound will be totally absorbed, the balance 
contributing to fecal excretion.
Biliary excretion
The biliary system, as a component of fecal excretion, contributes 
greatly to the removal of xenobiotics and their metabolites. The liver receives 
both arterial blood from the general circulation and portal venous blood from 
the intestinal system. This allows the liver to remove compounds entering the 
body from the intestines as well as other routes. The removal by the liver of 
compounds absorbed from the intestine before reaching the systemic 
circulation is refered to as the “first-pass effect”. This often allows an ingested 
toxic compound to be removed before it can be distributed to other parts of the 
body.
As compounds are biotransformed in the liver, more water soluble and 
excretable metabolites are generally formed. These metabolites are then 
excreted directly into the bile or passed through the kidneys for elimination.
The molecular weight of the parent compound or metabolite plays a significant 
role in the route of elimination. There is however, considerable species 
variation in these molecular weight ranges (1 99). Low molecular weight
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compounds are generally excreted into the urine while those with weight above 
about 325 generally are excreted into bile. For the most part, large 
amphipathic molecules tend to be excreted through biliary transport. The 
excretion of compounds into bile involves at least four transport systems, two 
systems for organic acids, one for organic bases, and one for neutral 
compounds (1.26,1.97). Analogous to renal tubular transport systems, similar 
compounds can compete for binding sites inhibiting excretion into the bile.
Some xenobiotics are removed from the systemic circulation by binding 
to intracellular proteins such as ligandin and metallothionein. The binding of 
the protein to the agent, while protecting cellular organelles from toxic effects, 
can sometimes restrict elimination into bile.
Intestinal excretion
In some situations, a xenobiotic can be directly transfered into the 
intestinal lumen from the blood, probably through passive diffusion (1.98).
Compounds excreted into the bile are not always eliminated from the 
body. The hydrolysis of conjuated xenobiotics by intestinal bacteria can 
transform the polar compound into a much more lipophilic one allowing for 
reabsorption. This process have been termed “enterohepatic circulation” and it 
often results in higher blood levels or longer half-lives for the compound than 
would ordinarily be expected (1.26,1.97).
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Toluenediamine elimination
Grantham et at. studied metabolism in male Fischer rats using an i.p. 
dose of radiolabeled 2,4-TDA (1.65). By the fifth day 98.6% of the dose was 
recovered with 76.4% excreted into the urine and 22.2% in the feces. At the 24 
hour time point (81% recovery), 73% was urinary excretion and 8% fecal.
Later Grantham etat. looked at the excretion levels of 2,4-TDA in both 
male Fischer rats and male NIH Swiss strain mice after i.p. dosing (1.48). 
Results revealed that almost 90% of radioactivity versus 74% was excreted in 
the urine of mice and rats respectively by the end of the experiment. Most of 
the urinary elimination was complete by 24 hours in both species while total 
excretion of radioactivity took only 48 hours in the mice compared to 6 days in 
the rats. Fecal excretion, as a percent of dose, was greater in rats than mice. 
After 24 hours, fecal excretion became the primary route of excretion in the rat.
Unger et at. also looked at excretion of 2,4-TDA in mice for 24 hours 
after i.p. administration (1.19). One hour after dosing, almost 50% of the label 
was excreted into the urine with a total of about 52% at 24 hours. Fecal 
excretion accounted for 22% of the label at the 24 hour period. Again it 
appears as though excretion shifts from urinary to fecal a few hours after a 
single i.p. dose. Urinary excretion was much less in the mouse than in the 
Grantham et al. study where approximately 90% of the dose was excreted in 
the urine by the 24 hour time point.
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Grantham’s results seemed to be confirmed in an i.p. 2,4-TDA study by 
Reddy et al. in male F344 rats. At 24 hours, about 70% of the administered 
dose was recovered in the urine (1.100).
When 2,4-TDA was administered orally or i.v. to F344 rats, urine 
excretion accounted for 64-72% of the dose while 20-31 % was recovered in the 
feces (1.35). There was no significant difference between a high and low dose 
oral administration of 2,4-TDA. Again with this study, the major excretion 
pathway was the urinary system and not the biliary system.
Cunningham et al. administered radiolabeled 2,6-TDA to male F344 rats 
by gavage (1.59). By 24 hours, about 86% of the label was recovered in the 
urine and less than 5% in the feces. By 72 hours, almost all label had been 
recovered with about 90% and 10% accounted for by urine and feces 
respectively.
The 2,6-TDA isomer appears to have a higher urinary excretion rate 
than 2,4-TDA. Both isomers, however, appear to be rapidly excreted with the 
majority of compound eliminated by 24 hours.
Mutagenesis
Introduction
Mutagenesis can be defined as the induction of DNA damage resulting 
in genetic alterations ranging from simple changes in DNA base pairs (gene 
mutations) to changes in chromosome structure (aberrations) or chromosome 
number. Early research in mutagenesis centered around the discovery that
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ionizing radiation induced mutations in Drosophila melanogaster. Mutations 
are now and will always be of vital interest because of potential impact on 
future generations. Mutations may involve either germ cells or somatic cells or 
both. Germ cell mutations may result in an increased incidence of genetic 
diseases in successive generations. Somatic mutations are believed to be an 
initial step in carcinogenesis.
Gene or point mutations
Point mutations are changes that occur in the DNA sequence within a 
gene. They are generally classified as either base-pair substitutions or frame- 
shift mutations.
In a base-pair substitution, the replacement of one base pair for another 
occurs (ex. G C by A T). Base-pair substitutions are either transitions or 
transversions. In a transition, the purine.pyrimidine orientation does not 
change (i.e. guanine is replaced by an adenine) while in a transversion, a 
purine would be replaced by a pyrimidine or vice versa (i.e. guanine is replaced 
with a thymine or cytosine). Chemical and physical mutagens often result in 
point mutations.
Frame-shift mutations can occur when base pairs are either losts or 
gained within a gene. The addition or deletion can cause a shift in the reading 
frame of the mRNA produced from an altered DNA template resulting in the 
failure to produce a functional protein.
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Chromosome aberrations
An aberration occurs when a mutation involves a change in the structure 
of a chromosome. An aberration may occur in only a small segment of a 
chromosome, on a single chromatid, or an entire chromosome. The changes 
associated with the mutation can be stable or unstable. Stable aberrations can 
be passed on through cell division becoming a permanent part of the cell 
population. The more common examples of stable mutations are deletions, 
duplications, inversions and translocations. These mutations may involve large 
segments of DNA encoding many genes. Unstable aberrations usually result in 
cell death because of the loss of needed genetic material. Evidence is often 
present as an acentric fragment, a ringed structure or dicentric chromosome. 
Unstable aberrations are easily detected and often used as evidence of 
chromosome damage or breakage (1.101,1.102).
Chromosome number
Mutagenic events can also lead to changes in chromosome number. 
When one or a few chromosomes are involved, the condition is termed 
aneuploidy. When complete sets of chromosomes are involved, the term is 
polyploidy (1.101). These types of mutations are generally referred to as 
numerical chromosome aberrations in contrast to the previously discussed 
structural aberrations.
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Msgiuwisros Qf  mutagenesis
A mutagen exerts its effect on an organism by altering the structure of its 
DNA. This alteration can be either physical, chemical or both in nature. With 
chemical mutagens, adduct formation is one possible result, that is the addition 
of some electrophilic product to the nucleophilic DNA structure. In some 
circumstances, DNA-adducts with aromatic amine compounds have been 
shown to result in transversion mutations. Activated aflatoxin B, induced G C 
to T A transversions possibly due to apurinic sites created within the DNA 
(1.103).
Aromatic amines were some of the earliest chemicals found to be 
carcinogenic. Years later that carcinogenicity was found to be linked to the 
formation of arylamine-DNA adducts (1.5). For the most part, the major sites 
for arylamine-DNA adducts have been the C8, N2 and O6 positions of guanine. 
The N6 and C8 position of adenine occurs much less frequently (1.104,1.105). 
Beland et al. examined a variety of N-hydroxylated arylamine compounds for 
DNA adduct formation relative to bladder cancer (1.106). In their study, the 
predominant adducts were C8 deoxyguanosine derivatives. They also found 
that these adducts resulted in frameshift mutations in the TA1538 strain of 
Salmonella typhimurium. Humphreys et al., in their work with aminofluorene, 
found evidence that these C8-guanine-arylamine adducts were formed through 
an intermediate N7-adduct utilizing an S,^ mechanism (1.105,1.107,1.108). 
Although the C8-guanine is prevelant in arylamine reactions, it is by no means
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the only adduct formed (1.109). Kadlubar et al. showed N-hydroxy-2- 
naphthylamine to react at the N2 and C8 position of guanine as well as the N6 
position of adenine in contrast to N-hydroxy-1-naphthylamine which forms 
primarily 0 6-guanine adducts (1.110,1.111). In their in vitro study, the C8 
adducts, comprising about 50% of the DNA binding, were found in both ring- 
open and ring-closed forms. Beland et al. examined a number of arylamine 
compounds including 1- and 2-naphthylamine, 4-aminobiphenyl and 4- 
acetylaminobiphenyl, 4-acetylamino-4'-fluorobiphenyl, 3,2'-dimethyl-4- 
aminobiphenyl, 2-acetylaminofluorene, benzidine and 2-acetylamino- 
phenanthrene (1.104). DNA adducts included deoxyguanosin-C8-, N2-, and 
0 6-derivatives, as well as deoxyadenosin-N6- and C8-derivatives.
Alterations in the DNA can also occur by non-covalent interactions with 
compounds. This transpires with the intercalation of xenobiotics between 
adjacent stacked base pairs in the double helix causing the DNA to unwind at 
that site. Intercalation usually occurs with planar aromatic compounds rather 
than bulky PAH type compounds. The resulting physical distortion of the DNA 
helix is thought to lead to the deletion or insertion of base pairs during DNA 
replication occasionally resulting in frame-shift mutations (1.101,1.112).
Freund et al. found that DNA sequences capable of transformation into the Z- 
DNA conformation may be hot spots for spontaneous deletions (1.113). Ames 
et al. looked at a number of known carcinogenic aromatic amine compounds 
and their metabolites and found them to be potent frameshift mutagens for
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Salmonella typhimurium (1.114). They also found that when the intercalating 
agent had side chain groups which were covalently bound to DNA, its potency 
as a frameshift mutagen was often dramatically increased.
Mutagenicity of 2.4- and 2.6-Toluenediamine
For years researchers have recognized both 2,4- and 2,6-TDA as 
mutagenic compounds. Early studies in rats also confirmed that the 2,4-isomer 
was carcinogenic in a number of organ systems (1.20,1.23). TDA has been 
studied in a number of bacterial and mammalian mutagenicity tests with 
contrasting results. Also, correlation of mutagenicity test results with 
carcinogenicity has been somewhat equivocal in many of the tests.
Basic mutagenicity tests
Tests for mutagenicity of natural substances, chemicals and 
pharmaceuticals is now a standard component of toxicology. Multiple 
experimental platforms have been used including bacteria, viruses, fungus, 
cultured plant and animal cells, insects and animals. Dozens of tests have 
been developed but most mutagenicity testing is carried out with a small 
battery of standardized tests. Test procedures relative to the mutagenicity of
2.4- and 2,6-toluenediamine are reviewed below.
2.4-Toluenediamine 
Ames test
The Ames Salmonella assay has been the mainstay of mutagenesis 
testing for many years. The test usually employs different Salmonella 
typhimurium strains developed by Dr. Bruce Ames that have been mutated at
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the histidine operon resulting in a histidine-dependent bacteria (1.115-1.118). 
These bacteria are unable to grow on media that is deficient in the amino acid 
histidine. Bacterial growth on histidine deficient media is an indication of 
reversion back to the wild-type histidine operon. The frequency of the 
appearance of these bacterial colonies have been correlated to the muta­
genicity of many of the compounds tested. Different strains of bacteria allow 
for detection and differentiation of point and frameshift mutations (1.101,1.115, 
1.118-1.120).
Over time, introduction of selected traits in these bacterial strains have 
made them much more sensitive to mutations. Some of these changes include 
deficiencies in DNA-repair and increases in ceil membrane permeability to 
larger molecules.
A major drawback of the Ames assay, the lack of phase I biotrans­
formation enzymes present in mammalian systems, was corrected by supplying 
rat liver post-mitochondrial supernatant to the bacteria in a special preparation 
termed ‘SS-mix1 (1.115,1.121). With the addition of biotransformation enzymes, 
a previously untested class of compounds gained access to a widely used 
bacterial mutagenicity assay.
Although there have been a few discrepancies in the test results with 
some strains, 2,4-TDA is considered mutagenic in the Ames assay. The 
frameshift tester strains, TA1537 and 1538, provide clear and reproducible 
results of mutagenicity while a newer strain, TA100, which incorporates a 
resistance transfer factor ( makes test more sensitive to certain classes of
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compounds) has been equivocal in its results (1.115). The TA98 strain, 
another R factor strain, has been consistently positive in its assay results.
All strains of the Ames Salmonella assay have required that 2,4-TDA 
undergo metabolic activation by some process in order for the compound to 
become mutagenic. This means that 2,4-TDA is not a direct acting mutagen. 
Although activation is usually accomplished with the S-9 mix, primary rat 
hepatocytes and even plant cell incubation assays have been utilized to 
metabolize the compound to the activated forms (1.17,1.122). When the S-9 
activation system was used with the Ames assay, it appeared that N- 
hydroxylation of the 4-amino nitrogen with subsequent acetylation carried out 
by an O-acetyltransferase in the Salmonella bacteria was responsible for the 
mutagenic qualities seen in 2,4-TDA. When an acetyltransferase-deficient 
bacterial strain (TA 98/1,8-DNP6) was used, mutagenic activity was severely 
curtailed while a strain with increased acetyltransferase activity (YG1024) 
resulted in increased mutagenic activity. Prior induction of rats using Aroclor®- 
1254, phenobarbital or 3-napthoflavone has also been shown to dramatically 
increase the mutagenicity of 2,4-TDA because of the resulting increased phase 
I biotransformation activity (1.17,1.123).
Multiple studies have shown that 2,4-toluenediamine is mutagenic in the 
Salmonella strains TA98, TA100, TA1537, TA1538, and YG1024 as long as 
metabolic activation has occurred. Mutagenicity has not occurred in any of 
these Salmonella bacteria strains without the presence of an activation system 
(1.17,1.100,1.122,1.124-1.126).
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Although the Salmonella assay is the most utilized, it is by no means the 
only test in the arsenal. 2,4-TDA has been extensively assayed in a number of 
in vivo and in vitro tests systems, often with equivocal results.
AiKaJine.eiutjon assay
The alkaline elution assay is a measure of DNA strand breakage. Cells 
are placed on a filter then lysed with a detergent solution. An alkaline solution 
is pumped through the filter in order to cause the DNA to unwind and separate 
into strands. DNA which has been damaged by genotoxic agents will result in 
strands of differing lengths and molecular weights. The smaller fragments 
elute faster than the larger segments. An increased rate of elution is indicative 
of DNA strand breakage (1.127,1.128).
Parodi et al. showed a weak positive response for 2,4-TDA in the in vivo 
alkaline elution assay. The assay was performed in young male Sprague 
Dawley rats after i.p. administration (1.129). In contrast, negative results were 
obtained by Sina et al. when the compound was tested in an in vitro alkaline 
elution/rat hepatocyte assay (1.130). These test results seem to suggest that
2,4-TDA is a weak “breaker" of DNA.
Unscheduled DNA synthesis (UPS)
Unscheduled DNA synthesis has been used as a measure of DNA repair 
in response to chemical exposure. It has been shown to be an indicator of both 
genotoxicity and carcinogenicity. The test is generally conducted in hepatocyte 
tissue cultures. In the cell, scheduled synthesis of DNA occurs during the S or 
DNA synthesis phase of the cycle. Unscheduled synthesis is that which occurs
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in the non-S-phase of the cycle. [3H]Thymidine, when incubated with cells in 
the S phase, is incorporated into the nucleus of the cultured cells and shows up 
as silver grains when examined autoradiographically. Cells not in S phase will 
not incorporate the [3H]thymidine into the nucleus. Cells which are exposed to 
toxic doses of chemicals will generally undergo DNA repair synthesis which 
can be detected by the tritiated thymidine label (1.131,1.132).
In the rat liver unscheduled DNA synthesis assay, two studies on 2,4- 
TDA using Fischer 344 rats produced positive results. Another study by 
George et al. on the same compound produced a weak positive result, but only 
when modifications were made from the Mirsalis study involving homogen­
ization of the dosing formulation (1.133-1.136). These results suggested that
2,4-TDA was capable of causing genotoxic effects.
Micronucleus test
The micronucleus test is a simple, commonly used assay for measuring 
chromosome damage. Micronuclei, or Howell-Jolly bodies as they are known 
in the medical field, are very small nuciei-looking bodies composed of 
chromosomal fragments. These micronuclei arise from disruptions in the 
mitotic or meiotic process or as a result of chromosomes not separating totally 
at anaphase. Polychromatic erythrocytes (PCE), present in large numbers in 
the bone marrow of the rat or mouse, are commonly used for the assay. The 
micronucleus, which is retained in the polychromatic erythrocyte after expulsion
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of the main nucleus, can be observed with a microscope or detected with flow 
cytometry. Generally 1000 polychromatic erythrocytes per animal are 
evaluated for micronuclei (1.137,1.138).
A F344 and PVG rat bone marrow micronucleus test on 2,4-TDA had a 
negative outcome. The test was later repeated but at a dose toxic to the cells, 
making the interpretation of the weak positive result questionable (1.133). 
HGPRT/CHO test
One of the most common forward-mutation assays is the HGPRT/CHO 
test. This assay detects a single mutation occurring in the HGPRT 
(hypoxanthine guanine phosphoribosyltransferase) locus of Chinese hamster 
ovary cells. The HGPRT gene is located on the X chromosome. The gene 
produces an enzyme that catalyzes the reaction that converts hypoxanthine 
and guanine to IMP (inosine monophosphate) and GMP (guanosine mono­
phosphate). The basis of the test involves substituting a purine analog (usually 
6-thioguanine, 6GT) for the base which results in a lethal nucleotide when 
phosphorylated by the enzyme. If the HGPRT gene is inactivated by mutation, 
the cells are able to grow because the toxic metabolite is not produced. 
Mutagenicity is calculated by the number of 6GT resistant cells found after 
chemical exposure of the cell population. The HGPRT assay is able to detect 
both base-pair and frame-shift mutations. It is a sensitive and reproducible test 
and unlike the Ames test, uses mammalian cells. Problems with the test 
include standardization of protocol, long test times and metabolic activation 
needed for indirect-acting compounds (1.139).
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L5178Y TK+/- assay
Like the HGPRT locus, the TK locus is also associated with a salvage 
pathway. The TK locus is generally associated with the L5178Y mouse 
lymphoma cell line. The thymidine kinase (TK) enzyme catalyzes thymidine 
monophosphate (TMP) production from exogenous thymidine. Thymidine 
kinase (TK) producing cells are selected against by growing them in a medium 
containing the thymidine anologs, bromodeoxyuridine (BUdR) or 
trifluorothymidine (F3TdR). These analogs are phosphorylated then 
incorporated into the cellular DNA where they become toxic to the cells. Only 
cells deficient in thymidine kinase survive. If the TK gene is inactivated by 
mutation, the cells are able to grow because the toxic metabolite is not 
produced (1.140).
Coppinger et al. evaluated the mutagenicity of 2,4-TDA in cultured 
mouse lymphoma and Chinese hamster ovary cells (1.141). The assay was 
performed at both the TK and HGPRT loci for each line of cells. 2,4-TDA was 
found to be mutagenic in both cell lines at the TK locus. However, in the 
mouse lymphoma cells, the positive result only occurred without S-9 metabolic 
activation. Both cell lines were non-mutagenic at the HGPRT locus with or 
without S-9 activation. It appears from this study that the TK locus may be a 
more sensitive indicator than the HGPRT locus for the mutagenicity of TDA.
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Sex-linked recessive lethal test
The sex-linked recessive lethal test (SLRL) in Drosophila melanogaster 
was first used in the 1920's for testing the mutagenicity of radiation. Over the 
years numerous modifications have been made to the assay allowing it to 
detect mutations ranging from single base pairs to large chromosome 
aberrations in the X chromosome of the test subject. The test exposes wild- 
type males to a potential mutagen. Post exposure, these males are individually 
mated at 2-3 day intervals to 3-5 virgin females containing multiple inverted 
chromosomes with appropriate genetic markers. The F1 females from these 
matings should each have one X chromosome from a treated wild-type male. 
These females are then mated with the genetically altered males and the F2 
generations examined. If a lethal mutation occurred on the X chromosome of 
the F1 female, then the wild-type males will not be present in the offspring 
(1.142-1.144).
Drosophila melanogaster was one of the first systems used as an 
indicator of mutagenesis. The sex-linked recessive lethal test is thought to be 
a very sensitive and reproducible assay. 2,4-TDA was found to be weakly 
mutagenic by Blijleven etal. in the SLRL assay (1.142).
Dominant lethal test in rodents
A dominant lethal mutation is a mutation in a germ cell which causes the 
death of the first generation progeny. The dominant lethal test in rodents is a 
measure of embryo and fetal lethality in the offspring of a treated male. The 
death of the embryo generally occurs between the two-cell stage and
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implantation. These lethal mutations are almost always clastogenic in nature. 
Males are first treated with the suspected mutagen usually at the maximum 
non-toxic concentration. They are then placed into cages with untreated 
females for mating. Females are killed at a set time after mating and the uterus 
examined for living embryos and post-implantation deaths. Mutagenicity can 
be determined by an increase in dead implantations, an increase in the number 
of females with non-viable implants, or a decrease in the number of live 
embryos. This test is economical but is insensitive and has a high 
spontaneous background frequency and a non-linear response. Because the 
test is designed to detect clastogenic events, a potent mutagen is generally 
required in order to detect a frequency of response above the background 
level. The response obtained is often a result of multiple mutagenic events 
rather than an event at just one locus (1.145).
Soares et al. tested 2,4-TDA for mutagenicity in both the dominant lethal 
assay and sperm morphology test in DBA/2J mice. The treated males were 
subsequently mated to CD-1 females. The females were killed 17 days after 
initial exposure to the males and the uterine contents examined. The assay 
was negative as there was no indication of an increase in lethals over control 
values. In the sperm morphology test, there was no detectable increase in 
abnormal sperm over controls (1.146).
Sister chromatid exchange
This test indicates that a reciprocal exchange of genetic material has 
occurred between homologous sections of two sister chromatids on a
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chromosome. One assay method used involves exposing possible mutated 
cells to BUdR (5-bromodeoxyuridine), a thymine analog, then allowing one 
round of DNA synthesis to occur. A second round of DNA synthesis in the 
absence of BUdR is carried out with the result that only one of the sister 
chromatids in each chromosome incorporates the thymine analog. Staining of 
the genetic material allows visualization and counting of the number of 
exchanges occurring in the chromosomes (1.120,1.132,1.147-1.149).
Parodi et al. tested 2,4-TDA for mutagenicity in the sister chromatid 
exchange (SCE) assay using Swiss male mice (1.150). Results indicated a 
weak positive response in the induction of SCEs in bone-marrow cells. 
2,6-Toluenediamine 
Ames test
Although the 2,6-TDA isomer has not been studied as extensively as
2.4-TDA, it has also been subjected to multiple mutagenicity assays. As with
2.4-TDA, metabolic activation was required for mutagenicity in all Salmonella 
tester strains that were used. Tester strains TA98, TA100 and TA1538 all 
showed that 2,6-TDA displayed mutagenic activity when first subjected to 
metabolic activation. The non-activated compound showed no mutagenic 
activity in any of the tester strains (1.59,1.151 -1.153).
Unscheduled DNA synthesis (UPS)
An evaluation of 2,6-TDA in primary rat hepatocytes using the 
unscheduled DNA synthesis (UDS) assay showed negative results at multiple
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concentrations and 20-hour in vitro exposures (1.154). This negative result 
was confirmed in UOS studies earned out by George et at. and Mirsalis et al. 
(1.133,1.136).
Alkaline elution assay
In the alkaline elution assay, a test measuring DNA strand breaks, 
results were different for rat liver in vivo vs. in vitro exposures. Rats exposed to 
an in vivo high dose of 2,6-TDA (2000 mg/kg) gave a positive response in 
primary rat hepatocytes while an exposure at half that amount was negative. 
When primary rat hepatocytes were exposed in vitro to concentrations ranging 
from 1 to 10 mM results were again negative (1.154).
Micronucleus test
George et al. conducted the rat bone marrow micronucleus test using 
F344 and PVG rats on 2,6-TDA. Their data showed a dose related weak 
positive response in contrast to a negative response in bone marrow and liver 
obtained in young male albino Sprague Dawley rats by Allavena et al. (1.133, 
1.154).
Sister chromatid exchange
Sister chromatid exchange assay in CHO cells without S-9 metabolic 
activation produced a positive result at concentrations of 50-160 pg/ml. When 
the assay was conducted with S-9, the highest concentration tested (500 pg/ml) 
gave only a weak positive result (1.148). A summary of the test results for both
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the 2,4- and 2,6-TDA isomers are compiled in Table 1.2 and illustrate the 
responses to the various tests.
Correlation of mutagenicity to carcinogenesis
Mutagenicity of a chemical compound has been looked upon as a 
sentinel for potential carcinogenic activity. This is the rationale behind the 
mutagenicity testing of a compound before a large investment is made in 
production. However, a major problem with mutagenicity testing has been in its 
ability to correctly predict carcinogenic compounds from non-carcinogenic 
ones. The mutagenicity of a compound does not automatically translate into 
carcinogenicity, and by the same token, a carcinogenic compound may not be 
mutagenic in all assays. The 2,4-TDA isomer has been found to be carcino­
genic in rats while the 2,6-TDA isomer has proven negative (1.17,1.20,1.23,
1.24,1.59,1.155). The 2,6-TDA isomer is considered to be a genotoxic 
noncarcinogen. Because of its structure and positive responses in many short 
term mutagenicity tests, it would be expected to be carcinogenic in nature. 
However, as can be seen in Table 1.2, the known carcinogenic 2,4-TDA isomer 
is negative in many mutagenicity assays while the non-carcinogenic 2,6-TDA is 
positive.
Of all the mutagenicity tests performed, the Salmonella/microsome test 
is the most used as a widespread screening test. McCann et al. reported that 
90% of the carcinogens they tested in the Salmonella/microsome test were 
mutagenic while other researchers claimed between 78 and 95% correlation

















Table 1.2 Compiled results from a battery of mutagenicity tests on both 2,4- and 2,6-toluenediamine. 
Abbreviations: w=weak, Pos=positive, neg=negative. Tests are discussed fully in text.
Test Strain Activation
2 .4 -T D A
Results
2 ,6 -T D A
References
Ames 1537 +S9 Pos {171}
Ames 1538 +S9 Pos Pos {121,126,196}
Ames TA100 +S9 Pos/Neg Pos {89,121,171,196}
Ames TA98 +S9 Pos Pos {51,65,89,171,196}
Ames YG1024 +S9 Pos {51}
Alkaline elution wPos Pos/Neg {305,106}
Alkaline elution Neg Neg {310,106}
UDS Pos, w Pos Neg/Neg {106,146,154,260,317}
Micronucleus Neg w Pos/Neg {106,146}
TK/CHO +/-S9 Pos {91}
TK/mouse lymphoma -S9 Pos {91}
HGPRT/CHO +/-S9 Neg {91}
HGPRT/mouse lymphoma +/-S9 Neg {91}
SLRL wPos {92}
Dominant lethal Neg {193}
Sperm morphology Neg {193}
S.C.E. w Pos {309}
S.C.E. -S9 Pos {351}
S.C.E. +S9 wPos {351}
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(1.124,1.156-1.158). Fassina etal. looked at the induction of 6-thioguanine 
resistant mutants in V79 Chinese hamster cells by a group of 12 carcinogenic 
aromatic amine compounds of differing oncogenic potency. Results showed 
there was no correlation between the carcinogenic potency and the mutagenic 
response obtained in this test system (1.159). In fact, 2,4-TDA, a potent 
carcinogen had a negative response in inducing the mutant cells. The 
dominant lethal test in rats, a very insensitive assay, showed no evidence of 
mutagenicity in the carcinogenic 2,4-TDA compound. Also, there was no 
indication of abnormal sperm formation in exposed rats (1.146). The 2,6-TDA 
isomer, a non-carcinogen, gave positive results in the SCE and chromosome 
aberration tests indicating a probable clastogenic effect. It also consistently 
produced a positive result in the Salmonella/micosome test (1.59,1.148, 
1.151-1.153).
These examples are given to illustrate that no one mutagenicity test 
should be relied upon in the determination that a compound is mutagenic or 
carcinogenic. Many factors must be considered in the evaluation of any 
compound as to how extensive the testing procedure must be. For example, 
how much of the compound will be produced? Will people or animals be 
directly exposed? Will environmental contamination be a factor? Is the 
compound stable and what, if any, are the breakdown products? As is always 
the case, monetary factors will be of concern. The Salmonella assay is 
relatively inexpensive while large scale long-term animal testing can be a 
significant investment, even for a large corporation. However, if one relies just
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on the Salmonella test, a false positive result could prematurely condemn a 
relatively safe and possible valuable compound from ever reaching the market.
Our present state of knowledge about mutagenicity and carcinogenicity, 
decreasing finances for extensive research and testing, and concerns about 
the use of animal models for test protocols leaves researchers with little choice 
but to rely on mutagenicity tests that may not always be consistent with results 




Ever since an association between chemical exposures and the onset of 
cancer was established in the late 1700's, there has been an active quest for 
the mechanisms involved in chemical carcinogenesis (1.2). In most areas of 
the world, cancer is a leading cause of death. Cancer generally refers to any 
disease caused by uncontrolled growth and metastasis or spread of abnormal 
cells. Even though industrial chemicals are a major focus in the cause of 
cancer, there are many other known and often more serious cancer causing 
agents. Life style choices regarding alcohol, tobacco, diet and exposure to 
excessive UV radiation account for the majority of new cancer cases each year. 
Fortunately, money spent on educating the public has the potential of 
producing large scale reductions in future cases of cancer or at least ensures 
that the choice can be made by the public. Despite the untold billions of dollars
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gleaned from the effort, the fact remains that approximately one out of every 
five deaths occuring in the United States results from cancer (1.160).
Lifestyle carcinogen exposures are generally elective in nature. There 
are however, many cancer causing chemical agents, both organic and 
inorganic, that the general public may contact through environmental, occu­
pational or medical exposure. Because the volume of material on chemical 
carcinogenesis is immense, the scope of this review will focus on arylamine 
compounds and on 2,4- and 2,6-toluenediamine.
Carcinogenic agents can be classified according to structure, mode of 
action or type of tumor produced. Most chemical carcinogens are classified 
according to their reactions with cellular macromolecules and whether or not 
the compound is active in the parent form or must be biotransformed to an 
active electrophile. A gentoxic chemical is one that is capable of chemically 
interacting with and altering the DNA within a cell. Genotoxic agents can be 
either activation-independent (direct acting) or activation-dependent (indirect- 
acting) chemicals. Direct acting carcinogens do not require metabolic 
activation in order to interact with macromolecules. These agents are often 
simple alkylating agents such as chloro-ethyl ether and methylnitrosourea 
(MNU) or inorganic substances such as nickel and cadmium. Activation- 
dependent chemicals become reactive electrophiles through biotransformation 
reactions. An epigenetic carcinogen does not act directly on DNA but rather
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involves some other biological mechanism in order to transform a normal cell 
(1.112,1.161,1.162).
The reaction between the carcinogenic aromatic amine electrophile and 
a cellular nucleophile is primarily Sn2 in nature (1.105,1.112). An Sn2 
(bimolecular nucleophilic substitution) reaction is characterized by the 
displacement of a leaving group from an electrophilic compound when attacked 
by a nucleophile. Before this displacement occurs, all the groups are involved 
in the formation of a planar transition state. As the leaving group departs, an 
inversion of the sterochemistry of the electrophilic compound results.
Indirect-acting carcinogens must be activated or biotransformed by 
enzyme systems in order to form an electrophile capable of a cellular 
interaction. Common examples of these carcinogens are the common 
polycyclic aromatic hydrocarbon (PAH) and aromatic amine compounds.
These compounds are often stable entities until acted upon by mammalian or 
bacterial enzyme systems producing either a detoxified or toxic species.
The mechanisms of carcinogenesis are extremely complex but some 
steps in the process have been elucidated. In order to characterize the 
neoplastic process, a multistage paradigm based on mouse skin models is 
generally employed. This model separates the process into initiation and 
promotion sequences. A third stage, the progression sequence, is considered 
by some to be a separate entity while others consider it to be part of promotion 
(1.162-1.165).
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Initiation
The initiation process is the sequence of steps in which a normal cell is 
converted into a neoplastic one. Initiation probably represents a mutagenic 
event caused by very low levels of carcinogenic agents (1.112). This process 
is thought to occur rapidly and appears to be irreversible (1.14). In order for 
the cell to undergo this transformation, the cellular constituents must first 
interact with the carcinogenic chemical. The carcinogenic potential of aromatic 
amine compounds varies with the ring system and the type and number of 
substitutions appearing on those rings. For example, a methyl group placed 
ortho to an amino group on the ring will often amplify the carcinogenic potential 
of the compound while ring hydroxylation tends to increase the detoxification 
process. Substitutents which block ring hydroxylation, increase lipid solubility, 
or influence other ring substitutents ability to react can greatly influence the 
carcinogenic potential of the chemical (1.166).
As previously mentioned, most aromatic amine compounds are indirect- 
acting in nature, that is, they must be activated from the parent compound to a 
proximate or ultimate carcinogen before they become reactive. This is evident 
for most arylamines because tumor formation generally occurs at sites not 
related to the route of administration (1.162). For most arylamines, this 
requires the formation of a N-hydroxy derivative usually catalyzed by the 
cytochrome P450 family of oxidative enzymes. These N-hydroxy arylamine 
electrophiles often either bind directly to DNA or form the basis for further
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metabolic activation to other reactive metabolites or ultimate carcinogens 
(1.15,1.64,1.166-1.168). The N-hydroxylated metabolites are not the only 
reactive metabolites, but they have been known to engage in nonenzymatic 
reactions forming covalent bonds with cellular macromolecules (1.168). 
Fortunately, the reactivity of many of these N-hydroxylated metabolites to 
nucleophiles appears to be quite low at neutral pH. However, the addition of a 
second metabolic activation step involving in vivo esterification of the N- 
hydroxy group often results in a much more carcinogenic and reactive 
electrophile, even at a neutral pH (1.15,1.79,1.167).
These electrophiliccarcinogens, compounds which are relatively 
deficient in electrons, are able to react with nucleophiles having electrons 
available for covalent binding. Nucleophilic sites are commonly found in DNA, 
RNA, and proteins (1.112). Selected oxygen and nitrogen atoms on DNA and 
RNA as well as sulfur, oxygen and nitrogen atoms in proteins are the sites 
commonly involved in these reactions. Parent and precarcinogen compounds 
are often metabolized to more than one metabolite resulting in multiple ultimate 
carcinogens. With the multiplicity of nucleophilic sites available, it is not un­
usual to observe different adducts from a single parent compound (1.14,1.162).
Kadlubar et al., working with N-hydroxyarylamines, showed that 
enzymatic glucuronidation of 1-and 2-naphthylamines and 4-aminobiphenyl 
resulted in N-glucuronidated metabolites which were subsequently excreted in 
the urine. Their study indicated that the normally acidic conditions in both
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human and dog urine resulted in acid hydrolysis of the N-glucuronides forming 
N-hydroxylamines. Subsequent elimination of the hydroxyl group on the 
nitrogen as water under protonating conditions produced extremely reactive 
lipophilic nitrenium ions capable of covalent binding to macromolecules in the 
bladder epithelium (1.64). Results from studies like this, indicate the 
importance of metabolic acitivation in the initiation process of most aromatic 
amine compounds.
Once a reactive species has been generated by metabolic activation, it 
may act directly on DNA (genetic effect) or act through some other biological 
pathway (epigenetic effect) to initiate a carcinogenic response (1.112).
Genetic effect (DNA adduct formation)
A reactive electrophilic carcinogen is capable of forming covalent bonds 
with almost all cellular macromolecules having a nucleophilic reaction site, 
resulting in what is commonly called an adduct (1.169). Adduct formation with 
RNA and proteins may produce toxic effects because these molecular products 
may compromise the function or pool size of critical cellular proteins. For 
example, proteins involved in gene expression, methylation enzymes or DNA 
repair can alter cellular function or disrupt damage control efforts (1.162,1.170- 
1.173).
Cellular DNA is often the target of covalent addition. These DNA 
adducts can have serious ramifications because of the critical role that DNA 
plays in cellular functions and cell reproduction. Fortunately multiple enzyme
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systems exist for the removal and repair of DNA damaged by adduct formation 
and in most cases the damaged cell will fully recover (1.101,1.174). However, 
DNA repair systems are not infallible and occasionally the system can become 
overwhelmed by steady-state or an intense exposure to electrophilic agents 
resulting in adducts which are not removed in an appropriate time frame.
With aromatic amines, DNA adduct formation can occur at nucleophilic 
sites on both deoxyguanosine (dG) and deoxyadenosine (dA). The N2-dG, O6- 
dG, C8-dG, C8-dA, and N6-dA derivatives are a few of the adducts observed 
from different arylamine compounds with the C8-dG and N2-dG being the most 
prevalent. The C8-dG or N-(deoxyguanosin-8-yl) derivative is thought to 
originate as a N7-dG derivative, which when deprotonated, undergoes a 
Stevens-like rearrangement producing a final C8-dG adduct (1.13,1.112,
1.167).
The importance of persistent in vivo DNA-arylamine adducts can be 
seen in the devastating consequences of gene mutations and cancer. DNA 
adducts are capable of inducing genetic mutations. Beland et al. looked at 
DNA adducts of the arylamines N-hydroxy-acetylbenzidine, N-hydroxy-2- 
aminofluorene, N-hydroxy-4-aminobiphenyl, and N-hydroxy-2-napthylamine 
using Salmonella typhimurium strains TA1535 and TA1538. Results indicated 
that a linear correlation existed between C8-deoxyguanosine adducts and the 
induction of frameshift mutations in the bacterial DNA system (1.106).
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Aromatic amine adducts including C8-dG, N2-dG and N6-dA may induce 
mispairing by changing the normal base-sugar conformation from anti to syn 
with resulting helical distortion. Transformation from the normal B-DNA to a 2- 
DNA conformation secondary to the DNA helix rotation is thought to occur 
(1.112,1.168,1.175). These changes can result in unusual base-pair 
alignments allowing bases that could not normally pair to form necessary 
hydrogen bonds.
If not corrected by DNA repair mechanisms, a gene mutation can persist 
during subsequent DNA replication. Bulky adducts on the DNA can also block 
DNA polymerase from progressing along the DNA double helix resulting in a 
possible deletion mutation (1.11,1.112).
DNA adduct formation is also associated with the initiation of carcin­
ogenesis evidenced with the activation of oncogenes and suppression of 
certain tumor-suppressor genes (1.170,1.172,1.173). Cancer formation, in 
many situations, is thought to result from the accumulation of damage to the 
genes in a single cell. The damage to the genetic code affects the ability of the 
cell to restrain normal cell growth and reproduction resulting in tumor formation. 
Ras genes, for example, are proto-oncogenes that are expressed at low levels 
in most cell types and are necessary for normal cell functions. They encode 
GTP-binding proteins involved in control of cell proliferation and differentiation. 
Point mutations are responsible for turning these normal genes into oncogenes 
by blocking an intrinsic GTPase activity preventing normal deactivation of the
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protein. Ras oncogenes have been isolated in almost all human cancers 
leading to speculation that they might be involved in the initiation process of 
neoplasia especially during times of cell proliferation. Other proto-oncogenes 
are known to be involved as signal transduction elements, protein kinases,
DNA binding proteins, and growth factors. Once these genes are activated to 
oncogenes, they have the ability to transform cells.
A similar situitation is seen with the p53 tumor suppressor gene. A 
simplified version of the function of the gene is that it normally blocks the 
division and growth of cells harboring damaged genes in which it is present by 
sending them to an apoptotic pathway. When the p53 gene is mutated, the 
cells are allowed to divide and grow with resulting tumor formation (1.162, 
1.172).
Covalent Binding of Toluenediamine to DNA
2,4-Toluenediamine irreversible binding, both in vitro and in vivo, to liver 
protein, RNA and DNA has been evaluated. In 1979, Aune et al. examined 
both in vitro and in vivo covalent binding (1.123). Incubation of liver micro- 
somes, NADPH and oxygen with tritiated 2,4-TDA resulted in products 
covalently bound to microsomal proteins. However, when calf thymus DNA 
was similarly incubated in microsomes, no indication of irreversible binding with 
TDA was found. Male Wistar rats were administered i.p. injections with 100 
mg/kg tritiated 2,4-TDA and sacrificed 4 hours later. Covalent binding of TDA 
to liver and kidney protein at 268 and 130 pmol/mg protein, respectively, was
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found. Liver ribosomal RNA also contained covalently bound TDA at 54 
pmol/mg. Interestingly, there was no evidence of covalently bound labeled 2,4- 
TDA to liver DNA. These DNA results were surprising in light of the RNA 
binding and the fact that 2,4-TDA is both mutagenic and carcinogenic. The 
authors speculated that possibly unstable adducts were lost in the DNA 
extraction process and therefore went undetected.
A few year later, Furlong et al. looked at the covalent binding of both
2.4- and 2,6-TDA to rat liver DNA (1.176). Hepatocytes from adult male F344 
rats were allowed to incubate with 100 pM [14C]-labeled 2,4-TDA for 0, 1,4, 8, 
and 24 hours. Isolated DNA showed a time-dependent linear increase of 
covalent binding peaking at about 700 pmol/mg at 24 hours. When repeated 
with both 2,4- and 2,6-TDA using the 24 hour time point, covalent DNA binding 
was measured at 960 and 246 pmol/mg DNA, respectively. The DNA binding 
was significantly lower for 2,6-TDA than 2,4-TDA which would be expected 
since the 2,6-isomer is considered to be non-carcinogenic. The isolation and 
identification of individual adducts was not attempted in the study.
Using “ P-postlabelling techniques, La et al. looked for covalently bound
2.4-TDA in liver, mammary gland, kidney and lung (1.177). Fischer-344 rats 
were administered a single i.p. injection of 2,4-TDA at doses ranging from 4.1 
to 2046 pmol/kg body weight. DNA adducts were found in all four tissues with 
differences in adduct quantity noted. Tissues showing greatest carcinogenic
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responses, liver and mammary gland, had the greatest number of adducts. At 
the highest concentration (2046 pmol/kg), 97 pmol/mg DNA were recovered.
Compared to previous in vitro results, the postlabelling experiment 
conducted at higher TDA concentrations resulted in lower DNA adduct yields. 
These results should be considered suspect as a review of the dosing 
calculations show that the reaction mixture contained only 14 pmol (100 pCi) of 
labeled ATP for binding to 6 nmol (2 pg) of DNA. The deficient amount of label 
relative to substrate could account for the lower covalent binding results 
obtained in the study.
Using amine-group specific monoclonal antibodies, Citro et al. showed 
that 80% of the 2,4-TDA-DNA adducts involved the p-amino group while 10% 
were attributable to the o-amino group (1.178). Metabolic activation of 2,4-TDA 
with S9-mix produced DNA adducts only at the poly-d(G) and poly-d(G-C) 
bases.
Epigenetic effects
Chemicals that interact with biological activities other than direct 
interaction with cellular DNA as a basis for carcinogenicity are termed epi­
genetic carcinogens. Many of these agents have the capacity to act as 
promotors, increase DNA synthesis, or affect mitosis and cellular reproduction. 
Many can interfere with or mimic hormone activity, cause immunosuppression 
or induce peroxisome proliferation (1.162).
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One prominent example of an epigenetic factor is methylation of the 
cytosine bases (5-methylcytosine) in DNA. Methylation of a gene is thought to 
be part of the control mechanism used by the gene in preventing or limiting 
expression of a protein product (1.171). The methylation characteristic of a 
gene is a somatic genetic trait. When DNA is replicated, a hemimethylated 
DNA strand is produced. In order to maintain the original methylation status, a 
maintenance methylase enzyme converts these hemimethylated strands into 
methylated strands using the cofactor S-adenosyl methionine. A mutation 
produced in the methylase enzyme with resulting hypomethylation of promotor 
sites or other controlling areas in the gene allows production of the protein 
product via increased transcriptional activity (1.170,1.179,1.180).
It becomes quite evident that the mechanisms leading to the initiation of 
neoplasia are diverse. Usually more than one event occurs in order for a cell 
to become neoplastic. Whatever the event or events are, the end result is a 
transformed cell with a different phenotype. These transformed cells may or 
may not progress to tumors, depending on control by adjacent cells through 
cell-to-cell communications involving gap junctions (1.162).
PromQtiQn
In the study of initiation and promotion, compounds are often divided 
into complete and incomplete carcinogens (1.164,1.181). A complete 
carcinogen is able to induce neoplasia without additional requirements such as 
other added agents or specific conditions. Incomplete carcinogens need the 
help of other agents or specific conditions in order to promote tumor activity.
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Because incomplete carcinogens require additional agents to induce tumor 
formation, they are routinely employed in the study of the promotional aspects 
of carcinogenicity.
The evolution of transformed cells to neoplastic cells can be separated 
into conversion and propagation stages according to Boutwell et al. (1.182). 
Little is known about the events occurring during the conversion step. The 
traditional model of conversion involves the transformation of an initiated cell 
into a dormant tumor cell. The conversion step, demonstrated in NMRI mouse 
skin models, was found to be reversible with about a 10 week half-time period 
(1.183). This reversal ability separated it from the irreversible initiation stage of 
carcinogenesis.
The propagation step centers around the activation of converted 
“dormant tumor cells” with subsequent clonal expansion of those cells. In most 
situations, propagation requires multiple exposures of a promotion agent and is 
often a reversible process. These agents are usually tissue specific, 
non-mutagenic and need not be metabolically activated in order to promote 
tumor production (1.165). Croton oil was one of the first substances found to 
act as a promoting agent. The most widely used compounds in the study of 
promotion mechanisms have been the phorbol esters. These diterpene esters 
can be very potent promotors depending on the molecular structure of the 
compound. The more potent promotor molecules generally contain both 
lipophilic and hydrophilic aspects in their structure causing them to be 
sequestered in cellular membranes (1.16,1.165). Most of the research related
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to promotion has been conducted in the mouse skin model with these agents, 
especially TPA (12-O-tetradecanoylphorboM 3-acetate) (1.163,1.184,1.185).
In addition to these diterpene esters, many other compounds have been used 
as promoting agents including fatty acids, fatty acid methyl esters, phenols, 
linear alkanes, bile acids, cigarette smoke condensate, DDT, PCB, hormones, 
saccharin, cycla-mate and phenobarbital, to name afew(1.163,1.165).
Over the years, the majority of data compiled on promotion has been 
gleaned through research using the mouse skin model. The mechanism of 
actions of phobol ester promotors are complex but are becoming clearer.
The repeated application of phorbol esters on mouse skin generally 
resulted in symptoms such as inflammation, erythema, edema, and hyperplasia 
(1.165). These skin changes, however, are the types of reactions often seen 
with non-promoting chemicals after topical application. Studies on the cellular 
and molecular aspects of phobol ester-skin interactions provided the infor­
mation needed for a deeper understanding of the promotion process.
The phorbol ester receptor site was identified by Ashendel et al. as a 
calcium phospholipid-dependent protein kinase C (1.186). The binding of 
phorbol esters to protein kinase C activates the enzyme with subsequent 
phosphorylation of multiple substrates resulting in a myriad of biochemical 
changes that occur with promotion. Second mesengers such as diacylglycerol 
affect cellular responses by binding to and activating a protein kinase. The 
phorbol ester is thought to mimic the actions of the second messenger 
diacylglycerol.
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Work by Hennings and Boutwell showed that promotors are capable of 
increasing both DNA and RNA synthesis (1.187). Changes in protein synthesis 
not related simply to increased cell division or cellular hyperplasia are also 
found in skin treated with promotor agents.
Ornithine decarboxylase (ODC), a polyamine biosynthesis rate-limiting 
enzyme, has been found to be induced by the application of TPA as well as 
other promotor agents. This enzyme is associated with tissue undergoing rapid 
cell division. Weeks et al. showed that TPA was able to increase ODC acitivity 
in mouse skin more than 100-fold upon application of the promotor. They also 
showed that epidermal putrescine levels were promotor dose-dependent and 
correlated with the size and growth rate of papillomas (1.112,1.184). It appears 
that promotor agents have the ability to increase ODC activity with a subse­
quent increase in polyamine synthesis. The regulation of these polyamines 
seems to play a relevant role in the mechanism of tumor formation.
Prostaglandin hormones have also been found to play a role in 
carcinogenesis (1.185). These hormones are synthesized from essential fatty 
acids in response to different physical, chemical and hormonal factors. 
Arachidonic acid, a component of the phospholipid cellular membrane, is 
released by the enzymatic action of phospholipase A^ The resulting free fatty 
acid is ultimately transformed into prostaglandin by prostaglandin synthetase. 
The prostaglandins are involved in multiple calcium-dependent regulatory 
enzymes including ATPase, protein kinase, phosphodiesterases and the 
cyclases.
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The role of prostaglandin in the promotion of neoplasia is still rather 
obscure. It is however, thought to influence at least some of the events 
responsible for tumor promotion. The tumor promotor TPA has been shown to 
produce a significant increase in PGE levels in topically treated mice (1.188). 
Also in vitro ODC activity induced by TPA is enhanced by prostaglandin PGE2 
and inhibited by indomethacin (1.185).
The inflammatory response that occurs in mouse skin after the 
application of phorbol esters appears to be a vital element in the carcinogenic 
process. Fischer et al. found a marked increase in vascular permeability in the 
skin of mice treated with TPA (1.189). This increased permeability is probably 
the result of released histamine binding to histamine receptors in the skin. This 
binding produces contraction of the endothelial cells resulting in exaggerated 
gaps between cells allowing the release of edema-forming plasma. In the 
study, an increase in the permeability and number of papillomas was found to 
be dose-dependent with TPA administration.
The phorbol ester TPA has been shown to produce alterations in a 
cellular plasma membrane Na7H+ exchange system. Rosoff et al. found that 
70273 pre-B-lymphocyte cell line exposure to TPA resulted in increased [Na+], a 
rise in cytoplasmic pH and a differentiation of the cell line. These ion transport 
alterations may be the result of protein kinase C activation caused by phorbol 
ester binding (1.164).
Inhibition of cell-to-cell communication has been attributed to exposure 
of phorbol esters. Low molecular weight substances, up to 1200 daltons, which
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regulate growth functions are able to pass from one cell to another through 
specialized cell membrane gap junctions (1.190). Klann et al. found that gap- 
junctional intercellular communication capacity decreased with successive 
stages of mouse skin carcinogenesis (1.191). It appears as though these low 
molecular weight substances may be prohibited from transferring the factors 
needed to prevent or inhibit the growth of initiated cells (1.192).
Studies indicate that free radicals are important in all stages of 
carcinogenesis. Free radicals can be generated either directly or indirectly by 
some carcinogens and tumor promotors (1.193). The inhibition of neoplasia by 
antioxidants has been shown to occur with a variety of carcinogens as well as 
radiation in multiple species and targets (1.181,1.194). Slaga et al. found that 
the covalent binding of B(a)P and DMBA to epidermal DNA could be inhibited 
by the widely used antioxidant food additives, butylated hydroxytoluene (BHT) 
and butylated hydroxyanisole (BHA) (1.181,1.195). Studies have shown that 
inhibition of neoplasia by antioxidants and related compounds can occur at the 
intiation (1.181,1.196) or promotion stage (1.181,1.196-1.199) as well as the 
progression stage (1.181,1.200,1.201).
Carcinogenicity testing of 2.4-Toluenediamine
As mentioned before, industrial uses of 2,4-TDA are primarily as 
intermediates in the synthesis of toluene diisocyanate, a cross-linking agent in 
the production of polyurethane foam. However it has also been used as a hair 
dye component, dyes in textiles, wood stains and pigments (1.17-1.19).
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Because of its worldwide use and extensive worker exposure, TDA has been 
and still is the focus of study by researchers. Recently, the discovery of low 
levels of TDA leaching out of polyurethane-covered silicone gel implants has 
spurred new research into toluenediamine carcinogenicity (1.202-1.205).
In a 1955 study, Umeda provided one of the first indications that 
toluenediamine might be carcinogenic (1.206). Twenty adult rats were injected 
subcutaneously on a weekly basis with a 0.4% solution of 2,4-toluenediamine 
in propylene glycol. After 28 injections, the 9 surviving rats had all developed 
subcutaneous rhabdomyosarcomas at the site of injection. However, Umeda 
found no metastasis and no internal organ changes in any of the rats.
Propylene glycol was questioned as possibly enhancing the carcinogenic 
potential of TDA.
In a 1969 study, Ito et a/, fed male Wistar rats diets of 0.1 or 0.06 
percent 2,4-toluenediamine for 36 weeks (1.23). One hundred percent of the 
rats fed the 0.1% TDA developed multiple hepatocellular carcinomas with 66% 
of these having metastatic lesions in lymph nodes, lungs, omentum or 
epididymis. The 0.06% group also developed multiple liver tumors in 64% of 
the rats with subsequent metastasis in the lymph nodes and omentum. In both 
groups, the primary tumors were only carcinomas of hepatic origin. As a direct 
result of this study, oxidation activated human hair dyes containing 2,4-TDA 
were removed from the market in 1971.
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The next two studies were conducted with topical applications of 2,4- 
TDA. Burnett et al. looked at the recently banned oxidation activated hair dyes 
containing 2,4-TDA (1.207). When applied topically to male and female Swiss 
Webster mice once a week or every other week for 18 months, no evidence of 
toxicity or carcinogenicity was seen. Giles et al. applied 0.2% and 0.6% 
solutions of 2,4-TDA to Swiss-Webster mice of both sexes in a 2 year skin- 
painting study (1.208). Even though these mice had a high spontaneous 
incidence of lung cancer, there were no significant differences in lung tumors 
over control groups. There were also no significant differences in skin tumors 
over control groups except for the positve controls. The results of both topical 
studies were in contrast to the outcomes obtained by Umeda and Ito.
Bridges et al. (1.209) were critical of the dermal study by Giles et al.
They concluded that statements pertaining to the noncarcinogenic nature of
2,4-TDA relative to mouse skin and lung cancer were misleading and possibly 
wrong due to small sample sizes and extremely high spontaneous cancer rates. 
They recommended that the study be repeated with adequate sample sizes.
In 1978 Weisburger ef al. conducted long-term toxicity tests on 2,4-TDA 
along with numerous other aromatic amines in both male Sprague Dawley rats 
and male and female HaM/ICR mice (1.210). Compounds were administered in 
the diet for approximately 24 months. The 2,4-TDA was dosed at both 250 and 
500 mg/kg (250 and 500 ppm) of diet. Male rats had a significant increase in 
subcutaneous fibromas plus an increased incidence of liver tumors. The study
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also resulted in rats with multiple tumors. Some of these multiple tumors 
involved a fibroma along with a transitional cell carcinoma, pituitary, skin, lung 
or thymic tumor. Treated mice showed no significant differences from controls 
but did show numerical increases in hepatocellular carcinomas and vascular 
tumors.
Another long term oral study was carried out on male and female F344 
rats by Cardy (1.211). Doses of 50 and 100 ppm were fed to the rats for a 
period of 2 years. Results indicated a significant increase in benign plus 
malignant liver neoplasms in males compared to the negative control group.
The females had an increased incidence but it was not significant. A new 
finding was the significant increase in benign and malignant mammary tumors 
in the female rats seen in both high and low dose groups. Lung tumors, 
mesotheliomas, pancreatic acinar and islet cell adenomas, subcutaneous 
fibromas and fibrosarcomas were also found but not at significant levels. The 
study also revealed significantly increased preneoplastic liver lesions and 
chronic renal disease in the treated rats. The mammary gland tumors raised 
new questions about the possible association of breast cancer and oxidation 
activated hair dye use by women.
A 1979 study by Reuber (1.212) was carried out on B6C3F, male and 
female mice using 2,4-TDA. Doses of 100 and 200 ppm were fed to the rats for 
a period of 100 weeks. High dose results showed 39% of females and 27% of 
males developed liver carcinomas. Low dose results revealed 30% of females
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and 32% of males developed liver carcinomas. None of the female controls 
developed liver carcinomas while 25% of the males did. Liver carcinomas were 
significantly elevated for female mice compared to controls while male mice 
showed no significant differences.
In 1979, the National Cancer Institute released the results of a bioassay 
on 2,4-toluenediamine fed to both F344 rats and B6C3F1 mice (1.20). Rats 
were dosed with 2,4-TDA at 125 or 250 ppm for 40 weeks. The low dose group 
was then dropped to 50 ppm until 63 weeks or time of death. The high dose 
group was decreased to 100 ppm and euthanized at an earlier time period.
Mice were dosed at either 100 or 200 ppm for 101 weeks. Both male and 
female rats showed dose-related incidences of hepatocellular carcinomas that 
were significantly different from control groups. Incidences of mammary gland 
carcinomas or adenomas in females were also dose related and highly 
significant compared to control rats. Male rats also showed a dose related 
incidence of subcutaneous fibromas that were significantly greater than the 
control group. Results from the mouse study showed a significant increase in 
both lymphomas and hepatocellular carcinomas in females. There were no 
significant increases in tumors in the male population compared to controls.
The exposure of workers to TDI (toluene diisocyanate) and associated
2,4-TDA and the results of numerous carcinogenicity studies prompted the 
National Institute for Occupational Safety and Health (NIOSHA) in 1991 to 
recommend that all isomers of both TDI and TDA be regarded as potential
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occupational carcinogens. They also recommended that worker exposure be 
limited to the lowest feasible concentrations of these compounds (1.213).
The conflicting outcomes regarding 2,4-TDA in long term high dose oral 
and subcutaneous studies compared to topical studies carried out at expected 
exposure concentrations must be addressed. Topical studies showed no 
evidence of carcinogenicity or toxicity at those expected exposure concen­
trations. Carcinogenicity was not elicited until massive doses were adminis­
tered to animals over long periods of time in routes of administration that would 
be unlikely in most situations. The effects of gut bacteria, pH, first-pass liver 
metabolism and possible effects on nutrients are just a few of the major 
differences between oral and topical administration. The most likely occu­
pational exposure scenario involves long- term, lovtKlose oral and dermal 
exposure. Questions and concerns about the type and relevance of 
carcinogenesis testing required by regulatory agencies has been debated for 
years.
A prime example about the extrapolation of high-dose, long-term animal 
studies to extremely low-dose, long-term human exposure is seen in women 
with polyurethane-covered breast implants. Polyurethane-sponge-covered 
silicone gel implants are hydrolyzed in vivo to the reactive monomers 2,4- and 
2,6-toluenediisocyanate which are then converted to 2,4- and 2,6-toluene- 
diamine (1.205). These degradation products have been detected in plasma 
and urine for many years after implantation. TDA has also been found
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covalently bound to plasma proteins allowing them to be used as biomarkers in 
these patients (1.204). In one study, plasma levels of TDA ranged from 0.4 to 
4 ng/ml plasma. These plasma levels were similar to those found in factory 
workers producing polyurethane products (1.204). Urine levels of TDA were 
also found to be consistant at very low levels over long time periods (1.202, 
1.203).
Basing the added risk of carcinogenesis from these implants from 
extrapolated rat and mouse studies leaves a degree of uncertainty. The effects 
of long-term or life-long low-dose exposures may never fully be known. 
Ultimately, society will have to determine what exposure risks it is willing to 
tolerate, not only for TDA but for all manufactured chemicals and products. 
Carcinogenicity testing of 2.6-Toluenediamine
The compound 2,6-TDA is a by-product in the manufacture of the 
carcinogen 2,4-TDA. It is extensively used in the syntheisis of toluene 
diisocyanate (TDI), dyes, foams, and elastomers and therefore has the 
potential for occupational exposure. The fact that 2,6-TDA is a known mutagen 
and its close structural relationship to the carcinogenic 2,4-TDA prompted the 
NCI to test the compound as part of its Carcinogenesis Testing Program.
In 1980, the National Cancer Institute issued the results from this study 
on 2,6-toluenediamine dihydrochloride (1.155). In this study male and female 
F344 rat were administered either 250 or 500 ppm 2,6-TDA in the diet for 103 
weeks. Male and female B6C3F1 mice were treated with 50 or 100 ppm of the
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agent for the same time period. The study showed that 2,6-TDA was not 
carcinogenic in either dose range for both rats and mice. There was, however, 
a significant weight gain depression of 27% and 17% for high-dose and low- 
dose female mice, respectively.
Conclusion
Results of multiple research studies on both 2,4- and 2,6-toluenediamine 
are fairly conclusive. 2,4-TDA is indeed both a mutagenic and carcinogenic 
compound while 2,6-TDA is mutagenic but not carcinogenic. Differences in 
carcinogenicity in these very similar compounds may be due in part to 
differences in biotransformation. Both compounds should be treated as 
hazardous to both animal and human populations and attempts should be 
made to limit exposure.
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CHAPTER 2
OETDA: PHYSICAL CHARACTERISTICS AND 
ANALYTICAL METHODS OF DETECTION
Introduction
The compound 2,4-toluenediamine (TDA) is widely used in industry as 
an intermediate. Its primary use is in the synthesis of toluene diisocyanate, a 
cross-linking agent in the production of polyurethane foam. It is also used as 
an intermediate in the synthesis of dyes used in textiles, wood stains and 
pigments (2.1-2.4).
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is a compound 
utilized as a polyurethane chain extender in reaction injection-mold 
applications. DETDA also has uses as a curing agent for polyurethanes and 
epoxies, as an antioxidant, lubricant, wire coating and as a replacement for 
more toxic industrial compounds, such as MOCA (4,4'-methylenebis-2- 
chloroaniline) and toluenediamine. DETDA has been manufactured by 
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years 
under the name Ethacure®100 (2.5). Through a proprietary process, Ethacure 
is synthesized from toluenediamine. It is commercially supplied as a mixture of 
isomers with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4- 
diamine (2,4-DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA) 
and 0.5-3% dialkylated m-phenylenediamine.
Results from a two-year feeding study of DETDA in rats showed 
effects on the pancreas, liver, thyroid and eyes as well as increased tumors in
105
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the liver and thyroid glands of male rats (2.5). These findings, along with the 
structural similarity to the known mutagenic noncarcinogenrcarcinogen pair 2,6- 
and 2,4-toluenediamine (TDA), dictated the need for a metabolic study of the 
DETDA mixture (2.1,2.6,2.7). DETDA was expected to be absorbed, 
distributed, metabolized and excreted in a similar manner to TOA. 
Biotransformation reactions were expected to produce metabolites similar to 
those found with TDA.
In order to conduct such a study, analytical methodology was required. 
In the development of these analytical methods of detection and quantitation, 
certain physical characteristics of the compounds of interest needed to be 
known. For example, the pK, values of a compound are essential information 
used in thin layer, HPLC and GC method development. Extinction coefficient 
and UV absorption data are used in determining the concentration of a solution 
and the best wavelength for monitoring. In the case of Ethacure, these 
characteristics were not defined.
Because Ethacure and 2,4-TDA are structurally similar (Fig. 2.1), it 
was expected that pK„ values and absorption characteristics would be 
comparable. Since Ethacure is a mixture of isomers (primarily 2,4-DETDA), 
characteristics were determined using the mixture rather than individual 
isomers. Therefore pK, and extinction coefficient values are representative of 
Ethacure and not DETDA alone.
To detect, identify, and quantify DETDA and associated possible 
acetylated metabolites (see Chapter 3 for synthesis of standards),


















Figure 2.1 Chemical structures of DETDA and TDA isomers.
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chromatography methods had to be established. Chromatography allows for 
the separation and resolution of a mixture into individual components or 
solutes. The degree of separation of the mixture depends on the sorption of 
the components by a stationary phase. For most forms of chromatography, 
migration through this stationary phase occurs by way of a mobile fluid (liquid 
chromatography) or an inert gas (gas chromatography). As the mobile phase 
carries the sample through the stationary phase, solutes that are more soluble 
in the mobile phase (less affinity for the stationary phase) travel faster through 
the column eluting at a faster rate (2.8,2.9). Such factors for DETDA needed to 
be determined.
The present study determined the pic, and extinction coefficient values 
for Ethacure and 2,4-toluenediamine. Both HPLC (high-performance liquid 
chromatography) and GC (gas chromatography) methods for DETDA analysis 
were developed incorporating multiple detection systems.
Materials and Methods
Equipment
The Orion pH meter (model 701 A) was purchased from Orion 
Research Incorporated, Cambridge, MA02138. A Coming Rugged Bulb 
Combination electrode (No. 476561) was purchased from Coming, Inc.,
Coming, NY 14831. A Compact Infusion Pump, Model 975 was obtained from 
Harvard Apparatus, Millis, MA. 02054. The Hitachi U-2000 Spectrophotometer 
was purchased from Hitachi Instruments, Inc., Houston, Tx 77272. Sigma Plot 
software was from Jandel Scientific, San Rafael, CA 94901. ESA Model 5200A
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Coulochem II electrochemical detector, Model 5010 standard analytical 
coulometric cell and ESA Model 580 solvent delivery module were purchased 
from ESA, Inc., Chelmsford, MA 01824. The Shimadzu LC-600 Liquid 
Chromatograph pump and Shimadzu SPD-10AV UV detector, Easychrome 
software and DT 2802 A/D converter board were obtained from Shimadzu 
Scientific Instruments, Columbia, MD 21046. A C18 Partisphere 5pm 
4.6x250mm reverse-phase column (No. 4621-1502), guard column (No. 4641- 
0002) and holder (No. 4651-0002) were purchased from Whatman Laboratory 
Division, Clifton, NJ 07014. Hewlett-Packard 5890 Gas Chromatograph, NP 
detector, 7673A automatic sampler, Hewlett-Packard 3392A integrator, 
Hewlett-Packard 5895A Gas Chromatograph and FID detector were all 
purchased from Hewlett-Packard Co., Wilmington, DE 19808. The DB-5 fused- 
silica capillary gas chromato-graph column (30m, 0.25 mm i.d. x 0.25 pm film) 
was purchased from J&W Scientific, Folsom, CA 95630.
Chemicals and supplies
The 2,4-diaminotoluene (2,4-TDA, 98%), barium oxide granules (No. 
22,360-3), dibutylamine (99%) and phosphoric acid (99.999%) were obtained 
from Aldrich Chemical Company, Inc., Milwaukee, Wl 53233. Sodium 
hydroxide pellets, methanol (Nanograde®) and hydrochloric acid were obtained 
from Mallinckrodt Chemicals, Paris, KY 40361. The acetonitrile was from 
Curtis Matheson Scientific, Inc., Houston, TX 77251. The potassium hydroxide 
(PX-1480-1) was purchased from EM Science, Gibbstown, NJ 08027. Vericel
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Membrane Filters (0.45pm, FP-450, 47mm No.66480) were purchased from 
Gelman Sciences, Ann Arbor, Ml 48106.
Determination of pK,
Determination of pKa was carried out using an Orion pH meter with a 
Coming combination electrode (2.10,2.11). Ethacure (1 g) or 2,4-TDA (500 
mg) was dissolved in 100 ml of 0.1 M HCI. Twenty-eight ml of sodium hydroxide 
(1M) was titrated into the HCI solution at a flow rate of 2.8 ml per minute using 
an infusion pump. The pH determinations were simultaneously recorded with a 
personal computer connected to the pH meter using an Omega A/D converter. 
The titration data were converted into graphic form using Sigma Plot software. 
Extinction coefficients
Extinction coefficients for 2,4-TDA and Ethacure 100 were calculated 
using a Hitachi U-2000 Spectrophotometer (2.12). A 0.135 pmol solution of 
Ethacure in methanol was prepared by serial dilution of a 0.0135 mmol solution 
and absorbance was measured from 200 to 440 nm. A 0.0122 pmol solution 
of2,4-TDA in methanol was also prepared by serial dilution of a 0.122 pmol 




An ESA Model 5200A Coulochem II electrochemical detector with a 
Model 5010 standard analytical coulometric cell was coupled to an ESA Model 
580 solvent delivery module. Data was collected using Easychrome software.
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Mobile phase
The mobile phase for the reverse phase system was 16.5% 
acetonitrile, 100 mM dibutylamine phosphate at a pH of 3.0 prepared as 
follows: place 165 ml of acetonitrile into a 1000 ml beaker and dilute to 900 ml 
using 18 mO cm'1 water. Add 16.8 ml of distilled dibutylamine3 and dilute with 
water to 980 ml. Adjust pH to 3.0 using full strength phosphoric acid then 
dilute with water to 1000 ml. Re-adjust pH if needed then filter through a 0.45 
pm membrane filter.
Hydrodynamic voltammetrv
Hydrodynamic voltammetry was used to determine the optimum 
oxidation or reduction potential of the compound to be used in electrochemical 
detection (Table 2.1 lists equipment settings for hydrodynamic voltammetry 
determinations). A set concentration of analyte was injected into the HPLC 
while maintaining a constant voltage. A voltage giving no or very little 
response was first used then increased in 50 mV increments until maximum 
peak values were obtained. The peak height or area was recorded and the 
potential then changed. After equilibration, another sample was injected. Peak 
height/area vs. potential were plotted creating a graph used in determining the 
optimum voltage for each compound of interest. The ideal potential should be 
about 50 mV above the voltage plateau on the graph. HDV determinations 
were carried out for Ethacure and 2,4-monoacetylated DETDA.
See Appendix A for distillation protocol.
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Table 2.1 Equipment settings for hydrodynamic voltammetry determinations 
Model 5200A Model 580 Solvent Series 4500 Microscribe
Coulochem II Delivery System Chart Recorder
Potential
(mV)
Variable Flow Rate 
(ml/min)
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Chromatography conditions
A Whatman C18 Partisphere 5pm 4.6x250mm and guard column was 
used in the reverse-phase system for chromatography separation. For best 
separation and detection of 2,4- and 2,6-DETDA, the detector potential was set 
at +500 mV versus a Ag/AgCI reference electrode. For the monoacetylated 
metabolites, the best potential was +725 mV. This latter potential was higher 
than anticipated from the hydrodynamic voltammetry values obtained. Guard 
cell potential was set at +850 mV and the E3 electrode set at 100 mV. Flow 
rate was set at 1ml/min.
HPLC-UV detection 
Instrumentation
All HPLC-UV analyses were performed on a Shimadzu LC-600 Liquid 
Chromatograph pump and a Shimadzu SPD-10AV UV detector. Data was 
collected using Easychrome software.
Mobile Phase
Mobile phase for the reverse phase system was 16.5% acetonitrile,
100 mM dibutylamine phosphate at a pH of 3.0. To prepare, place 165 ml of 
acetonitrile into a 1000 ml beaker and dilute to 900 ml using 18 mQ cm'1 water. 
Add 16.8 ml of distilled dibutylamine and dilute with water to 980 ml. Adjust pH 
to 3.0 using full strength phosphoric acid then dilute with water to 1000 ml. Re­
adjust pH if needed then filter through a 0.^5 pm membrane filter.
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Chromatography conditions
A Whatman C18 Partisphere 5pm 4.6x250mm column and guard 
column was used in the reverse-phase system for chromatography separation. 
The best separation and resolution was achieved using a 100 mM dibutylamine 
phosphate buffer (pH 3.0) and a flow rate of 0.5 ml/min. A detector setting of 
295 nm was used for the 2,4- and 2,6-DETDA isomers while 240 nm was used 
for the acetylated metabolites.
Gas chromatography-NP detector 
Instrumentation
Analysis was performed using a Hewlett-Packard 5890 Gas 
Chromatograph equipped with a NP detector, 7673A automatic sampler and 
3392A integrator.
Chromatography conditions
The GC-NP conditions used for the analysis of DETDA and 
acetylated-DETDA metabolites were as follows: chromatographic separations 
were achieved using a 30 m J&W Scientific DB-5 capillary column (0.25 mm 
i.d. x 0.25 pm film); helium carrier gas (60 p.s.i.g.) was set at a flow rate of 
approximately 30 ml min'1; hydrogen gas (20 p.s.i.g.) was set at a flow rate of 
approximately 4 ml min'1; air (30 p.s.i.g.) was set at a flow rate of approximately 
100 ml min'1; GC oven temperature was programmed (Table 2.2) from 120°C to 
300°C (final hold 1 min.) at 5°C min'1; injector and detector temperatures were
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Table 2.2 Initial QC parameters for a Hewlett Packard 5890 Gas 
Chromatograph, NP detector, 7673A autosampler and a 
30 meter J&W Scientific DB-5 capillary column.
Oven Initial Final Inject Det. Rate Initial Final Run
Temp Temp Temp Temp Temp °C/min Time Time Length
°C °C °C °C °C__ (min) (min) (min)
120 120 300 250 300 5 0 1 37
Table 2.3 GC parameters for a Hewlett Packard 5890 Gas
Chromatograph, FID detector and a 30 meter J&W 
Scientific DB-5 capillary column.
Oven Initial Final Inject Det. Rate Initial Final Run
Temp Temp Temp Temp Temp °C/min Time Time Length
°C °C °C °C °C_________ (min) (min) (min)
100 100 188 250 320 30 0
188 200 3
200 300 30 0 25.73
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set at 250°C and 300°C respectively; injections (0.5 min. splitless) were 
performed either manually (2 pi) or by autosampler (1 pi).
Gas chromatography-FID detector 
Instrumentation
Analyses were performed using a Hewlett-Packard 5895A Gas 
Chromatograph equipped with a flame ionization detector (FID) and 
ChemStation software.
Chromatography conditions
The GC-FID conditions used for the analysis of DETDA and 
acetylated-DETDA metabolites were as follows: chromatographic separations 
were achieved using a 30 m J&W Scientific DB-5 capillary column (0.25 mm 
i.d. x 0.25 pm film); the helium carrier gas (60 p.s.i.g.) was set at a flow rate of 
approximately 20 ml min'1; the hydrogen gas (20 p.s.i.g.) was set at a flow rate 
of approximately 30 ml min'1; air (30 p.s.i.g.) was set at a flow rate of 
approximately 400 ml min'1; the GC oven temperature was programmed from 
100°C to 188°C at 30°C min'1, then 3°C min'1 to 200°C, then 30°C min'1 to 
300°C (Table 2.3); injector and detector temperatures were set at 250°C and 
320°C respectively; injections (0.5 min. splitless) were performed manually (2.6 
Ml).
Results
BK^values for 2.4-TPA and Ethacure
Before the start of the titration, the amine groups (-NH2) of both 
Ethacure and 2,4-toluenediamine are mostly in an ionized form (-NH3+) due to
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the dissociation of HCL into hydrogen protons and chloride counter ions 
present in the solubilized solvent. Each amine group is capable of acting as a 
proton donor and as such is referred to as an acid. As the hydroxide is added, 
the (NH3+) dissociates. The resulting free H+ reacts with the hydroxide (OH ) 
forming water and a nonionized amine group (-NH2) . At the midpoint of the 
titration, the concentration of (-NH3+) equals that of (-NH2). The pH at this point 
is equal to the pIC, of the amine group (2.10).
Each compound has two amine groups, each with its own pIC,. Figure 
2.2 plots pH against the amount of NaOH added over time. The pK„ of each 
amine group for Ethacure and TDA is the pH at the midpoint of the curved 
segments on the graph. For Ethacure those pK, points are at pH 2.5 and 4.6 
while for 2,4-TDA the values are 2.6 and 5.3.
ExIipgtiQn coefficient?
The absorbance or optical density (OD) of a substance is a measure 
of the amount of light absorbed by that substance. Each substance has a 
characteristic wavelength at which maximum absorbance takes place. This 
wavelength can be used as an aid in the identification of that substance when 
presented as an unknown. Two pure substances with maximum absorption 
atthe same wavelength can often be identified by differences in their extinction 
coefficients. The extinction coefficient is a measure of the absorbance per 
mole of the substance in question.
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Figure 2.2 Top: graph depicting pKa of 2,4-TDA amine groups (pH 2.6 and
5.3) Bottom: graph depicting pKa of Ethacure amine groups (pH 
2.5 and 4.6).
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The extinction coefficient is a derivative of the Beer-Lambert Law (Fig.
2.3). Depending on the units of concentration, the extinction can be expressed 
as either molar or millimolar. Maximum absorption of Ethacure and 2,4-TDA 
was found to occur at 296 and 241 nm respectively. Using the Beer-Lambert 
Law equation, millimolar concentrations of Ethacure and 2,4-TDA, and a 
cuvette with a 1-cm light path, the extinction coefficients were determined to be 
2790 mM'1 cm'1 and 8493 mM'1 cm'1 (Table 2.4), respectively.
Hydrodynamic voltammetry
The hydrodynamic voltammetry results for Ethacure are presented in 
Table 2.5 and Figure 2.4. Maximum peak height was obtained at a potential of 
500 mV. HDV results for monoacetylated 2,4-DETDA revealed a peak 
potential of 550 mV as seen in Table 2.6 and Figure 2.5.
Retention Times for Chromatography 
Electrochemical detection
The 2,4- and 2,6-DETDA retention times were 4.07 and 4.73 
respectively. The monoacetylated metabolites of 2,4-DETDA had retention 
times of 5.33 and 5.59 minutes. Because the acetyl metabolites could not be 
resolved satisfactory, work on the electrochemical detector was discontinued. 
UV detection
The 2,4- and 2.6-DETDA isomer retention times were 4.3 and 5.0 
minutes respectively. The 2,4-monoacetylated-DETDA metabolites eluted as a 
single peak at 5.6-5.8 minutes. The 2,6-monoacetylated-DETDA metabolite, as
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Table 2.4 Tabulation of absorption characteristics and pKa of Ethacure and
2,4-TDA.
Compound Extinction pK^ pK^
________________(mM) @ A_____________________________
Ethacure 100 2790 @ 296 2.5 4.6
2,4 TDA 8493 @241 2.6 5.3
Figure 2.3 The Beer-Lambert Law used to determine the extinction
coefficient of a substance once the absorbance and concentration 
are known. E=extinction coefficient, A=absorbance of the 
substance in solution, t=length of the light path through the 
solution (usually 1 cm), C=concentration of the substance in 
solution.
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Table 2.5 Hydrodynamic voltammetric results for Ethacure™100 (20 ng 
sample of Ethacure). Equipment settings listed in Table 2.1.
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Figure 2.4 Graphical results of Table 2.5. Note maximum peak height for 
hydrodynamic voltammetry of Ethacure is at 500 mV.
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Table 2.6 Hemodynamic voltammetric results for a 20 ng sample of 2,4-
acetylated-DETDA. Note peak potential at 550 mV for both the 2- 
and 4-position amine groups.
Potential (mV) Peak Height Peak




















400 450 500 550 600 650 700 750 
Potential (mV)
Figure 2.5 Graphical results of Table 2.6. Note maximum peak height for 
both the 2- and 4-position amine groups occurs at 550 mV.
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expected, eluted as a single peak at 7.6 minutes. The diacetylated metabolites 
of 2,4- and 2,6-DETDA had retention times of 11.2 minutes and 19.2 minutes 
respectively. As with the electrochemical detector, resolution of the acetylated 
metabolites was unsatisfactory (see Appendix B for representative example). 
The HPLC-UV system was, however, later used to verify the purity of tritiated
2,4- and 2,6-DETDA (Chapters 5 and 6).
Gas chromatography-NP detector
Retention times for 2,4- and 2,6-DETDA as well as 2,4- and 2,6-mono- 
and diacetylated-DETDA metabolites analyzed using GC-NP chromatography 
were recorded in Table 2.7. Although the NP detector system proved to be a 
satisfactory method of analysis, unresolvable equipment problems forced a 
switch to the GC-FID system.
Gas chromatography-FID detector
Retention times for 2,4- and 2,6-DETDA as well as 2,4- and 2,6-mono- 
and diacetylated-DETDA metabolites and internal standard diazepam using 
GC-FID chromatography were recorded in Table 2.8. This GC-FID analytical 
method was utilized in an extraction efficiency experiment (Chapter 3) and in 
preliminary metabolism studies (Chapter 4).
Discussion
The piC, values, structure, and molecular weight of Ethacure and 2,4- 
TDA are very close. Therefore, based on the Henderson-Hasselbalch 
equation, the ratio of ionized to non-ionized compound at varying pH levels
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Table 2.7 2,4- and 2,6-DETDA, 2,4- and 2.6-monoacetylated DETDA
metabolites, 2,4- and 2,6-diacetylated metabolites were analyzed 
with a Hewlett Packard 5890 Gas Chromatograph, NP detector, 
7673A automatic sampler and a 30 meter J&W Scientific DB-5 
capillary column giving the following retention times.
Compound Retention Time (min)
2,4-DETDA 14.65
2,6-DETDA 15.46
2,4-monoacetylated DETDA (Pos. 4) 21.16




Table 2.8 2,4- and 2,6-DETDA, 2,4- and 2.6-monoacetylated DETDA
metabolites, 2,4- and 2,6-diacetylated metabolites and internal 
standard diazepam were analyzed with a Hewlett-Packard 5890 
Gas Chromatograph, FID detector and 30 meter J&W Scientific 
DB-5 capillary column giving the following retention times.
Compound Retention Time (min)
2,4-DETDA 5.93
2,6-DETDA 6.24
2,4-monoacetylated DETDA (Pos. 4) 9.47
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should be very close. The ionization status of a compound directly affects its 
ability to be absorbed across cellular membranes as diffusion will occur 
primarily in the part of the intestinal tract where the compound can exist in the 
non-ionized, or lipid-soluble form (2.13). Based on pIC, values alone, DETDA 
would be expected to be orally absorbed in a similar manner to toluenediamine. 
However, such absorption is dependent on other parameters as well.
Knowledge of pKa values for DETDA will be useful in HPLC method 
development by providing information needed for reverse-phase column buffer 
selection. Extinction coefficients provide needed absorption information for 
HPLC and spectrophotometry analysis.
The HPLC and GC analytical methods developed provided more than 
adequate detection and separation of the primary isomers composing Ethacure 
(2,4- and 2,6-DETDA). Significant problems were encountered in the 
development of the HPLC method. As a weak base, DETDA presented a 
chromatography challenge common to many aromatic amine compounds. 
Band-tailing, resolution and excessive retention time problems had to be 
addressed (2.14). Band-tailing is commonly caused by the sample compound 
interacting with silanol groups in the column packing. Mobile phase modifiers 
are often used with basic compounds to block these secondary-retention sites 
thereby reducing the effects (2.15). Dibutylamine phosphate (pH 3.0) was able 
to provide a solution to these problems for the 2,4- and 2,6-isomers (2.14).
The adsorption of positively charged lipophilic ions to the non-polar surface of
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the column results in a positively charged surface. The positive charged basic 
compound is then less able to bind to the column, probably due to electrostatic 
repulsion. As seen in the reported retention times for HPLC-UV, 2,4- and 2,6- 
DETDA eluted first followed by the monoacetylated metabolites and finally the 
diacetylated species. This would be expected as the parent compound would 
have the first amine groups positively charged (the second amine group 
minimally ionized) followed by monoacetylated metabolites with a single 
positive charge and diacetylated metabolites with no positive charges.
Despite the addition of mobile phase modifiers and the use of an end- 
capped column, excessive band-tailing of the monoacetylated metabolites 
could not be resolved adequately.
HPLC chromatography coupled with an electrochemical detector has 
been shown to provide a significant increase in sensitivity over UV detection for 
some compounds (2.9). As a sample enters the analytical cell, the electro­
chemical detector measures a change in current as the potential across a cell 
is held constant. This current change translates into characteristic peaks for 
the analyte of interest.
The study showed, as expected, that HPLC-Electrochemical Detection 
provided a reliable and reproducable method of detection for both 2,4- and 2,6- 
DETDA. As with the HPLC-UV method, the conditions employed provided 
good 2,4- and 2,6-DETDA separation. However, the 2,4- and 2,6-mono­
acetylated metabolites again exhibited excessive band-tailing making positive
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identification questionable. The diacetylated-DETDA metabolites did not 
undergo adequate oxidation or reduction and therefore were not able to be 
detected by this method. Because each metabolite has its own ideal oxidation- 
reduction potential, the ability to analyze multiple components of a mixture 
would be limited using electrochemical detection. It would however, be ideal 
for monitoring trace amounts of DETDA parent compound in urine samples.
The problems encountered by HPLC chromatography were resolved 
with gas chromatography. The separation and resolution of the compounds of 
interest was adequate for both identification and quantitation using either the 
NP or FID detector.
In conclusion, HPLC chromatography proved to be an adequate 
method of analytical detection for DETDA isomers but not for the associated 
acetylated metabolites. Gas chromatography provided good separation, 
resolution and acceptable retention times for both DETDA and metabolites.
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CHAPTER 3
SYNTHESIS AND EXTRACTION OF ACETYL 
METABOLITES OF DETDA 
Introduction
2,4-Toluenediamine is an intermediate compound widely used in 
industry. Its primary use is in the synthesis of toluene diisocyanate, a cross- 
linking agent in the production of polyurethane foam. It is also used as an 
intermediate in the synthesis of dyes used in textiles, wood stains and 
pigments (3.1-3.4).
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is a compound 
utilized as a polyurethane chain extender in reaction injection-mold 
applications. DETDA also has uses as a curing agent for polyurethanes and 
epoxies, as an antioxidant, lubricant, wire coating and as a replacement for 
more toxic industrial compounds, such as MOCA (4,4'-methyienebis-2- 
chloroaniline) and toluenediamine. DETDA has been manu-factured by 
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years 
under the name Ethacure®100 (3.5). Through a proprietary process, Ethacure 
is synthesized from toluenediamine. It is commercially supplied as a mixture of 
isomers with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4- 
diamine (2,4-DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA) 
and 0.5-3% dialkylated m-phenylenediamine. DETDA is a proprietary 
compound, thus there is little information in the open literature on this material
130
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except for patents dealing with synthesis and industrial use. Because of 
structural similarities to TDA, DETDA is expected to be absorbed, distributed, 
metabolized and excreted like TDA. Biotransformation of DETDA is expected 
to produce metabolites similar to those found with TDA.
Multiple studies in rats have shown the relevance of N-acetylation in 
the metabolism of toluenediamine. In two separate studies in Fischer 344 male 
rats, Grantham et al. reported that 4-acetylamino-2-aminotoluene (5.7% and 
5.2% of dose) and 2,4-diacetylaminotoluene (2.6% and 1.4% of dose) were 
significant urinary excretion products (3.6,3.7). Waring et al. found a high 
percentage of phenolic metabolites and less than 3% mono- and di-acetylated 
products in female Wistar rats (3.2). Timchalk et al. found comparable levels of 
free 2,4-TDA and acetylated metabolites when oral and i.v. 3 mg 2,4-[14C]- 
TDA/kg were administered to Fischer 344 rats (3.8). Comparing the ratio 
between free plus acetylated 2,4-TDA to total acid-labile metabilites they found 
61 % of detected metabolites as free or acetylated and 39% as other conjugates 
when administered a 60 mg/kg oral dose while a 3 mg/kg dose resulted in 
about 85% free and acetylated metabolites.
Using hamster liver cytosol, Glinsukon et al. found 2,4-TDA 
metabolized to 3 acetylaminotoluene products (3.9). The primary metabolite 
was 4-acetyl-amino-2-aminotoluene of which a small percentage was then 
metabolized to 2,4-diacetyl-aminotoluene. The 2-acetylamino-4-aminotoluene 
was also found to be further metabolized to 2,4-diacetylaminotoluene. From all
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indications, it appeared that the monoacetyl metabolite, 2-acetylamino-4- 
aminotoluene was only a very minor metabolite and was probably further 
metabolized to the diacetylaminotoluene product.
In order to detect and quantify acetylated biotransformation products, 
the expected metabolite standards were needed. The first metabolites to be 
synthesized would be the mono- and diacetylated-DETDA species.
In order to analyze these compounds, isolation from the tissue or 
matrix of interest must be carried out. This usually involves some form of 
extraction procedure. Extracting the analytes out of a urine matrix is usually 
done by either solvent extraction or employing some form of solid bonded- 
phase. The goal of all extraction processes is to separate the compound of 
interest from as many interfering compounds as possible. Solvent extraction 
utilizes a two-phase system into which a compound from an aqueous phase is 
partitioned into a second phase which is often organic in nature (3.10). The 
ability to extract a compound from a matrix is determined to a large degree on 
its ionization state. Selective extraction can be realized by altering the pH of 
the matrix partitioning its components into acidic, basic, and neutral 
compounds which can then be partitioned into the appropriate solvent phase 
for collection.
Sorbent extraction involves both a liquid and and solid phase (3.11). 
This solid phase is generally a functional group covalently bonded (stationary) 
to a silica substrate. An aqueous matrix (mobile phase) with the dissolved 
analyte is allowed to pass through the sorbent bed. If a compound has a
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greater affinity for the functional group on the stationary versus the mobile 
phase, it binds to the bed surface. Other components in the aqueous phase 
then pass on through the bed and are eliminated. Solid Phase Extraction was 
chosen because it provided a method for washing away much of the inter­
ference caused by the urine matrix resulting in cleaner chromatographs with 
lower background interference and fewer unwanted peaks. It also allowed 
multiple samples to be processed simultaneously.
This project details the synthesis of the mono- and diacetylated 
metabolites of both 2,4- and 2,6-DETDA. NMR and/or GC/MS structural 
identification of these metabolites are presented. Solid phase extraction 
methods were developed (3.12) and extraction efficiencies obtained for DETDA 
isomers and associated acetylated standards.
Materials and Methods 
Equipment
The Hewlett-Packard 5890 Gas Chromatograph, 5970 Series MS 
Detector and 7673A autosampler were purchased from Hewlett-Packard 
Company, Wilmington, DE 19808. The DB-5 fused-silica capillary gas 
chromatograph column was purchased from J&W Scientific, Folsom, CA 
95630. Bond Elut LRC®, 1211-3002, 10 cc/100 mg C-8 bonded phase 
extraction columns were from Varian sample preparation products, Harbor City, 
CA 90710. The Filter Tube Vacuum Filtration Manifold System (VFM 3 No. 
5503) was purchased from Amicon Corporation, Danvers, MA 01923. The 
EVAPO-MIX® was obtained from Buchler Instruments, Fort Lee, NJ 07024. The
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Vortex-2 Genie was purchased from Scientific Industries, Inc., Bohemia, NY 
11716.
Chemicals
Methanol (Nanograde®), isopropanol (Nanograde®), chloroform 
(ChromAR®), dichloromethane (Nanograde®) and acetic anhydride were 
purchased from Mallinckrodt Chemicals, Paris, KY 40361. Acetonitrile was 
obtained from Curtis Matheson Scientific, Inc., Houston, TX 77251. DRIERITE 
(calcium sulfate anhydrous) was purchased from W.A. Hammond Drierite 
Company, Xenia, OH 45385. Pure 2,4-diethyltolunediamine and 2,6-diethyl- 
tolunediamine provided by Albemarle Corporation, Baton Rouge, LA 70801. 
Diazepam-d5 was purchased from Sigma Chemical Co., St. Louis, MO 63178. 
Dimethyl sulfoxide-d6 99.9 atom% D (2206-27-1, No. 23,692-6) was purchased 
from Adrich Chemical Co., Inc., Milwaukee, Wl 53233. Potassium dihydrogen- 
phosphate (KH2P04) was purchased from Fisher Scientific Co., Fair Lawn, NJ 
07410. Potassium hydroxide was purchased from EM Science, Gibbstown, NJ 
08027.
Synthesis of acetvl metabolites
Monoacetyl and diacetyl metabolites of 2,4- and 2,6-diethyltoluene- 
diamine were synthesized (Figure 3.1) following adaptations of procedures 
published by Glinsukon et al. (3.13).
The 2-acetylamino-4-amino-3,5-diethyltoluene and 4-acetylamino-2- 
amino-3,5-diethyltoluene monoacetyl metabolites (Figure 3.2) were made by 
dissolving 2.5 g (14 mmol) of 2,4-DETDA (diethyltoluenediamine) in 12.5 ml of
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Figure 3.1 Structures of the synthesized mono- and di-acetylated metabolite
standards for 2,4- and 2,6-DETDA. Because the 2,6-DETDA is a 
symetrical molecule, there is only 1 possible monoacetylated 
derivative.
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Figure 3.2 Synthesis of 2-acetylamino-4-amino-3,5-diethyltoluene and 4- 
acetylamino-2-amino-3,5-diethyltoluene from 2,4- 
diethyltoluenediamine starting material.
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dichloromethane. Acetic anhydride (1.321 ml, 14 mmol) was added dropwise 
to the solution and stirred on medium speed for 60 minutes. Unreacted acetic 
anhydride was quenched by stirring in 8 ml of 50:50 v/v chloroform/methanol 
solution. The mixture was dried under a stream of nitrogen gas then dissolved 
in 8 ml of hot 50:50 v/v isopropanol/water. The solution was fully cooled at 5°C 
then stored at -20°C overnight. The resulting precipitate was suction filtered 
and dried under CaS04 in a vacuum desiccator for 72 hours.
2,6-DETDA monoacetylated metabolites
The 2,6 monoacetylated metabolites (Figure 3.3) were synthesized by 
dissolving 2.5 grams (14 mmol) of 2,6-DETDA in 12.5 ml of dichloromethane. 
Acetic anhydride (1.321 ml, 14 mmol) was added dropwise to the solution and 
stirred on medium speed for 70 minutes. Remaining unreacted acetic anhy­
dride was quenched by stirring in 8 ml of a 50:50 v/v chloroform/methanol 
solution. The mixture was dried under a stream of nitrogen gas then dissolved 
in 8 ml of hot 50:50 v/v isopropanol/water. The solution was fully cooled at 5°C 
then stored at -20°C overnight. The resulting precipitate was suction filtered 
and dried under CaS04 in a vacuum desiccator for 48 hours.
2,4-DETDA diacetylated metabolites
The 2-acetylamino-4-acetylamino-3,5-diethylto!uene diacetyl 
metabolites (Figure 3.4) were prepared by dissolving 2.5 g (14 mmol) of 2,4- 
DETDA in 12.5 ml of dichloromethane. Acetic anhydride (5.284 ml, 56 mmol) 
was added drop-wise to the solution and stirred on medium speed for 30







Figure 3.3 Synthesis of 2,6-monoacetylated DETDA from 2,6-DETDA 
starting material. Because the 2,6-DETDA is a symetrical 
molecule, only 1 product is produced.
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Figure 3.5 Synthesis of 2,6-diacetylamino-3,5-diethyltoluene from 2,6- 
diethyltoluenediamine starting material.
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minutes. Unreacted acetic anhydride was quenched by adding 10 ml of a 
50:50 v/v solution of chloroform/methanol. The mixture was dried under a 
stream of nitrogen gas then dissolved in 10 ml of hot 50:50 v/v 
isopropanol/water. The solution was fully cooled at 5°C then stored at -20°C 
overnight. The resulting precipitate was suction filtered and dried under CaS04 
in a vacuum desiccator for 48 hours.
2,6-DETDA diacetylated metabolites
The 2-acetylamino-6-acetylamino-3,5-diethyltoluene diacetyl 
metabolites (Figure 3.5) were prepared by dissolving 2.5 grams (14 mmol) of
2,4-DETDA in 12.5 ml of dichloromethane. Acetic anhydride (5.284 m l, 56 
mmol) was added dropwise to the solution and stirred on medium speed for 30 
minutes. Unreacted acetic anhydride was quenched by adding 10 ml of a 
50:50 v/v chloroform/methanol solution. The mixture was dried under a stream 
of nitrogen gas then dissolved in 15 ml of hot 50:50 v/v isopropyl/water. The 
solution was fully cooled at 5°C then stored at -20°C overnight. The resulting 
precipitate was suction filtered and dried under CaS04 in a vacuum desiccator 
for 48 hours.
Spectra of DETDA and acetvl metabolites 
Nuclear magnetic resonance spectra
2,4-DETDA, 2,4-Ac-DETDA (2-acetylamino-4-amino-3,5-diethyltoluene 
and 4-acetylamino-2-amino-3,5-diethyltoluene), 2,6-DETDA, and 2,6- 
monoacetylated-DETDA were submitted in d6-(DMSO) for 1H and 13C NMR
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anaylsis at the Chemistry Department of LSU using a Bruker AM 400 MHz 
machine.
Gas chromatography-mass spectroscopy
2,4-DETDA, 2,4-Ac-DETDA (2-acetylamino-4-amino-3,5-diethyltoluene 
and 4-acetylamino-2-amino-3,5-diethyltoluene), 2,4-Ac2-DETDA (2-acetyl- 
amino-4-acetylamino-3,5-diethyltoluene), 2,6-DETDA, 2,6-monoacetylated- 
DETDA and 2,6-Ac2-DETDA (2-acetylamino-6-acetylamino-3,5-diethyltoluene) 
were analyzed on a Hewlett Packard 5890 Gas Chromatograph coupled to a 
Hewlett Packard 5970 Series MS Detector and a 7673A autosampler. 
Chromatographic separations were achieved using a DB-5 fused-silica 
capillary gas chromatograph column. The GC/MS conditions used in the 
identification of DETDA isomers and acetylated metabolites were as follows: a 
30 m DB-5 column (0.25 mm i.d. x 0.25 pm film thickness); helium carrier gas 
(80 p.s.i.g.) was set at approximated 2 ml min'1; GC oven temperature was 
programmed from 50°C (hold for 1 min.) to 300°C (hold for 10 min.) at 30°C 
min'1; injector port tempature was set at 250°C; interface temperature was set 
at 300°C; splitless valve time was set at 0.75 min; mass range was set from 40 
to 650 and multiplier voltage set at 2200.
Sample extraction procedure
One-half ml of urine sample, 10 ppm of diazepam (internal standard), 
and 2.0 ml of 0.1 M potassium phosphate buffer (pH 7.0)4 was added to a
See Appendix A for all buffer preparations.
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16x100 mm borosilicate glass culture tube (3.12). The mixture was vortexed on 
a Vortex-2 Genie for 5 seconds on medium speed and the pH adjusted 
between 7.0 and 8.0 with KOH or phosphoric acid if needed.
C-8 Bond Elute Certify™ columns, placed into Teflon stopcocks and 
18- guage needles, were inserted into a modified vacuum filtration manifold. 
Unused ports were plugged in order to control vacuum pressure. The columns, 
while under less than 5 inches Hg vacuum pressure, were conditioned by 
adding 2.0 ml of methanol followed by 2.0 ml of potassium phosphate buffer 
(pH 7.0). The columns were not allowed to dry out during conditioning. The 
sample mixtures were pipetted into labeled columns and allowed to pass 
through. This process took at least 2 minutes to complete with the vacuum set 
to less than 5 inches Hg. The column was washed by adding 4ml of potassium 
phosphate buffer (pH 7.0). It was further washed with 2ml of 6% acetonitrile- 
94% potassium phosphate buffer (pH 7.0) then dried under a full vacuum (15 
inches Hg) for 10 minutes. The vacuum manifold cover was removed and the 
needle tips blotted dry. A rack with labelled culture tubes was then placed into 
the manifold in preparation for collection of eluted compounds. Compounds of 
interest were then eluted with 1.0 ml of a 50:50 v/v acetonitrile/methanol 
solution with no vacuum present. After 1 minute, 5 inches Hg vacuum was 
applied to remove any residual eluent. Samples were then placed into an 
EVAPO-MIX® at 45°C and evaporated to dryness under a stream of nitrogen
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gas. Samples were then restored to 0.5 ml with methanol, vortexed for 30 
seconds, and transfered to labeled vials for later GC analysis.
Extraction efficiency
In order to ascertain the extraction efficiency of the solid phase 
system, rat urine samples were spiked with DETDA, associated acetylated 
metabolites, and diazepam (internal standard) at concentrations of 10, 5, 1 and 
0.5 ppm. These samples were then extracted and prepared for GC-FID 
analysis according to the stated extraction protocol. These urine samples were 
compared to methanol spiked controls at the same concentrations. To 
minimize variation in the study, unspiked normal rat urine samples were passed 
through SPE C-8 columns using the same procedure as the spiked urine 
samples. After nitrogen drying the eluent, these unspiked urine samples were 
restored with methanol which was then used in the preparation of the spiked- 
methanol controls. Three sets of urine-spiked samples and methanol-spiked 
controls were prepared. Each set was analyzed 3 times for a total of 9 runs at 
each concentration.
Results
The resulting yields of the synthesized 2,4-Ac-DETDA, 2,6-Ac-DETDA,
2.4-AC2-DETDA and 2,6-Ac2-DETDA metabolites were approximately 86%,
80%, 78% and 89% respectively. Structural conformation of the synthesized 
metabolites were obtained by NMR and/or GC/MS.
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Nuclear magnetic resonance spectra
2,4 DETDA, 2,6 DETDA and the monoacetyl metabolites were 
analyzed using a Bruker AM 400 MHz machine. Data presented in Tables 3.1 
and 3.2 provided conformation of the anticipated monoacetylated derivatives. 
Gas chromatography-mass spectroscopy
2,4-DETDA, 2,4-Ac-DETDA (2-acetylamino-4-amino-3,5-diethyltoluene 
and 4-acetylamino-2-amino-3,5-diethyltoluene), 2,4-Ac2-DETDA (2-acetyl- 
amino-4-acetylamino-3,5-diethyltoluene), 2,6-DETDA, 2,6-monoacetylated- 
DETDA and 2,6-Ac2-DETDA (2-acetylamino-6-acetylamino-3,5-diethyltoluene) 
mass spectra data is presented in Table 3.3.
Extensive fragmentation of the DETDA isomers and metabolites 
occured during the electron ionization. Molecular ions were observed for all 
compounds analyzed. For the 2,4- and 2,6-DETDA isomers, the base peak 
resulted from the loss of the aromatic methyl group. Ethyl group fragmentation 
was notably missing in the 2,6-monoacetylated species. For the most part, the 
2,6 species was similar to the 2,4 species in the fragmentation pattern 
presented.
Extraction efficiency
The extraction efficiencies of the 2,4- and 2,6-DETDA isomers were 
between 79% and 86%. Extraction efficiencies of associated acetylated 
metabolites ranged from 89% to 116%. Extraction efficiencies for the 
compounds at different concentrations are listed in Table 3.4.
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Table 3.1 NMR proton analysis data for 2,4 DETDA and monoacetylated 
metabolites. Abrv. S=singlet, bS=broad singlet, d=doublet, 
t=triplet, m=multiplet, q=quartet, H=protons, j=correlation 
constant, ppm=parts per million, Ar=aromatic, subscripted 
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Table 3.2. NMR proton analysis data for 2,6-DETDA isomer and
monoacetylated metabolites. Abrv. S=singlet, bS=broad singlet, 
d=doublet, t=triplet, m=multiplet, q=quartet, H=protons, 
j=correlation constant, ppm=parts per million, Ar=aromatic, 





Ar-CH3 1.85 ppm 1.86 ppm
S, 3H S, 3H
H2 - N2 4.07 ppm 4.33 ppm
bS, 2H d, 2H
h2- c3 2.34 ppm 2.34 ppm
q, 2H m, 2H
j=7.47 j=7.50
H3-C3 1.05 ppm 1.02 ppm
t, 3H m, 3H
j=7.38 j=7.46
H-C4 6.42 ppm 6.65 ppm
S, 1H S, 1H
h2- c5 2.34 ppm 2.47 ppm
q, 2H m, 2H
j=7.47 j=5.09
h3- c= 1.05 ppm 1.10 ppm
t, 3H m, 3H
j=7.38 j=5.37
(̂1-2) ■ N6 4.07 ppm 8.99 ppm
bS, 2H S, 1H
H3 -N6 , NA 1.99 ppm
acetate S, 3H

















Table 3.3 GC-MS data confirming the structures of 2,4-and 2,6-DETDA, 2,4-and 2,6-monoacetylated 
DETDA and 2,4- and 2,6-diacetylated DETDA. Data presented as m/z and relative intensity 
(%) which is shown in parenthesis.
ft
X01 -CH2CH3 -COCHj -NHCOCHj -COCHs
-CHjCHj
-NHCOCHs
-C O C H j
-NHCOCHj
-N H C O C H j
C om pound M+ M-15 M-29 M-43 M-58 M-72 M-101 M-116
2,4-DETDA 178 (75) 163 (100) 149 (10)
2,4-Ac-DETDA(4) 220(100) 205 (36) 191 (38) 177 (70) 148(14)
2,4-Ac-DETDA(2) 220 (76) 205 (32) 191 (15) 177 (60) 162 (22) 148(15)
2,4-Ac2-DETDA 262 (38) 233 (20) 204 (20) 161 (75) 146 (40)
2,6-DETDA 178 (90) 163 (100) 149(14)
2,6-Ac-DETDA 220 (55) 205 (46) 177 (95) 162 (18) 148 (25)
2,6-Ac2-DETDA 262(100) 233(10) 219(75) 204 (16) 161 (70) 146 (30)
-4
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Table 3.4 Extraction efficiencies using solid phase extraction for DETDA 
isomers, associated acetylated metabolites and diazepam 
(internal standard) in rat urine relative to fortified methanol at 





Compound Methanol Urine % Extraction
2,4-DETDA 2105.43 1816.78 86.29
2,6-DETDA 1995.51 1762.36 88.32
2,4-Ac(4) 764.47 813.88 106.46
2,4-Ac(2) 1072.51 1129.04 105.27
2,6-Ac 1782.40 1857.52 104.21
2,4-A^ 1779.60 1796.60 100.96
2,6-ACj 1681.64 1758.06 104.54
Diazepam 1777.84 1882.14 105.87
2,4-DETDA 1082.90 919.95 84.95
2,6-DETDA 1024.71 867.35 84.64
2,4-Ac(4) 397.71 416.19 104.65
2,4-Ac(2) 550.91 573.45 104.09
2,6-Ac 908.23 947.57 104.33
2.4-AC2 875.63 886.34 101.22
2.6-AC2 811.57 839.12 103.39
Diazepam 892.77 935.42 104.78
2,4-DETDA 199.90 171.81 85.95
2,6-DETDA 201.70 169.22 83.90
2,4-Ac(4) 76.04 87.86 115.54
2,4-Ac(2) 110.27 114.24 103.60
2,6-Ac 167.92 184.63 109.95
2.4-ACj 154.81 158.47 102.36
2.6-AC2 139.83 143.66 102.74
Diazepam 170.68 175.71 102.95
2,4-DETDA 104.21 82.67 79.33
2,6-DETDA 110.78 88.77 80.13
2,4-Ac(4) 38.87 40.08 103.11
2,4-Ac(2) 57.61 56.37 97.85
2,6-Ac 85.80 87.82 102.35
2,4-ACj 77.41 74.08 95.70
2,6-Ac, 68.36 60.57 88.60
Diazepam 85.90 92.88 108.13
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Discussion
The synthesis of both monoacetylated and diacetylated DETDA 
metabolites was successful and reproducible. The structures of the 2,4- and
2,6-DETDA isomers and the 2,4- and 2,6-monoacetylated DETDA metabolites 
were confirmed by both NMR and GC/MS analysis. The 2,4- and 2,6-di- 
acetylated metabolites were confirmed by GC/MS spectra. Molecular ions, 
extensive fragmentation patterns, and NMR confirmation of the monoacetylated 
DETDA structures provided the confidence level needed for confirmation of the 
diacetylated species.
As noted in Figure 3.1, monoacetylation of the 2,4-DETDA isomer was 
expected to result in the 2-acetylamino-4-amino-3,5-diethyltoluene and 4- 
acetylamino-2-amino-3,5-diethyltoluene metabolites. NMR analysis of the 2,4- 
monoacetylated DETDA mixture confirms that a greater percentage of the 
position 2 acetylated species was present in the sample. Stearic hindrance 
from the ethyl groups ortho to the 4-position amino group was thought to be 
responsible for a decreased yield for 4-acetylamino-2-amino-3,5-diethyltoluene 
( approx. 42%) compared to 2-acetylamino-4-amino-3,5-diethyltoluene (approx. 
58%).
The Varian Bond Elut LRC® C-8 bonded phase extraction columns 
provided an efficient and reproducible method for extracting DETDA, its 
monoacetylated and diacetylated metabolites from urine. Resulting GC-FID
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chromatographs had minimal background interference and few unwanted 
peaks.
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CHAPTER 4 
METABOLISM OF DIETHYLTOLUENEDIAMINE 
Introduction
2,4-Toluenediamine is an intermediate compound widely used in 
industry (Figure 4.1). Its primary use is in the synthesis of toluene diiso­
cyanate, a cross-linking agent in the production of polyurethane foam. It is also 
used as an intermediate in the synthesis of dyes used in textiles, wood stains 
and pigments (4.1-4.4).
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is a compound 
utilized as a polyurethane chain extender in reaction injection-mold appli­
cations. DETDA also has uses as a curing agent for polyurethanes and 
epoxies, as an antioxidant, lubricant, wire coating and as a replacement for 
more toxic industrial compounds, such as MOCA (4,4'-methylenebis-2- 
chloroaniline) and toluenediamine. DETDA has been manu-factured by 
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years 
under the name Ethacure®100 (4.5). Through a proprietary process, Ethacure 
is synthesized from toluenediamine. It is commercially supplied as a mixture of 
isomers with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4- 
diamine (2,4-DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA) 
and 0.5-3% dialkylated m-phenylenediamine. DETDA is a proprietary 
compound, thus there is little information in the open literature on this material 
except for patents dealing with synthesis and industrial use.
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Figure 4.1 Chemical structures of DETDA and TDA isomers.
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Several studies in rats have shown the relevance of N-acetylation in 
the metabolism of toluenediamine. In two separate studies in Fischer 344 male 
rats, Grantham et al. reported that4-acetylamino-2-aminotoluene (5.7% and 
5.2% of dose) and 2,4-diacetylaminotoluene (2.6% and 1.4% of dose) were 
signif-icant urinary excretion products (4.6,4.7). Waring et al. found a high 
percent-age of phenolic metabolites and less than 3% mono- and diacetylated 
products in female Wistar rats (4.2). Timchalk et al. found comparable levels of 
free 2,4-TDA and acetylated metabolites when oral and i.v. 3 mg 2,4-[14C]/kg 
TDA were administered to Fischer 344 rats (4.8). Comparing the ratio between 
free plus acetylated 2,4-TDA to total acid-labile metabilites they found 61 % of 
detected metabolites as free or acetylated and 39% as other conjugates when 
admin-istered a 60 mg/kg oral dose while a 3 mg/kg dose resulted in about 
85% free and acetylated metabolites.
Using hamster liver cytosol, Glinsukon ef al. found 2,4-TDA 
metabolized to 3 acetylaminotoluene products (4.9). The primary metabolite 
was 4-acetyl-amino-2-aminotoluene of which a small percentage was then 
metabolized to 2,4-diacetyl-aminotoluene. The 2-acetylamino-4-aminotoluene 
was also found to be further metabolized to 2,4-diacetylaminotoluene. From all 
indications, it appears that the monoacetyl metabolite, 2-acetylamino-4- 
aminotoluene is only a very minor metabolite and is probably further 
metabolized to the diacetyl-aminotoluene product.
Results from a two-year feeding study of DETDA in rats showed 
effects on the pancreas, liver, thyroid and eyes as well as increased tumors in
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the liver and thyroid glands of male rats (4.5). These findings, along with the 
structural similarity to the known mutagenic noncarcinogen:carcinogen pair 2,6- 
and 2,4-toluenediamine (TDA), dictated the need for a metabolic study of the 
DETDA mixture (4.1,4.10,4.11). DETDA was expected to be absorbed, 
distributed, metabolized and excreted in a similar manner to TDA. Biotrans­
formation reactions were expected to produce metabolites similar to those 
found with TDA (Figure 4.2).
Using synthesized acetylated DETDA standards (Chapter 3), a pre­
liminary rat study was performed to determine the extent of acetylation 
occurring with DETDA during metabolism.
Materials and Methods 
Materials 
Chemicals
Methanol (Nanograde®) was purchased from Mallinckrodt Chemicals, 
Paris, KY 40361. Acetonitrile was obtained from Curtis Matheson Scientific,
Inc., Houston, TX 77251. Potassium dihydrogenphosphate (KH2P04) was from 
Fisher Scientific Co., Fair Lawn, NJ 07410. Hydrochloric acid was obtained 
from Mallinckrodt Chemicals, Paris, KY 40361. Dibutylamine (99%) and 
phosphoric acid (99.999%) were obtained from Aldrich Chemical Company,
Inc., Milwaukee, Wl 53233. Potassium hydroxide (PX-1480-1) was purchased 
from EM Science, Gibbstown, NJ 08027. Wayne®Autoclavable Rodent BLOX® 
8656 diet was purchased from Laboratory Diets, Madison, Wl 53711. Pure 2,4- 
diethyltolunediamine, 2,6-diethyltolunediamine and Ethacure®100 provided by

























Figure 4.2 Structures of synthesized mono- and di-acetylated metabolite 
standards of 2,4- and 2,6-DETDA expected in analysis of urine 
from Ethacure treated rats.
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Albemarle Corporation, Baton Rouge, LA 70801. Diazepam-d5 was purchased 
from Sigma Chemical Co., St. Louis, MO 63178. Vericel Membrane Filter
0.45pm (FP-450, 47mm No.66480) was from Gelman Sciences, Ann Arbor, Ml 
48106.
Equipment
Bond Elut LRC® (1211-3002) 10 cc/100 mg C-8 bonded phase 
extraction columns were from Varian sample preparation products, Harbor City, 
CA 90710. The Filter Tube Vacuum Filtration Manifold System (VFM 3 No. 
5503) was purchased from Amicon Corporation, Danvers, MA 01923. The 
EVAPO-MIX® was obtained from Buchler Instruments, Fort Lee, NJ 07024. The 
Vortex-2 Genie was purchased from Scientific Industries, Inc., Bohemia, NY 
11716. Hewlett-Packard 5895A Gas Chromato-graph, FID detector and 
ChemStation software were purchased from Hewlett-Packard Co., Wilmington, 
DE 19808. The DB-5 fused-silica capillary gas chromatograph column was 
purchased from J&W Scientific, Folsom, CA 95630.
Methods 
Treatment protocol
One group of 4 young adult (10-12 weeks) male (1 control and 3 
treatment, 172-186 g) Sprague Dawley rats (obtained from the L.S.U. Labora­
tory Animal Medicine breeding colony) were randomly selected and placed into 
individual metabolism cages for urine collection. Rats were fed a powdered 4% 
fat diet (Wayne®Autoclavable Rodent BLOX® 8656 diet) and maintained in a
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12-hour light-dark cycle environment. They were placed into cages 24 hours 
prior to dosing and were fasted for 16 hours to eliminate the effects of gastric 
contents on absorption. Water was given ad libitum during the entire 
experiment. Rats were orally dosed at 179 pmol/kg from a solution of 56 
pmoi/ml of Ethacure in water using a 1.0 ml Hamilton #1001 syringe and a 
curved ball-tipped 18-gauge x 3" feeding needle.
The urine from each rat was collected in iced containers for 4 time 
periods (0-4, 4-8, 8-16 and 16-32 hours). Urine samples were prepared for 
analysis using the solid phase extraction protocol established in Chapter 3.
A four-point standard curve (20,10,1, and 0.5 pg/ml) containing 2,4- 
and 2,6-DETDA, 2,4- and 2,6-monoacetylated-DETDA, and 2,4- and 2,6- 
diacetylated-DETDA in methanol was used to determine a limit of quantitation. 
Sample extraction procedure
One-half ml of urine sample, 10 ppm of diazepam (internal standard), 
and 2.0 ml of 0.1 M potassium phosphate buffer (pH 7.0)5 was added to a 
16x100 mm borosilicate glass culture tube. The mixture was vortexed on a 
Vortex-2 Genie for 5 seconds on medium speed and the pH adjusted between
7.0 and 8.0 with KOH or phosphoric acid if needed.
C-8 Bond Elute Certify™ columns, placed into Teflon stopcocks and 
18- gauge needles, were inserted into a modified vacuum filtration manifold. 
Unused ports were plugged in order to control vacuum pressure. The columns,
See Appendix A for all buffer preparations.
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while under less than 5 inches Hg vacuum pressure, were conditioned by 
adding 2.0 ml of methanol followed by 2.0 ml of potassium phosphate buffer 
(pH 7.0). The columns were not allowed to dry out during conditioning. The 
sample mixtures were pipetted into labeled columns and allowed to pass 
through. This process took at least 2 minutes to complete with the vacuum set 
to less than 5 inches Hg. The column was washed by adding 4ml of potassium 
phosphate buffer (pH 7.0). It was further washed with 2ml of 6% acetonitrile- 
94% potassium phosphate buffer (pH 7.0) then dried under a full vacuum (15 
inches Hg) for 10 minutes. The vacuum manifold cover was removed and the 
needle tips blotted dry. A rack with labeled culture tubes was then placed into 
the manifold in preparation for collection of eluted compounds. Compounds of 
interest were then eluted with 1.0 ml of a 50:50 v/v solution of acetonitrile and 
methanol with no vacuum present. After 1 minute, 5 inches Hg vacuum was 
applied to remove any residual eluent. Samples were then placed into an 
EVAPO-MIX® at 45°C and evaporated to dryness under a stream of nitrogen 
gas. Samples were then restored to 0.5 ml with methanol, vortexed for 30 
seconds, and transferred to labeled vials for later GC analysis. 
Chromatography 
Instrumentation
Analysis was performed using a Hewlett-Packard 5895A Gas 
Chromato-graph equipped with a FID (flame ionization detector) detector and 
Chem-Station software (Chapter 2).
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Chromatography conditions
The GC-FID conditions used for the analysis of DETDA and 
acetylated-DETDA metabolites were as follows: chromatographic separations 
were achieved using a 30 m J&W Scientific DB-5 capillary column (0.25 mm
i.d. x 0.25 pm film); helium earner gas (60 p.s.i.g.) was set at a flow rate of 
approximately 20 ml min'1; hydrogen gas (20 p.s.i.g.) was set at a flow rate of 
approximately 30 ml min'1; air (30 p.s.i.g.) was set at a flow rate of approx­
imately 400 ml min'1; GC oven temperature was programmed from 100°C to 
188°C at 30°C min'1, then 3°C min'1 to 200°C, then 30°C min'1 to 300°C; 
injector and detector temperatures were set at 250°C and 320°C respectively; 
2.6 pi manual injections (0.5 min. splitless) were made. Standard curves were 
run before and after the sample analysis.
Results
Only 2 of the 3 rats administered Ethacure were quantitatively 
evaluated because of the questionable dosage administered to one of the rats. 
In the first rat, 4.0% of the administered dose was recovered as both 2,4- and
2,6-DETDA (parent compound) by 32 hours. In the second rat, 4.4% of the 
administered dose was recovered as both 2,4- and 2,6-DETDA. None of the 
expected acetylated DETDA metabolites were detected in the urine above 500 
ng/ml (limit of quantitation) in any of the 3 rats treated (see Appendix C).
Discussion
Acetylation is considered to be one of the major biotransformation 
reactions for aromatic amines in most species (4.12). It was therefore expected
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that both mono-acetylated- and/or diacetylated-DETDA metabolites would 
encompass a portion of the biotransformation profile of DETDA. The lack of 
acetylated metabolites in the urine of the Ethacure treated male Sprague 
Dawley rats was surprising. The experiment was repeated with a single male 
Sprague Dawley rat to confirm the results. The outcome was the same with 
4.3% recovery of the 2,4- and 2,6-DETDA isomers and no acetylated 
metabolites seen by 32 hours. Extraction efficiency of 2,4- and 2,6-DETDA 
isomers from the urine matrix ranged from 79.33% to 88.32% (Chapter 3).
Excretion studies (Chapter 5 and 6) for 2,4- and 2,6-DETDA showed 
that the majority of label was eliminated through the urinary system. Because 
no attempt was made to assay the bile for metabolites, any acetylated 
metabolites excreted via the biliary system were undetected.
This study was designed as a preliminary experiment to ascertain the 
presence or absence of parent compound and acetylated metabolites in urine 
samples. Protocols to determine a limit of detection was not incorporated in 
this study but was estimated to be approximately 200 ppb. The limit of 
quantitation for 2,4- and 2,6-DETDA and the mono- and diacetylated-DETDA 
metabolites was approximately 500 ppb determined by 4 point standard curves 
(1^=0.998-0.999). The unexpected results from this preliminary study prompted 
a change in direction for the DETDA project. Radiolabeled compound was 
incorporated into the remainder of the study precluding the further use of GC- 
FID.
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Reasons for the lack of acetylated DETDA metabolites in the urine are 
unknown at this time. Possible explanations for the outcome could be species, 
strain and sex variations, extremely low affinity for the acetyl transferase 
enzyme and/or high affinity for other biotransformation enzymes. Extremely 
low levels of acetylated metabolites might have gone undetected by a 
moderately sensitive FID detector. Since toluene-diamine is known to be 
acetylated in Fischer 344 rats, differences in structural conformation in DETDA 
(ethyl groups) are most likely contributing to the lack of or extremely low levels 
of acetylation. Because DETDA is easily acetylated with acetic anhydride 
(Chapter 3), the ethyl groups do not appear to sterically hinder acetylation, 
however it is more likely that the ethyl groups prevent the acetyltransferase 
enzyme from binding in an optimal orientation.
The 2,4-toluenediamine compound has been reported to be carcino­
genic in rodents (4.1,4.10,4.13). Results from a two-year feeding study of 
DETDA in rats showed effects on the pancreas, liver, thyroid and eyes as well 
as increased tumors in the liver and thyroid glands of male rats (4.5). The 
carcinogenic potential of Ethacure appears to be much less than 2,4-TDA. 
Whether the abscence or reduction in acetylation with DETDA could be related 
to the decreased carcinogenicity relative to TDA needs to be further explored.
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CHAPTER 5
DISTRIBUTION, EXCRETION, AND COVALENT 
BINDING OF 2,4-DIETHYLTOLUENEDIAMINE
Introduction
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is an industrial 
compound utilized as a polyurethane chain extender in reaction-injection 
molded (RIM) applications. DETDA has also been used as a curing agent for 
polyurethanes and epoxy resins, as an antioxidant, lubricant, a wire coating 
and as a replacement for more toxic industrial compounds, such as 
toluenediamine (TDA) and 4,4'-methylenebis-2-chloroaniline (MOCA) (5.1). 
DETDA has been manufactured by Albemarle Corporation (formerly Ethyl 
Corporation) under the name Ethacure®100 for more than 20 years. Ethacure 
is a mixture of compounds (Figure 5.1) composed mostly of 2 major isomers,
2,4-DETDA (75-81%) and 2,6-DETDA (18-20%). Because it is a proprietary 
compound, there is little information in the literature on this material except for 
patents dealing with synthesis and industrial use. DETDA is expected to be 
absorbed, distributed, metabolized and excreted in a similar manner to TDA, a 
widely used industrial compound, because of structural similarities (5.2-5.4).
Standard laboratory studies, including acute and subchronic toxicity 
tests, have been conducted on Ethacure. Results from a two-year feeding 
study in rats, conducted by Albemarle suggested that DETDA may affect the 
pancreas, liver, thyroid and eyes (5.5). These studies, and an interest by
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Figure 5.1 Chemical structures of DETDA and TDA isomers.
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Albemarle in full understanding of the potential toxicity of DETDA prompted a 
metabolic study of the mixture. Understanding of the distribution and excretion 
of DETDA in a mammalian system is important to help establish proper safety 
guidelines.
Tritiated Ethacure was prepared by the catalytic exchange of tritium 
gas on Ethacure. The tritium label is characteristically exchanged at the less 
labile benzylic positions on the ring (5.6). Labile tritium from the crude product 
was removed but no attempt at purification or separation of isomers was made.
Distribution, excretion and covalent DNA-binding studies on the 2,4- 
and 2,6-DETDA isomers needed to be conducted. Before the tritiated Ethacure 
could be used, it was necessary to determine the stability of the label then 
separate the mixture into major isomers.
This study entailed the oral administration of tritiated 2,4-DETDA to 
adult male Sprague Dawley rats. Distribution and excretion profiles over time 




The Hitachi U-2000 Spectrophotometer was purchased from Hitachi 
Instruments, Inc., Houston, Tx 77272. The Shimadzu LC-600 Liquid Chromato­
graph pump, Shimadzu SPD-10AV UV detector, Easychrome software and DT 
2802 A/D converter board were obtained from Shimadzu Scientific Instruments,
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Columbia, MD 21046. The C18 Partisphere 5pm 4.6x250mm reverse-phase 
column (No. 4621-1502), guard column (No. 4641-0002) and holder (No. 4651- 
0002) were purchased from Whatman Laboratory Division, Clifton, NJ 07014. 
The PrepPak 25x10 Bondapak™ cartridge, (10 pm No.38505), PrepPak 25x10 
pPorasil cartridge (10 pm No.38504) and RCM 25x10 cartridge holder 
(No. 15814) were purchased from Millipore Corp., Waters Chromatography 
Division, Milford, MA 01757. The Buchner Fractomette® Alpha 400 fraction 
collector was purchased from Buchler Instruments, Fort Lee, NJ 07024. The 
Packard Tri-Carb 4640 and 1900TR Liquid Scintillation Analyzer were 
purchased from Packard Instrument Co., Meriden, CT 06450. The Wheaton 
Overhead Stirrer (No. 903475) was purchased from Wheaton Instruments, 
Millville, NJ 08332. The 10 ml Potter-Elevehjem Grinder (No. 358038) was 
purchased from Wheaton, Millville, NJ 08332. The Burrell Model 75 Wrist 
Action® Shaker was obtained from Burrell Corp., Pittsburgh, PA 15201. The 
Sorvall GLC-2B General Lab Centrifuge was from Dupont Instruments,
Newtown, CN 06470. The Vortex-2 Genie was purchased from Scientific 
Industries, Inc., Bohemia, NY 11716. The Eppendorf Microcentrifuge (No.
5415C) was purchased from Brinkmann Instruments, Inc., Westbury, NY 
11590. The Ohaus E400D balance was purchased from Ohaus Corporation, 
Florham Park, NJ 07932. Sigma Plot software was purchased from Jandel 
Scientific, San Rafael, CA 94901. The Gilson Differential Respirometer (SC- 
14) was purchased from Gilson Medical Electronics, Middleton, Wl 53562.
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Chemicals and supplies
Ethacure®100 was obtained from the Albemarle Corp., Baton Rouge, 
LA 70801. Toluene, sodium hydroxide pellets, methanol (Nanograde®), 
calcium chloride (No. 4160) and hydrochloric acid were obtained from 
Mallinckrodt Chemicals, Paris, KY 40361. Ethanol (reagent grade, #AX0445- 
1), sodium chloride and potassium hydroxide (PX-1480-1) were from EM 
Science, Gibbstown, NJ 08027. Ethanol (dehydrated, absolute-200 proof) was 
purchased from McCormick Distilling Co., Inc., Weston, MS 64098.
Acetonitrile, acetone (high purity) and ethyl acetate were purchased from Curtis 
Matheson Scientific, Inc., Houston, TX 77251. Dibutylamine (99%), 
magnesium chloride (hexahydrate, 99%), hydrogen peroxide (30 wt. %, No.
21,676-3) and phosphoric acid (99.999%) were purchased from Aldrich 
Chemical Company, Inc., Milwaukee, Wl 53233. Guanidine isothiocyanate 
ultrapure™ was purchased from Bethesda Research Laboratories,
Gaithersburg, MD 20877. Phenol:chloroform premixed with isoamyl alcohol 
and EDTA (disodium salt dihydrate, >99% purity) were obtained from 
Amresco®, Solon, OH 44139. Ammonium acetate, Trizma® hydrochloride, and 
calf thymus DNA (sodium salt, D-1501) were purchased from Sigma Chemical 
Co., St. Louis, MO 63178. Tris Base (ultrapure) was purchased from Tyron®, 
Okemos, Ml 48664. SDS (sodium dodecyl sulfate, ultrapure) was purchased 
from Life Technologies, Inc., Gathensburg, MD 20898. Millipore ultra free-MC 
Low binding Cellulose 5,000 NMWL (No. UFC3LCC00) filters were purchased
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from Millipore Corporation, Milford, MA 01757. Vericel Membrane Filters 
(0.45pm, FP-450, 47mm No.66480) were purchased from Gelman Sciences, 
Ann Arbor, Ml 48106. Hionic-Fluor™ liquid scintillation cocktail (No.6013319), 
Soluene-350, Pico-Prias vial, 6.5ml (No.6000192), and Vented Pico Holder 
Adapter (No. 6013400) were purchased from Packard Instrument Co., Meriden, 
CT 06450. Harvard perfectum animal feeding needle (curved ball-tipped 18- 
gauge x 3", No. 7914) was purchased from Popper & Sons, Inc., Newhyde 
Park, NY 11640. Wayne®Autoclavable Rodent BLOX® 8656 diet (powdered 4% 
fat diet) was purchased from Laboratory Diets, Madison, Wl 53711. 50 ml 
Coming polypropylene centrifuge tubes (No. 25331-50) were purchased from 
Coming Inc., Coming, NY 14631. Nalgene® Wide-Mouth HDPE Bottles (No. 
2104-0004,125 ml) were purchased from the Nalge Company, Rochester, NY 
14602. Culture tubes (borosilicate) were purchased from Kimble Glass, Inc., 
Vineland, NJ 08360. Micro-centrifuge tubes (flat top/graduated, 1.5 and 2.0 ml) 
were purchased from Dot Scientific, Inc., Burton, Ml 48519. Chemicals 
purchased were reagent grade quality unless otherwise indicated.
Tritiated Ethacure was prepared by Amersham Life Science, Inc., 
Arlington Heights, IL 60005. The product was stored and shipped in 25 ml of 
ethanol, had a total activity of 6.72 mCi/ml, a specific activity of 1.2 Ci/mmol 
and a concentration of 0.0082 mmol/ml.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
171
Experimental Methods 
Determination of tritiated Ethacure stability
A 1 mg/ml solution of Ethacure®100 (134 pCi/ml) was prepared by 
mixing 20 pi of the 6.72 pCi/ml tritiated compound with 980 pi of a 1 mg/ml 
solution of unlabeled Ethacure. 100 pg/ml solutions in water, 0.1M HCL and 
0.1 M NaOH were made using the stock labeled solution then incubated for 1 
hour. Samples were then neutralized using sodium acetate or glacial acetic 
acid.
Fifty pi samples were chromatographed using a Shimadzu LC-600 
Liquid Chromatograph, Shimadzu SPD-10AV detector (295 nm) and a 
Whatman C18 Partisphere 5pm 4.6x250mm column. A 16.5% acetonitrile, 
100mM dibutylamine phosphate buffer (pH 3.0) mobile phase (see Chapter 2) 
was used at a 1 ml/min flow rate. Eluent was collected into 6.5 ml polyethylene 
liquid scintillation vials using a Buchner Fractomette® Alpha 400 fraction 
collector at 6 second intervals. Five ml of Hionic-Fluor™ liquid scintillation 
cocktail was added to each vial and the radioactivity measured on a Packard 
Tri-Carb 4640. Sigma Plot software was used to convert the raw data into 
chromatographs for analysis.
Separation and purification of tritiated Ethacure
A 10 mCi aliquot of [3H]-Ethacure®100 (1.5 ml in ethanol) was 
evaporated under a stream of nitrogen then restored to 0.75 ml using a 60:40 
v/v solution of toluene and ethanol. Isomer separation was achieved under a 
normal-phase preparative HPLC method using a Shimadzu LC-600 Liquid
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Chromatograph, a Shimadzu SPD-10AV detector (295 nm) and a PrepPak 
25x10 pPorasil cartridge in a RCM 25x10 cartridge holder. ThelOmCi 
sample was injected via a Rheodyne 1526 injector through a 1000 pi injection 
loop and eluted at 2ml/min for 60 minutes in a filtered 60:40 toluene:ethanol 
isocratic mobile phase. The 2,4- and the 2,6-DETDA fractions were collected 
referenced to unlabeled Ethacure chromatographed under identical 
parameters. Each fraction was collected, diluted to 10 ml with toluene, then 
stored at -20°C (5.7).
The tritiated 2,4-DETDA fraction was checked for purity using a 
Whatman C-18 reversed-phase column, a Shimadzu LC-600 Liquid 
Chromatograph and a Shimadzu SPD-10AV detector (295 nm). To prepare the 
sample, 5.36 pCi of [3H]-2,4-DETDA was placed into a 13x100mm borosilicate 
culture tube and evaporated to dryness. One ml of a 50 pg/ml solution of 
Ethacure dissolved in mobile phase was added to the tube and vortexed. A 50 
pi sample was injected via a Rheodyne 1526 injector through a 50 pi injection 
loop and eluted at 0.5 ml/min for 15 minutes in a 16.5% acetonitrile, 100 mM 
dibutylamine phosphate buffer (pH 3.0) isocratic mobile phase (5.8).
After injecting the sample, 63 fractions were collected into 6.5ml 
Pico-Prias liquid scintillation vials at 0.2 minute intervals using a Buchner 
Fracto-mette® Alpha 400 fraction collector. Five ml of Hionic-Fluor™ liquid 
scintillation cocktail was added to each vial and the radioactivity measured on 
a Packard Tri-Carb 4640 Liquid Scintillation Counter. Quattro Pro 6.0 was
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used to generate graphs from the UV and CPM data. CPM values from each 
peak on the generated graphs were totaled and the sums used to compute 
isomer purity.
Distribution studies
Five groups of 4 young adult male (10-12 weeks, 216-293 g) Sprague 
Dawley rats (obtained from the L.S.U. School of Veterinary Medicine,
Laboratory Animal Medicine breeding colony) were randomly selected and 
placed into individual metabolism cages for urine and feces collection. Rats 
were placed into cages 72 hours prior to dosing, fed a powdered 4% fat diet 
(Wayne®Autoc!avable Rodent BLOX® 8656 diet) and maintained in a 12-hour 
light-dark cycle environment. Rats were fasted for 16 hours prior to dosing 
eliminating the effects of gastric contents on absorption. Water was given ad 
libitum during the entire experiment. Tritiated 2,4-DETDA was diluted with non- 
tritiated Ethacure (84 pmol/ml) in water to provide a labeled mixture with a 
specific activity of 0.46 pCi/pmol. Rats were then orally dosed at 179 pmol/kg 
from this solution of 84 pmol/ml of Ethacure using a 1.0 ml Hamilton #1001 
syringe and a curved ball-tipped 18-gauge x 3" feeding needle.
Urine, feces, blood and tissues were collected at 5 time points: 1, 4, 8, 
24 and 48 hours. A day 6 tissue distribution time point was incorporated in the 
6 day excretion study. Rats were anesthetized with isoflurane at each time 
point. Blood samples were taken by cardiac puncture using a heparinized 12 
ml syringe with a 22-gauge needle then placed into labeled serum collection 
tubes for later processing.
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Urine was collected into ice-filled containers until the time of 
euthanasia. Each cage was washed with 12 ml of distilled water which was 
added to the total urine collection. Urines were measured and samples were 
refrigerated until analysis.
To remove any residual label, each cage was rinsed with 
approximately 20 ml of methanol which was collected in 50 ml Coming 
polypropylene centrifuge tubes. Tubes were centrifuged for 5 minutes at 2800 
rpm in a Sorvall GLC-2B General Lab Centrifuge preparing a clarified 
supernatant. After later analysis, methanol sample counts were added to urine 
sample counts providing a total urine count.
All feces in the cage at each time point were collected and placed into 
a 50 ml Coming polypropylene centrifuge tube. Small intestine contents were 
placed into the tube along with the caecum and large intestine and a small 
amount of water. This tissue was minced with a scissors then water added to 
the 45 ml mark. The 24 and 48 hour samples required placement into 125 ml 
polyethylene bottles which were filled to the 110 ml mark. All samples were 
weighed then throughly mixed for a minimum of 48 hours using a Burrell Model 
75 Wrist Action® Shaker.
The following tissues were removed from each rat at the time of death: 
fat (epididymal fat pad), skin (ventral midline), skeletal muscle (right 
quadriceps), thymus, lung (right caudal lobe), heart (apex), spleen (caudal 
end), pancreas, bladder, kidney (right caudal area), liver (right caudal lobe),
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stomach (greater curvature), proximal duodenum, caecum (apex), colon 
(proximal ascending), thyroid, and brain (right frontal lobe). Each tissue was 
removed, trimmed and weighed. A small piece of tissue (about 100 mg, except 
thyroid) was sampled from the same area of each organ, weighed and placed 
into labeled 6.5 ml polyethylene liquid scintillation counting vials for 
preparation.
In order to determine the percent of administered dose in each tissue 
sampled, the organ weight was needed. The skin, stomach, small intestine, 
caecum and colon presented difficult weighing problems at sampling time. To 
obtain the needed weights, these organs were harvested from 5 untreated 
young adult male Sprague Dawley rats. An average weight for each organ as a 
percent of body weight was calculated. Also, the anatomy of the rat pancreas 
made total dissection difficult and uncertain. To minimize variation, an average 
pancreatic tissue weight from 30 rats in the distribution and excretion study was 
calculated relative to body weight. This average weight was used in place of 
individual weights for the purpose of calculating percent of administered dose. 
Excretion studies
Five young adult male (10-12 weeks, 251-296 g) Sprague Dawley rats 
(obtained from the L.S.U. School of Veterinary Medicine, Laboratory Animal 
Medicine breeding colony) were randomly selected and placed into individual 
metabolism cages for urine and feces collection. Rats were placed into cages 
72 hours prior to dosing, fed a powdered 4% fat diet (Wayne®Autoclavable
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Rodent BLOX® 8656 diet) and maintained in a 12-hour light-dark cycle 
environment. Rats were fasted for 16 hours prior to dosing eliminating the 
effects of gastric contents on absorption. Water was given ad libitum during 
the entire experiment.
Tritiated 2,4-DETDA was diluted with non-tritiated Ethacure (84 
pmol/ml) in water to provide a labeled mixture with a specific activity of 0.48 
pCi/pmol. Rats were then orally dosed at 179 pmol/kg from this solution of 84 
pmol/ml of Ethacure using a 1.0 ml Hamilton #1001 syringe and a curved ball- 
tipped 18-gauge x 3" feeding needle.
Urine and feces were collected into ice-filled containers at 24 hour 
intervals for 6 days. Each cage was washed with 12 ml of distilled water which 
was added to the total urine collection. Urines were measured and samples 
were refrigerated until analysis.
Feces in the cage at each time point were placed into 125 ml 
polyethylene bottles. On day 6, rats were anesthetized with isoflurane and 
blood collected by cardiac puncture using a 12 ml heparinized syringe and 22- 
gauge needle. Contents from the stomach, small intestine, caecum, and large 
intestine were added to the day 6 time points. Water was added to the 110 ml 
level of all bottles and the weights recorded. Bottles were then shaken for a 
minimum of 48 hours using a Burrell Model 75 Wrist Action® Shaker ensuring 
equal and through mixing of intestinal contents.
The following tissues were removed from each rat at the time of death 
for a day 6 distribution study: fat (epididymal fat pad), skin (ventral midline),
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skeletal muscle (right quadriceps), thymus, lung (right caudal lobe), heart 
(apex), spleen (caudal end), pancreas, bladder, kidney (right caudal area), liver 
(right caudal lobe), stomach (greater curvature), proximal duodenum, caecum 
(apex), colon (proximal ascending) and brain (right frontal lobe). Each tissue 
was removed, trimmed and weighed. A small piece of tissue (about 100 mg, 
except thyroid) was sampled from the same area of each organ, weighed and 
placed into labeled 6.5 ml polyethylene liquid scintillation counting vials for 
preparation.
Characterization of urine fractions
Five urine samples from the [3H]-2,4-DETDA excretion experiment (24 
hour time point) were analyzed to determine the percent of excreted label that 
was water soluble, organic soluble or present as acid-labile conjugates. 200 pi 
of each urine sample was placed directly into Hionic-Fluor™ liquid scintillation 
cocktail and counted. To determine the total organic fraction, 200 pi urine 
samples in 1.5 ml Eppendorf microcentrifuge tubes were extracted 3 times with
1.0 ml of ethyl acetate. The 3 extracts were placed directly into Hionic-Fluor™ 
liquid scintillation cocktail and counted. To determine total acid-labile 
conjugates, urine samples were acid hydrolyzed (5.9). Each 200 pi sample 
was placed into a 2.0 ml Eppendorf microcentrifuge tube, acidified with 3 drops 
of 1M HCL, heated to 100°C for 60 minutes then neutralized with 3 drops of 1M 
NaOH. Each hydrolyzed sample was extracted 3 times with 1.0 ml of ethyl 
acetate. The combined extracts were placed into 20 ml liquid scintillation vials
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
178
containing Hionic-Fluor™ liquid scintillation cocktail and counted on a Packard 
1900TR Liquid Scintillation Analyzer.
Ionic and hydrostatic binding of DETDA with DNA
Besides the covalent binding seen between DNA and macromolecules 
or xenobiotics, other forms of binding must be considered. Ionic or 
electrostatic, hydrogen and Van der Waals bonds are sometimes formed 
between these molecules (5.10). In order to determine if covalent binding had 
occurred between DETDA and DNA, these other types of binding had to be 
ruled out (5.11).
A 1 mg/ml solution of calf thymus DNA and a 5 mg/ml solution of 
Ethacure was prepared in TE buffer. In a 15 ml borosilicate test tube was 
mixed 1 ml of the DNA solution, 1.0 ml of TE buffer and 200 pi of a 2.98 pCi/ml 
solution of [3H]-2,4-DETDA in TE buffer. The mixture was incubated for 1 hour 
at 37°C in a Gilson shaking water bath. A 400 pi sample of this mixture was 
pipetted into Hionic-Fluor™scintillation cocktail and counted with a Packard 
1900TR Liquid Scintillation Analyzer. To determine if DNA binding had 
occurred, another 400 pi of the tritiated mixture was passed through a Millipore 
5000 molecular weight cutoff filter. The filter was centrifuged for 30 minutes at
14,000 rpm on a Eppendorf microcentrifuge. The filter was then rinsed with 
300 pi of TE buffer. The eluent, minus the DNA with possible labeled DETDA, 
and the TE buffer wash was then counted. To release any DNA-bound tritiated 
DETDA trapped by the filter, 500 pi of a 5 mg/ml solution of Ethacure was
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passed through the filter system by centrifugation. The Ethacure, by 
competitive binding, should have displaced any labeled DETDA from the DNA 
and allowed it to be washed through the filter and counted.
To determine if any labeled DETDA was bound to the filter, control 
samples without DNA were also run. 400 pi of the 2.98 pCi/ml solution of [3H]-
2,4-DETDA in TE buffer was added to 3.6 ml of TE buffer. 400 pi of this 
solution was centrifuged through a Millipore filter. The filter was washed with 
TE buffer and the combined eluents counted. Evidence of ionic binding was 
achieved by comparing non-filtered labeled DETDA to labeled DETDA that 
passed through the cut-off filter before and after competitive binding with 
Ethacure. This data was then compared to data obtained with the control 
samples. All procedures were conducted in triplicate, the results of which were 
averaged.
Covalent binding studies
Three young adult male (10-12 weeks, 159-211g) Sprague Dawley 
rats (obtained from the L.S.U. School of Veterinary Medicine, Laboratory 
Animal Medicine breeding colony) were randomly selected and placed into 
individual metabolism cages. Rats were placed into cages 72 hours prior to 
dosing, fed a powdered 4% fat diet (Wayne®Autoclavable Rodent BLOX® 8656 
diet) and maintained in a 12-hour light-dark cycle environment. They were 
fasted for 16 hours prior to dosing to minimize the effects of gastric contents on 
absorption. Water was given ad libitum during the entire experiment.
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ONA extraction from the livers of rats previously exposed to tritiated 
DETDA at levels of 0.05 pCi/g of body weight resulted in counts just above 
background level. In order to place confidence in the study, a much higher 
dose of tritiated DETDA was administered. Tritiated 2,4-DETDA was diluted 
with unlabeled Ethacure to attain a specific activity of 8.42 pCi/pmol. Rats 
were dosed at 179 pmol/kg from labeled solutions of 84 pmol/ml of Ethacure in 
water prepared the morning of the experiment. A 1.0 ml Hamilton #1001 
syringe and a curved ball-tipped 18-gauge x 3" feeding needle was used to 
gavage the rats.
Twenty-four hours after dosing, rats were placed under isofiurane 
anesthesia then euthanized by exsanguination at which time the livers were 
harvested and weighed. Small pieces of liver tissue (about 100 mg) were 
excised, weighed and placed into labeled 6.5 ml polyethylene liquid scintillation 
counting vials for preparation.
DNA Extraction
The extraction of nucleic acid from the selected tissue required lysis of 
the cellular membranes followed by the separation of the nucleic acid from the 
resulting cellular debris. The nucleic acids were then partitioned into the 
aqueous phase using phenol-chloroform-isoamyl alcohol. The remainder of the 
cellular debris, including the proteins, entered into the organic fraction or the 
interface phase.
Liver samples (about 1g) were weighed before DNA extraction. To 
disrupt the cellular membranes, 10 volumes of 3M guanidine isothiocyanate
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solution was added to each tissue. Using a Wheaton overhead stirrer and a 10 
ml Potter-Elevehjem grinder, the mixture was throughly homogenized 
(5.12-5.14). To partition the nucleic acids into the aqueous phase, 1 volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the homogenate. 
After through mixing (45 seconds) with a Vortex-2 Genie, the phases were 
separated by centrifuging the mixture at 2800 rpm for 10 minutes in a Sorvall 
GLC-2B General Lab Centrifuge. The lower organic phase was removed and 
transferred to a 50 ml Coming centrifuge tube. The entire process was 
repeated twice more after which the top aqueous phase was transferred to a 50 
ml centrifuge tube.
Nucleic acid precipitation
One-tenth volume of 5M sodium chloride and 2 (original) volumes of 
100% ethanol was added to the aqueous layer producing a stringy precipitate 
of DNA. The 5M sodium chloride was used to reduced the amount of RNA in 
the precipitated nucleic acid (5.15). Each tube was centrifuged for 10 minutes 
at 2800 rpm and the supernatant poured off. The DNA was washed 2 times in 
ethanol, dried, then resuspended in 4 ml of TE buffer by shaking overnight in a 
60°C water bath.
Twenty units (0.2ml) of RNase A was added to each sample then 
incubated for 60 min at 37°C to remove any residual RNA (5.12). The samples 
were again extracted 3 times with 1 volume of phenol:chloroform:isoamyl 
alcohol (25:24:1). DNA from the resulting aqueous layer was precipitated with
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2 volumes of ethanol. The samples were centrifuged and the supernatant 
removed. The DNA was washed 2 times in ethanol, dried under nitrogen, then 
resuspended in 2 ml of TE buffer by shaking overnight in a 60°C water bath. 
DNA concentration was determined by absorbance using a Hitachi U-2000 
spectrophotometer. 200 pi of each sample was placed into a 6.5 ml liquid 
scintillation vial containing Hionic-Fluor™ scintillation cocktail then counted on 
a Packard 1900TR Liquid Scintillation Analyzer.
Protein precipitation
Precipitation of cellular protein was accomplished by adding 1.5 
volumes of acetone to the combined organic phases. After centrifuging the 
tubes for 10 minutes at 2800 rpm, the supernatants were poured off. The 
protein pellets were washed 2 times in acetone, dried in a vacuum desiccator, 
weighed, then processed for liquid scintillation counting.
Tissue preparation for liquid scintillation counting
Because radiolabeled biological samples could not be analyzed 
directly using a liquid scintillation counter, sample preparation methods were 
vitally important for obtaining accurate counts. A homogenous mixture of the 
biological sample and the liquid scintillation cocktail was needed. Some 
tissues such as urine could be added directly to the cocktail, while others 
required extensive preparation (5.16).
Blood
To a 50 pi sample of blood was added 1 ml of a 50:50 mixture of 
isopropanol:Soluene-350. The mixture was incubated for 30 minutes at 50°C.
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To decolorize the sample, 500 pi of 30% hydrogen peroxide was added 
dropwise while swirling. The mixture was incubated for 60 minutes at 50°C. 
Finally 4.5 ml of Hionic-Fluor™ scintillation cocktail was added for counting. 
Urine
200 pi of urine was added directly to 5.5 ml of Hionic-Fluor™ Liquid 
scintillation cocktail.
Methanol cage wash sample
200 pi of each methanol wash sample was added to 5.5 ml of Hionic- 
Fluor™ Liquid scintillation cocktail.
Feces
100-200 ml of the mixed fecal solution was added to 1 ml of Soluene- 
350, swirled till mixed, then incubated for 2 hours at 50°C. Isopropyl alcohol 
(0.5 ml) was added, the mixture vortexed, then again incubated for 2 hours at 
50°C. Hydrogen peroxide (300 pi of 30% solution), if needed, was added drop- 
wise while swirling and the sample incubated for 60 minutes at 50°C. Four ml 
of Hionic-Fluor™ scintillation cocktail was then added for counting.
Tissue
One ml of Soluene-350 was added to all sample tissues. Each sample 
was incubated a minimum of 4 hours at 50°C. After digestion, 4.5 ml Hionic- 
Fluor™ scintillation cocktail was added for counting. Hydrogen peroxide (200 
pi of 30% solution), if needed, was added dropwise while swirling. The 
samples were then incubated for 60 minutes at 50°C.
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Samples were dark adapted overnight then counted in a Packard Tri- 
Carb 1900 TR Liquid Scintillation Analyzer. Normalization and quench curves 
were conducted before samples were run. Each sample was counted for 10 
minutes.
Results
The stability of tritiated Ethacure
There appeared to be no significant differences in peak areas, 
shapes, and retention times between the 3 chromatograms. There was no 
obvious breakdown or exchange of label of the tritiated Ethacure occurring 
under acidic, neutral, or basic conditions. This suggested that the tritiated 
material would be stable under physiological conditions as well as under DNA 
extraction protocols used in the isolation procedures.
Separation and purification of tritiated Ethacure
Final analysis depicted purity levels of 95.5% for the [3H]-2,4-DETDA 
isomer. The identity of the 2,4-DETDA isomer was confirmed by the graphic 
relationship of the UV chromatograph relative to the LS spectrometry (Figure 
5.2). The purity level was considered adequate for the ensuing distribution and 
excretion studies.
Distribution and excretion studies for 2.4-DETDA
Calculated values for the weights of the skin, stomach, small intestine, 
caecum and colon used in determining the percent of administered dose in the 
distribution and excretion studies are listed in Table 5.1. The average weight
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Figure 5.2 Graphical confirmation of tritiated 2,4-DETDA (bottom) after 
separation of tritiated Ethacure’s (top) 2,4- and 2,6-DETDA 
isomers.
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Table 5.1 Average organ weights used in the determination of percent of 
administered dose in distribution and excretion experiments. 
Tissues were from adult male Sprague Dawley rats obtained from 
the L.S.U. School of Veterinary Medicine, Laboratory Animal 
Medicine breeding colony.
Skin
Rat No. Tissue Wt. Body Wt. % Body Wt. Rat No.
Stomach 
Tissue Wt. Body Wt. % Body Wt.
1 42.120 263 16.015 1 1.454 263 0.553
2 38.560 251 15.363 2 1.492 251 0.594
3 44.800 280 16.000 3 1.788 280 0.639
4 40.640 296 13.730 4 1.752 296 0.592
5 40.070 285 14.060 5 1.505 285 0.528
Avg. 15.033 Avg. 0.581
S.D. 1.079 S.D. 0.042
Duodenum Caecum
Rat No. Tissue Wt. BodyWt. % Body Wt. Rat No. Tissue Wt. BodyWt. % Body Wt.
1 4.038 263 1.535 1.059 263 0.403
2 4.771 251 1.901 1 1.200 251 0.478
3 4.264 280 1.523 2 1.240 280 0.443
4 3.481 296 1.176 3 1.370 296 0.463
5 3.950 285 1.386 4 1.392 285 0.488
Avg. 1.504 5 Avg. 0.455
S.D. 0.265 S.D. 0.034
Colon
Rat No. Tissue Wt. BodyWt. % BodyWt.
1 1.033 263 0.393
2 1.016 251 0.405
3 1.342 280 0.479
4 1.270 296 0.429
5 0.911 285 0.320
Avg. 0.405
S.D. 0.058
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for the pancreas was determined to be 3.569 ± 0.438 mg/100 g of body weight. 
Percent of body weight values used for blood (5.17), fat (5.18), and muscle 
(5.19) were 7%, 7.6% and 50% respectively.
Results of the tritiated 2,4-DETDA tissue distribution study presented 
as pmol of 2,4-DETDA per gram of tissue are depicted in Table 5.2 and Figures
5.3, 5.4 and 5.5. The data showed very high levels of label occurred in the 
gastrointestinal system and bladder during the first 8 hours reflecting 
compound that was either unabsorbed, distributed or excreted. The metabolic 
and excretory organs, liver and kidney, also showed moderate levels. Label in 
the thyroid and pancreas was much higher than expected, for non-excretory 
organs, with thyroid levels exceeding even that of liver tissue. The 
concentration of radioactivity in all tissues except the stomach, duodenum, 
caecum, colon, bladder and thyroid was greatest at 4 hours. With the 
exception of the stomach, duodenum, caecum, colon, bladder and thyroid, 
tissues exhibited a classic biphasic model of distribution and excretion with the 
onset of the slow phase occurring after the 4 hour time point. Thyroid levels, at 
24 and 48 hours, were the highest of all tissues examined at that time point. As 
can be gleaned from the 24 and 48 hour time frames, DETDA was rapidly 
cleared from all tissues. Day 6 residual levels of label (Figure 5.5) were fairly 
uniform in all tissues examined. Distribution levels for day 6 thyroid were 
unavailable, but the 48 hour time point values suggested that the thyroid levels 
at day 6 were probably elevated relative to other tissues.

















Table 5.2 Summation of the tritiated 2,4-DETDA distribution study in the male Sprague Dawley rat. Values
represent pmol of 2,4-DETDA/g of tissue (n=4) and the standard deviation (S.D.) for each tissue and 
time point.










Stomach 2.0995 0.8939 1.5740 0.7113 1.1185 0.7555 0.0277 0.0025 0.0121 0.0007
Duodenum 1.5464 1.1347 1.0137 0.5575 0.5623 0.2728 0.0216 0.0049 0.0116 0.0027
Caecum 0.1268 0.0552 0.2263 0.2240 0.5840 0.2663 0.1762 0.2029 0.0460 0.0362
Bladder 0.3338 0.1437 0.3162 0.2209 0.2930 0.1408 0.0747 0.0438 0.0172 0.0015
Colon 0.2593 0.1440 0.1806 0.0344 0.2356 0.1052 0.0679 0.0196 0.0157 0.0045
Thyroid 0.5114 0.5281 0.2024 0.1897 0.2335 0.1388 0.1465 0.0766 0.0987 0.0296
Pancreas 0.1290 0.0726 0.2454 0.0741 0.1299 0.0149 0.0174 0.0010 0.0126 0.0024
Liver 0.0993 0.0485 0.2335 0.1502 0.1627 0.0443 0.0392 0.0140 0.0277 0.0020
Kidney 0.0869 0.0379 0.1237 0.0240 0.1032 0.0403 0.0309 0.0045 0.0211 0.0043
Fat 0.0401 0.0285 0.1360 0.0229 0.1020 0.0273 0.0100 0.0051 0.0061 0.0027
Lung 0.0511 0.0158 0.1211 0.0642 0.0601 0.0086 0.0280 0.0040 0.0209 0.0027
Heart 0.0222 0.0049 0.0418 0.0032 0.0332 0.0067 0.0161 0.0037 0.0097 0.0018
Spleen 0.0370 0.0265 0.1077 0.0288 0.0551 0.0145 0.0174 0.0038 0.0136 0.0038
Blood 0.0230 0.0066 0.0461 0.0035 0.0440 0.0082 0.0245 0.0016 0.0169 0.0018
Skin 0.0438 0.0255 0.0755 0.0318 0.0419 0.0021 0.0220 0.0019 0.0160 0.0032
Muscle 0.0217 0.0151 0.0372 0.0153 0.0276 0.0039 0.0150 0.0017 0.0130 0.0025
Thymus 0.0186 0.0007 0.0380 0.0041 0.0320 0.0079 0.0170 0.0018 0.0103 0.0026
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Figure 5.3 Graphical representation of the tritiated 2,4-DETDA study in the adult male Sprague Dawley rat.
Values represent pmol of 2,4-DETDA/g of tissue (n=4). Higher and lower range of values are 




































Graphical representation of the tritiated 2,4-DETDA distribution study in the adult male Sprague 
Dawley rat. Values represent pmol of 2,4-DETDA/g of tissue (n=4). Higher and lower range of values 
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Figure 5.5 Results of the tritiated 2,4-DETDA tissue distribution study in the adult male Sprague Dawley rat. 
Values represent pmol of 2,4-DETDA/g of tissue remaining at the day 6 time point (n=5).
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The 2,4-DETDA tissue distribution results presented as percent of 
administered dose are depicted in Table 5.3 and Figures 5.6, 5.7 and 5.8. 
Radioactivity in the gastrointestinal system followed the expected profile of 
declining values over the entire length. Label in the stomach and small 
intestine peaked at 1 hour, reflecting the absorption of the compound, followed 
by declining values over time. Caecal counts peaked at 8 hours then declined 
at a steady rate. Large body mass tissues (muscle, skin and fat) had peaked 
by the hour 4 time period and, as expected, accumulated relatively large 
amounts of label. Fecal and urinary values represented an accumulation of 
excreted label at each time point. By 8 hours, urinary excretion became the 
primary route of elimination. By 24 hours, over 60% of the labeled compound 
had been excreted and by 6 days (Table 5.4) only 3.7% of label remained in 
the tissues. As expected, at day 6 , the majority of label was present in the 
muscle, skin, and fat. Elevated levels in liver and kidney were probably 
representative of metabolism and excretion functions. Blood levels remained 
relatively constant up to 48 hours reflecting label diffusing out of body tissues 
prior to excretion.
Figure 5.9 plots the accumulated excretion profile for the 2,4-DETDA 
isomer over 6 days. Approximately 46% of the administered dose of tritiated
2,4-DETDA was excreted in the first 24 hours. Accumulated urine and fecal 
levels of label peaked at 24 hours with urine levels double that of fecal. Urine 
levels dropped rapidly over the next 24 hours while fecal levels remained

















Table 5.3 Summation of the tritiated 2,4-DETDA distribution study in the male Sprague Dawley rat. Values
represent the percent of administered dose (n=4) and the standard deviation (S.D.) for each tissue and 
time point.
Tissue 1 hour 4 hour 8 hour 24 hour 48 hour
% of dose S.D . % of dose S.D. % of dose S.D . % of dose S.D . % of dose S.D.
Feces 7.752 11.464 12.279 9.721 14.108 2.743 22.923 2.705 24 .190 6.145
Urine 1.321 1.744 9.297 3.928 22 .538 5.359 42.992 4.545 40 .460 5.872
Muscle 7.485 5.221 12.837 5.283 9.539 1.338 5.190 0.590 4.501 0.848
Skin 4.546 2.647 7.834 3.302 4.347 0.217 2.280 0.195 1.665 0.333
Blood 1.112 0.320 2.229 0.167 2.126 0.395 1.182 0.076 0.913 0.088
Fat 2.103 1.494 7.134 1.204 5.350 1.430 0.523 0.270 0.319 0.141
Liver 2.553 1.371 5.099 2.835 3 .790 1.299 1.135 0.324 0.708 0.177
Caecum 0.398 0.173 0.717 0.703 1.834 0.843 0.553 0.637 0.144 0.114
Stomach 6.419 3.584 6.312 2.852 4.485 3.030 0.111 0.010 0.049 0.003
Sm. Intest. 16.052 11.779 10.523 5.787 5.837 2.832 0.224 0.051 0.120 0.028
Kidney 0.484 0.223 0.652 0.127 0 .545 0.178 0.170 0.019 0.116 0.018
Thymus 0.032 0 .009 0.043 0.005 0.042 0.011 0.025 0.003 0.012 0.003
Lung 0.139 0.053 0.297 0.254 0.161 0.025 0.084 0.011 0.060 0.011
Heart 0.053 0.009 0.099 0.015 0.082 0.015 0.036 0.008 0.022 0.004
Spleen 0.053 0.041 0.126 0.031 0.062 0.022 0.023 0.005 0.016 0.004
Pancreas 0.316 0 .179 0.605 0.183 0.320 0.037 0.043 0.003 0.032 0.006
Bladder 0.054 0.023 0.079 0.066 0.059 0.035 0.016 0.006 0.004 0.001
Thyroid 0.028 0.030 0.009 0.007 0.011 0.007 0.006 0.002 0.005 0.001
Brain 0.093 0.024 0.164 0.031 0.131 0.029 0.082 0.013 0.056 0.012































Graphical representation of the tritiated 2,4-DETDA distribution study in the adult male Sprague 
Dawley rat. Values represent the percent of administered dose (n=4). Higher and lower range of 





















Figure 5.7 Graphical representation of the tritiated 2,4-DETDA distribution study in the adult male Sprague 
Dawley rat. Values represent the percent of administered dose (n=4). Higher and lower range of 
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Figure 5.8 Results of the tritiated 2,4-DETDA tissue distribution study in the adult male Sprague Dawley rat.




Table 5.4 Summary for Day 6 of the tritiated 2,4-DETDA distribution study in 
the male Sprague Dawley rat. Values represent either the 
percent of administered dose or the ymol/g of 2,4-DETDA in the 
tissue.
Tissue % of Dose Stnd. Dev. Tissue pmol/g Stnd.Dev.
Blood 0.360 0.079 Blood 0.0075 0.0016
Fat 0.192 0.080 Fat 0.0037 0.0015
Skin 0.718 0.127 Skin 0.0069 0.0009
Muscle 1.899 0.266 Muscle 0.0055 0.0008
Thymus 0.004 0.002 Thymus 0.0059 0.0013
Lung 0.022 0.002 Lung 0.0065 0.0009
Heart 0.013 0.001 Heart 0.0053 0.0009
Spleen 0.017 0.001 Spleen 0.0061 0.0010
Pancreas 0.014 0.003 Pancreas 0.0056 0.0012
Bladder 0.002 0.001 Bladder 0.0062 0.0013
Kidney 0.048 0.008 Kidney 0.0090 0.0018
Liver 0.253 0.039 Liver 0.0104 0.0020
Stomach 0.021 0.002 Stomach 0.0054 0.0006
Sm. Intest. 0.054 0.010 Duodenum 0.0054 0.0012
Caecum 0.013 0.003 Caecum 0.0042 0.0012
Colon 0.016 0.004 Colon 0.0059 0.0015
Brain 0.025 0.005 Brain 0.0066 0.0016
Total 3.671
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Figure 5.9 Urinary and fecal excretion profile of tritiated 2,4-DETDA over 6 
days. Data points represent the percentage of administered dose 
of 2,4-DETDA (n=5) accumulated over time from urine and fecal 
samples.
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constant. By 48 hours, the excretion of 2,4-DETDA was almost complete with 
only slight amounts excreted over the next 4 days. Approximately 44% of the 
label was eliminated through the urinary system compared to about 36% in the 
feces (Table 5.5). The amount of labeled material recovered in the 2,4-DETDA 
6-day excretion study from the urine, feces, and tissue ranged from 62.1% to 
91.5% with an average of 83.1 %. Individual rat recovery percentages were as 
follows: 91.48%, 62.12%, 88.66%, 89.97% and 85.15%.
Characterization of urine fractions
Analysis of the data from the 24-hour time point urine samples 
revealed that 18.2% of labeled material was contained in the organic fraction. 
Acid hydrolysis demonstrated that 37.6% of the labeled material was in the 
form of acid-labile conjugates. The remaining 44.2% of the labeled material 
was composed of the non acid-labile water soluble fraction (Table 5.6).
Ionic and hydrostatic binding of DETPA with DNA
An 8.7% reduction in label counts was recorded for tritiated 2,4- 
DETDA samples incubated with the calf thymus DNA. Samples in which 
Ethacure was used competitively to displace labeled compound from the DNA 
resulted in a 6.1% decrease in counts. The decrease in label counts 
suggested that some binding might be occurring, however, control samples 
without DNA resulted in a 10.5% decrease. These results seem to indicate that 
the decrease was due to the binding of label to the filter and not non-covalent 
binding to the DNA.
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Table 5.5 Summary of the 6 day tritiated 2,4-DETDA excretion study in the 
adult male Sprague Dawley rat. Values represent the percent of 
administered dose of tritiated 2,4-DETDA excreted at each time 
point (n=5).
Urines Feces
Day % of Dose Stnd. Dev. % of Dose Stnd. Dev.
1 29.32 2.46 16.19 3.00
2 11.44 3.64 15.86 3.63
3 1.43 0.18 2.14 0.22
4 0.76 0.16 0.99 0.25
5 0.54 0.16 0.38 0.04
6 0.47 0.08 0.29 0.08
Totals 43.96 35.85
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Table 5.6 Classification of labeled compounds extracted from the 24 hour 
time point urine samples in the tritiated d2,4-DETDA excretion 
study. Ethyl acetate extraction partitioned labeled compounds 
into organic and water soluble fractions. Acid hydrolysis released 
acid-labile conjugates from the water soluble fraction. Group 
A=non extracted urine samples, Group B=ethyl acetate extracted 
urine samples, Group C=acid hydrolyzed and ethyl acetate 
extracted urine samples. Calculations: organic fraction = B/A, 
acid-labile conjugates = (C-B)/A, non acid-labile water soluble 
fraction = 100 - (organic fraction + acid labile conjugates).
Group A Group B Group C
Sample DPM Sample DPM Sample DPM
1 29304.2 1 4584.67 1 17039.7
2 29898.7 2 5575.56 2 17122.3
3 31473.9 3 6206.20 3 18111.1
4 31033.0 4 5951.76 4 16746.6












Non Acid-Labile Water Soluble Fraction_______ 44.2
Total 100.0
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Covalent binding studies
Binding study results of DETDA to DNA and protein is compiled in 
Table 5.7. Relative to Ethacure (80.8% 2,4-DETDA, 19.2% 2,6-DETDA), 16 
pmol of 2,4-DETDA/pmol of DNA was found covalently bound. For the 2,4- 
DETDA isomer, 55% of the label was bound to the protein fraction equating to 
108 nmol 2,4-DETDA per gram of liver protein. The 260/280 ratio for the 
samples was 1.9.
Discussion
It is obvious from the data that the 2,4-DETDA isomer was rapidly 
absorbed from the gastrointestinal system. The distribution profile suggests 
that the compound has both water and fat soluble properties. The relatively 
greater accumulation of label in the thyroid, pancreas, and liver tissue may 
reflect the possible toxic qualities encountered in the long term feeding study. 
The data also suggest that 2,4-DETDA was distributed to most, if not every 
tissue in the body. Excretion data showed that the primary route of elimination 
of the labeled 2,4-DETDA was the urinary system with fecal elimination closely 
following. The majority of urinary elimination occurred during the first 24 hours 
while fecal excretion occurred over 48 hours with equal amounts being 
eliminated both days. The 83.1% recovery of labeled material was lower than 
expected. Metabolism cages were rinsed with only 12 ml of water then washed 
between time points. The low recovery of the number 2 rat (62.12%) and the
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Table 5.7 Tritiated 2,4-DETDA covalent binding on rat liver DNA and 
protein.
Isomer pmol DETDA nmol DETDA % of label on 
per pmol DNA per g Protein protein
2,4-DETDA 16 108 55
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loss of label due to insufficient rinsing was credited for the lower than expected 
recovery.
Acid hydrolysis of 24-hour time point urine samples resulted in 38% 
acid-labile conjugated metabolites. This compared with the 34% and 39% 
conjugates excreted in the urine of rats administered an oral dose of 50 and 60 
mg/kg respectively for the structurally similar compound 2,4-TDA (5.20,5.21). 
This conjugation data suggests that 2,4-DETDA may be metabolized in a 
similar manner to 2,4-TDA. However, unlike 2,4-TDA which produced between 
1.4 and 5.7% acetylated metabolites (5.20,5.22,5.23), early metabolic work on
2,4-DETDA resulted in no acetylated species (Chapter 4). How closely the 
metabolic profile of DETDA is to TDA will remain unknown until further 
metabolic studies are undertaken.
Cellular DNA is often the target of covalent addition. These DNA 
adducts can have serious ramifications because of the critical role that DNA 
plays in cellular functions and cell reproduction. The importance of persistent 
in vivo DNA-arylamine adducts can be seen in the devastating consequences 
of gene mutations and cancer (5.24-5.29).
This In vitro DNA binding study with 2,4-DETDA demonstrated that no, 
or very little, non-covalent binding took place while this in vivo study showed 
moderate levels (16 pmol of 2,4-DETDA/pmol DNA) of covalent binding.
When 30 pmol of 2,4-TDA was incubated with rat liver hepatocytes for 
24 hours, approximately 145 pmol of TDA/pmol DNA resulted (5.30). This 
compares to the 16 pmol of 2,4-DETDA/pmol DNA observed in the present
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study. Although the 2,4-TDA study was an in vitro assay, results suggest that 
compared to TDA, 2,4-DETDA is less likely to be involved in covalent binding 
to DNA. DETDA does however, seem to have considerable affinity for protein. 
Consequences of this DETDA protein binding, if any, are unknown at the 
present time.
Ethacure has been used successfully for over 20 years as a 
replacement chemical for known toxic compounds. The results of this study 
shows that 2,4-DETDA, the major component of Ethacure, clears quickly after 
an orally administered dose, such that by 24 hours, less than one-third of the 
label remains in the tissues. There also appears to be very little accumulation 
in tissue by day 6 after exposure.
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CHAPTER 6
DISTRIBUTION, EXCRETION, AND COVALENT 
BINDING OF 2,6-DIETHYLTOLUENEDIAMINE
Introduction
Diethyitoluenediamine (DETDA, CAS 68479-98-1) is an industrial 
compound utilized as a polyurethane chain extender in reaction-injection 
molded (RIM) applications. DETDA has also been used as a curing agent for 
polyurethanes and epoxy resins, as an antioxidant, lubricant, a wire coating 
and as a replacement for more toxic industrial compounds, such as 
toluenediamine (TDA) and 4,4'-methylenebis-2-chloroaniline (MOCA) (6.1). 
DETDA has been manufactured by Albemarle Corporation (formerly Ethyl 
Corporation) under the name Ethacure®100 for more than 20 years. Ethacure 
is a mixture of compounds (Figure 6.1) composed mostly of 2 major isomers,
2,4-DETDA (75-81%) and 2,6-DETDA (18-20%). Because it is a proprietary 
compound, there is little information in the literature on this material except for 
patents dealing with synthesis and industrial use. DETDA is expected to be 
absorbed, distributed, metabolized and excreted in a similar manner to TDA 
(Figure 6.1), a widely used industrial compound, because of structural 
similarities (6.2-6.4).
Standard laboratory studies, including acute and subchronic toxicity 
tests, have been conducted on Ethacure. Results from a two-year feeding 
study in rats, conducted by Albemarle suggested that DETDA may affect the
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Figure 6.1 Chemical structures of DETDA and TDA isomers.
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pancreas, liver, thyroid and eyes (6.5). These studies, and an interest by 
Albemarle in full understanding of the potential toxicity of DETDA prompted a 
metabolic study of the mixture. Understanding of the distribution and excretion 
of DETDA in a mammalian system is important to help establish proper safety 
guidelines.
Tritiated Ethacure was prepared by the catalytic exchange of tritium 
gas on Ethacure. The tritium label is characteristically exchanged at the less 
labile benzylic positions on the ring (6.6). Amersham removed labile tritium 
from the crude product but did not attempt purification or separation of 
isomers.
Distribution, excretion and covalent DNA-binding studies on the 2,4- 
and 2,6-DETDA isomers needed to be conducted. Before the tritiated Ethacure 
could be used, it was necessary to determine the stability of the label then 
separate the mixture into major isomers.
This study entailed the oral administration of tritiated 2,6-DETDA to 
young adult male Sprague Dawley rats. Distribution and excretion profiles over 





The Hitachi U-2000 Spectrophotometer was purchased from Hitachi 
Instruments, Inc., Houston, Tx 77272. The Shimadzu LC-600 Liquid
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Chromatograph pump, Shimadzu SPD-10AV UV detector, Easychrome 
software and DT 2802 A/D converter board were obtained from Shimadzu 
Scientific Instruments, Columbia, MD 21046. The C18 Partisphere 5pm 
4.6x250mm reverse-phase column (No. 4621-1502), guard column (No. 4641- 
0002) and holder (No. 4651-0002) were purchased from Whatman Laboratory 
Division, Clifton, NJ 07014. The PrepPak 25x10 Bondapak™ cartridge, (10 pm 
No.38505), PrepPak 25x10 pPorasil cartridge (10 pm No.38504) and RCM 
25x10 cartridge holder (No. 15814) were purchased from Millipore Corporation, 
Waters Chromatography Division, Milford, MA 01757. The Buchner 
Fractomette® Alpha 400 fraction collector was purchased from Buchler 
Instruments, Fort Lee, NJ 07024. The Packard Tri-Carb 4640 and 1900TR 
Liquid Scintillation Analyzer were purchased from Packard Instrument Co., 
Meriden, CT 06450. The Wheaton Overhead Stirrer (No. 903475) was 
purchased from Wheaton Instruments, Millville, NJ 08332. The 10 ml Potter- 
Elevehjem Grinder (No. 358038) was purchased from Wheaton, Millville, NJ 
08332. The Burrell Model 75 Wrist Action® Shaker was obtained from Burrell 
Corporation, Pittsburgh, PA 15201. The Sorvall GLC-2B General Lab 
Centrifuge was from Dupont Instruments, Newtown, CN 06470. The Vortex-2 
Genie was purchased from Scientific Industries, Inc., Bohemia, NY 11716. The 
Eppendorf Microcentrifuge (No. 5415C) was purchased from Brinkmann 
Instruments, Inc., Westbury, NY 11590. The Ohaus E400D balance was 
purchased from Ohaus Corporation, Florham Park, NJ 07932. Sigma Plot
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software was purchased from Jandel Scientific, San Rafael, CA 94901. The 
Gilson Differential Respirometer (SC-14) was purchased from Gilson Medical 
Electronics, Middleton, Wl 53562.
Chemicals and supplies
Ethacure®100 was obtained from the Albemarle Corporation, Baton 
Rouge, LA 70801. Toluene, sodium hydroxide pellets, methanol (Nanograde®), 
calcium chloride (No. 4160) and hydrochloric acid were obtained from 
Mallinckrodt Chemicals, Paris, KY 40361. Ethanol (reagent grade, #AX0445- 
1), sodium chloride and potassium hydroxide (PX-1480-1) were purchased from 
EM Science, Gibbstown, NJ 08027. Ethanol (dehydrated, absolute-200 proof) 
was purchased from McCormick Distilling Co., Inc., Weston, MS 64098. 
Acetonitrile, acetone (high purity) and ethyl acetate were purchased from Curtis 
Matheson Scientific, Inc., Houston, TX 77251. Dibutylamine (99%), 
magnesium chloride (hexahydrate, 99%), hydrogen peroxide (30 wt. %, No. 
21,676-3) and phosphoric acid (99.999%) were purchased from Aldrich 
Chemical Company, Inc., Milwaukee, Wl 53233. Guanidine isothiocyanate 
ultrapure™ was purchased from Bethesda Research Laboratories,
Gaithersburg, MD 20877. Phenolichloroform premixed with isoamyl alcohol 
and EDTA (disodium salt dihydrate, >99% purity) was obtained from Amresco®, 
Solon, OH 44139. Ammonium acetate, Trizma® hydrochloride and calf thymus 
DNA (Sodium salt, D-1501) were purchased from Sigma Chemical Co., St.
Louis, MO 63178. Tris base (ultrapure) was purchased from Tyron®, Okemos,
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Ml 48664. SDS (sodium dodecyl sulfate, ultrapure) was purchased from Life 
Technologies, Inc., Gathensburg, MD 20898. Millipore ultra free-MC Low 
binding Cellulose 5,000 NMWL (No. UFC3LCC00) filters were purchased from 
Millipore Corp., Milford, MA 01757. Vericel Membrane Filters (0.45pm, FP-450, 
47mm No.66480) were purchased from Gelman Sciences, Ann Arbor, Ml 
48106. Hionic-Fluor™ liquid scintillation cocktail (No.6013319), Soluene®-350, 
Pico-Prias vial, 6.5ml (No.6000192), and Vented Pico Holder Adapter (No. 
6013400) were purchased from Packard Instrument Co., Meriden, CT 06450. 
Harvard perfectum animal feeding needle (curved ball-tipped 18-gauge x 3",
No. 7914) was purchased from Popper & Sons, Inc., Newhyde Park, NY 11640. 
Wayne®Autoclavable Rodent BLOX® 8656 diet (powdered 4% fat diet) was 
purchased from Laboratory Diets, Madison, Wl 53711. 50 ml Coming 
polypropylene centrifuge tubes (No. 25331-50) were purchased from Coming 
Inc., Coming, NY 14631. Nalgene® Wide-Mouth HDPE Bottles (No. 2104- 
0004,125 ml) were purchased from the Nalge Company, Rochester, NY 14602. 
Culture tubes (borosilicate) were purchased from Kimble Glass, Inc., Vineland, 
NJ 08360. Micro-centrifuge tubes (flat top/graduated, 1.5 and 2.0 ml) were 
purchased from Dot Scientific, Inc., Burton, Ml 48519. Chemicals purchased 
were reagent grade quality unless otherwise indicated.
Tritiated Ethacure was prepared by Amersham Life Science, Inc., 
Arlington Heights, IL 60005. The product was stored and shipped in 25 ml of 
ethanol, had a total activity of 6.72 mCi/ml, a specific activity of 1.2 Ci/mmol 
and a concentration of 0.0082 mmol/ml.
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Experimental Methods
Determination of tritiated Ethacure stability
A 1 mg/ml solution of Ethacure (134 pCi/ml) was prepared by mixing 
20 pi of the 6.72 pCi/ml tritiated compound with 980 pi of a 1 mg/ml solution of 
unlabeled Ethacure. 100 pg/ml solutions in water, 0.1M HCL and 0.1 M NaOH 
were prepared using the stock labeled solution then incubated for 1 hour. 
Samples were then neutralized using sodium acetate or glacial acetic acid.
50 pi samples were chromatographed using a Shimadzu LC-600 
Liquid Chromatograph, Shimadzu SPD-10AV detector (295 nm) and a 
Whatman C18 Partisphere 5pm 4.6x250mm column. A 16.5% acetonitrile, 
100mM dibutylamine phosphate buffer (pH 3.0) mobile phase (see Chapter 2) 
was used at a 1 ml/min flow rate. Eluent was collected into 6.5 ml polyethylene 
liquid scintillation vials using a Buchner Fractomette® Alpha 400 fraction 
collector at 6 second intervals. Five ml of Hionic-Fluor™ liquid scintillation 
cocktail was added to each vial and the radioactivity measured on a Packard 
Tri-Carb 4640. Sigma Plot software was used to convert the raw data into 
chromatographs for analysis.
Separation and purification of tritiated Ethacure
A 10 mCi aliquot of [3H]-ethacure (1.5 ml in ethanol) was evaporated 
under a stream of nitrogen then restored to 0.75 ml using a toluene:ethanol 
(60:40) solution. Isomer separation was achieved under a normal-phase 
preparative HPLC method using a Shimadzu LC-600 Liquid Chromatograph, a
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Shimadzu SPD-10AV detector (295 nm) and a PrepPak 25x10 pPorasil 
cartridge in a RCM 25x10 cartridge holder. The 10 mCi sample was injected 
via a Rheodyne 1526 injector through a 1000 pi injection loop and eluted at 
2ml/min for 60 minutes in a filtered 60:40 toluene:ethanol isocratic mobile 
phase. The 2,4- and the 2,6-DETDA fractions were collected referenced to 
unlabeled Ethacure chromatographed under identical parameters. Each 
fraction was collected, diluted to 10 ml with toluene, then stored at -20°C (6.7).
The tritiated 2,6-DETDA fraction was checked for purity using a 
Whatman C-18 reversed-phase column, a Shimadzu LC-600 Liquid 
Chromatograph and a Shimadzu SPD-10AV detector (295 nm). To prepare the 
sample, 2.40 pCi of [3H]-2,6-DETDA was placed into a 13x100mm borosilicate 
culture tube and evaporated to dryness. One ml of a 50 pg/ml solution of 
Ethacure dissolved in mobile phase was added to the tube and vortexed. A 50 
pi sample was injected via a Rheodyne 1526 injector through a 50 pi injection 
loop and eluted at 0.5 ml/min for 15 minutes in a 16.5% acetonitrile, 100 mM 
dibutylamine phosphate buffer (pH 3.0) isocratic mobile phase (6.8).
After injecting the sample, 63 fractions were collected into 6.5ml 
Pico-Prias liquid scintillation vials at 0.2 minute intervals using a Buchner 
Fractomette® Alpha 400 fraction collector. Five ml of Hionic-Fluor™ liquid 
scintillation cocktail was added to each vial and the radioactivity measured on 
a Packard Tri-Carb 4640 Liquid Scintillation Counter. Quattro Pro 6.0 was 
used to generate graphs from the UV and CPM data. CPM values from each
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peak on the generated graphs were totaled and the sums used to compute 
isomer purity.
Distribution studies
Five groups of 4 young adult male (10-12 weeks, 189-296 g) Sprague 
Dawley rats (obtained from the L.S.U. School of Veterinary Medicine,
Laboratory Animal Medicine breeding colony) were randomly selected and 
placed into individual metabolism cages for urine and feces collection. Rats 
were placed into cages 72 hours prior to dosing, fed a powdered 4% fat diet 
(Wayne®Autoclavable Rodent BLOX® 8656 diet) and maintained in a 12-hour 
light-dark cycle environment. Rats were fasted for 16 hours prior to dosing 
eliminating the effects of gastric contents on absorption. Water was given ad 
libitum during the entire experiment. Tritiated 2,6-DETDA was diluted with non- 
tritiated Ethacure (84 pmol/ml) in water to provide a labeled mixture with a 
specific activity of 0.39 pCi/pmol. Rats were then orally dosed at 179 pmol/kg 
from this solution of 84 pmol/ml of labeled Ethacure using a 1.0 ml Hamilton 
#1001 syringe and a curved ball-tipped 18-gauge x 3" feeding needle.
Urine, feces, blood and tissues were collected at 5 time points: 1, 4, 8, 
24 and 48 hours. A day 6 tissue distribution time point was incorporated in the 
6 day excretion study. Rats were anesthetized with isoflurane at each time 
point. Blood samples were taken by cardiac puncture using a heparinized 12 
ml syringe with a 22-gauge needle then placed into labeled serum collection 
tubes for later processing.
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Urine was collected into ice-filled containers until the time of 
euthanasia. Each cage was washed with 20 ml of distilled water which was 
added to the total urine collection. Urines were measured and samples were 
refrigerated until analysis.
To remove any residual label, each cage was rinsed with 
approximately 35 ml of methanol which was collected in 50 ml Coming 
polypropylene centrifuge tubes. Tubes were centrifuged for 5 minutes at 2800 
rpm in a Sorvall GLC-2B General Lab Centrifuge preparing a clarified 
supernatant. After later analysis, methanol sample counts were added to urine 
sample counts providing a total urine count.
All feces in the cage at each time point were collected and placed into 
a 50 ml Coming polypropylene centrifuge tube. Small intestine contents were 
placed into the tube along with the caecum and large intestine and a small 
amount of water. This tissue was minced with a scissors then water added to 
the 45 ml mark. The 24 and 48 hour samples required placement into 125 ml 
polyethylene bottles which were filled to the 110 ml mark. All samples were 
weighed then throughly mixed for a minimum of 48 hours using a Burrell Model 
75 Wrist Action® Shaker.
The following tissues were removed from each rat at the time of death: 
fat (epididymal fat pad), skin (ventral midline), skeletal muscle (right 
quadriceps), thymus, lung (right caudal lobe), heart (apex), spleen (caudal 
end), pancreas, bladder, kidney (right caudal area), liver (right caudal lobe),
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stomach (greater curvature), proximal duodenum, caecum (apex), colon 
(proximal ascending), thyroid, brain (right frontal lobe) and testes (right cranial 
pole). Each tissue was removed, trimmed and weighed. A small piece of 
tissue (about 100 mg, except thyroid) was sampled from the same area of each 
organ, weighed and placed into labeled 6.5 ml polyethylene liquid scintillation 
counting vials for preparation.
In order to determine the percent of administered dose in each tissue 
sampled, the organ weight was needed. The skin, stomach, small intestine, 
caecum and colon presented difficult weighing problems at sampling time. To 
obtain the needed weights, these organs were harvested from 5 untreated 
young adult male Sprague Dawley rats. An average weight for each organ as a 
percent of body weight was calculated. Also, the anatomy of the rat pancreas 
made total dissection difficult and uncertain. To minimize variation, an average 
pancreatic tissue weight from 30 rats in the distribution and excretion study was 
calculated relative to body weight. This average weight was used in place of 
individual weights for the purpose of calculating percent of administered dose. 
Excretion studies
Five young adult male (10-12 weeks, 216-293 g) Sprague Dawley rats 
(obtained from the L.S.U. School of Veterinary Medicine, Laboratory Animal 
Medicine breeding colony) were randomly selected and placed into individual 
metabolism cages for urine and feces collection. Rats were placed into cages 
72 hours prior to dosing, fed a powdered 4% fat diet (Wayne®Autoclavable
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Rodent BLOX® 8656 diet) and maintained in a 12-hour light-dark cycle 
environment. Rats were fasted for 16 hours prior to dosing eliminating the 
effects of gastric contents on absorption. Water was given ad libitum during 
the entire experiment.
Tritiated 2,4-DETDA was diluted with non-tritiated Ethacure (84 
pmol/ml) in water to provide a labeled mixture with a specific activity of 0.295 
pCi/pmol. Rats were then orally dosed at 179 pmol/kg from this solution of 84 
pmol/ml of labeled Ethacure using a 1.0 ml Hamilton #1001 syringe and a 
curved ball-tipped 18-gauge x 3" feeding needle.
Urine and feces were collected into ice-filled containers at 24 hour 
intervals for 6 days. Each cage was washed with 20 ml of distilled water which 
was added to the total urine collection. Urines were measured and samples 
were refrigerated until analysis.
To remove any residual label, each cage was rinsed with 
approximately 35 ml of methanol which was collected in 50 ml Coming 
polypropylene centrifuge tubes. Tubes were centrifuged for 5 minutes at 2800 
rpm in a Sorvall GLC-2B General Lab Centrifuge preparing a clarified 
supernatant. After analysis, methanol sample counts were added to urine 
sample counts providing a total urine count.
Feces in the cage at each time point were placed into 125 ml 
polyethylene bottles. On day 6, rats were anesthetized with isoflurane and 
blood collected by cardiac puncture using a 12 ml heparinized syringe and 22- 
gauge needle. Contents from the stomach, small intestine, caecum, and large
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intestine were added to the day 6 time points. Water was added to the 110 ml 
level of all bottles and the weights recorded. Bottles were then shaken for a 
minimum of 48 hours using a Burrell Model 75 Wrist Action® Shaker ensuring 
equal and through mixing of intestinal contents.
The following tissues were removed from each rat at the time of death 
for a day 6 distribution study: fat (epididymal fat pad), skin (ventral midline), 
skeletal muscle (right quadriceps), thymus, lung (right caudal lobe), heart 
(apex), spleen (caudal end), pancreas, bladder, kidney (right caudal area), liver 
(right caudal lobe), stomach (greater curvature), proximal duodenum, caecum 
(apex), colon (proximal ascending) and brain (right frontal lobe). Each tissue 
was removed, trimmed and weighed. A small piece of tissue (about 100 mg, 
except thyroid) was sampled from the same area of each organ, weighed and 
placed into labeled 6.5 ml polyethylene liquid scintillation counting vials for 
preparation.
Ionic and hydrostatic binding of DETDA with DNA
Besides the covalent binding seen between DNA and macromolecules 
or xenobiotics, other forms of binding must be considered. Ionic or 
electrostatic, hydrogen and Van der Waals bonds are sometimes formed 
between these molecules (6.9). In order to determine if covalent binding had 
occurred between DETDA and DNA, these other types of binding had to be 
ruled out (6.10).
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A 1 mg/ml solution of calf thymus DNA and a 5 mg/ml solution of 
Ethacure was prepared in TE buffer. In a 15 ml borosilicate test tube was 
mixed 1 ml of the DNA solution, 1.0 ml of TE buffer and 200 pi of a 2.98 pCi/ml 
solution of [3H]-2,4-DETDA in TE buffer. The mixture was incubated for 1 hour 
at 37°C in a Gilson shaking water bath. A 400 pi sample of this mixture was 
pipetted into Hionic-Fluor™ scintillation cocktail and counted with a Packard 
1900TR Liquid Scintillation Analyzer. To determine if DNA binding had 
occurred, another 400 pi of the tritiated mixture was passed through a Millipore 
5000 molecular weight cutoff filter. The filter was centrifuged for 30 minutes at 
14,000 rpm on a Eppendorf microcentrifuge. The filter was then rinsed with 
300 pi of TE buffer. The eluent, minus the DNA with possible labeled DETDA, 
and the TE buffer wash was then counted. To release any DNA-bound tritiated 
DETDA trapped by the filter, 500 pi of a 5 mg/ml solution of Ethacure was 
passed through the filter system by centrifugation. The Ethacure, by 
competitive binding, should have displaced any labeled DETDA from the DNA 
and allowed it to be washed through the filter and counted.
To determine if any labeled DETDA was bound to the filter, control 
samples without DNA were also run. 400 pi of the 2.98 pCi/ml solution of [3H]-
2,4-DETDA in TE buffer was added to 3.6 ml of TE buffer. 400 pi of this 
solution was centrifuged through a Millipore filter. The filter was washed with 
TE buffer and the combined eluents counted. Evidence of ionic binding was 
achieved by comparing non-filtered labeled DETDA to labeled DETDA that
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passed through the cut-off filter before and after competitive binding with 
Ethacure. This data was then compared to data obtained with the control 
samples. All procedures were conducted in triplicate, the results of which were 
averaged.
Covalent binding studies
Three young adult male (159-211g) Sprague Dawley rats (obtained 
from the L.S.U. School of Veterinary Medicine, Laboratory Animal Medicine 
breeding colony) were randomly selected and placed into individual 
metabolism cages. Rats were placed into cages 72 hours prior to dosing, fed a 
powdered 4% fat diet (Wayne®Autoclavable Rodent BLOX® 8656 diet) and 
maintained in a 12-hour light-dark cycle environment. They were fasted for 16 
hours prior to dosing to minimize the effects of gastric contents on absorption. 
Water was given ad libitum during the entire experiment.
DNA extraction from the livers of rats previously exposed to tritiated 
DETDA at levels of 0.05 pCi/g of body weight resulted in counts just above 
background level. In order to place confidence in the study, a much higher 
dose of tritiated DETDA was administered. Tritiated 2,6-DETDA was diluted 
with unlabeled Ethacure to attain a specific activity of 4.41 pCi/pmol. Rats 
were dosed at 179 pmol/kg from labeled solutions of 84 pmol/ml of Ethacure in 
water prepared the morning of the experiment. A 1.0 ml Hamilton #1001 
syringe and a curved ball-tipped 18-gauge x 3" feeding needle was used to 
gavage the rats.
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Twenty-four hours after dosing, rats were placed under isoflurane 
anesthesia then euthanized by exsanguination at which time the livers were 
harvested and weighed. Small pieces of liver tissue (about 100 mg) were 
excised, weighed and placed into labeled 6.5 ml polyethylene liquid scintillation 
counting vials for preparation.
DNA extraction
The extraction of nucleic acid from the selected tissue required lysis of 
the cellular membranes followed by the separation of the nucleic acid from the 
resulting cellular debris. The nucleic acids were then partitioned into the 
aqueous phase using phenol-chloroform-isoamyl alcohol. The remainder of the 
cellular debris, including the proteins, entered into the organic fraction or the 
interface phase.
Liver samples (about 1g) were weighed before DNA extraction. To 
disrupt the cellular membranes, 10 volumes of 3M guanidine isothiocyanate 
solution was added to each tissue. Using a Wheaton overhead stirrer and a 10 
ml Potter-Elevehjem grinder, the mixture was throughly homogenized 
(6.11-6.13). To partition the nucleic acids into the aqueous phase, 1 volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the homogenate. 
After through mixing (45 seconds) with a Vortex-2 Genie, the phases were 
separated by centrifuging the mixture at 2800 rpm for 10 minutes in a Sorvall 
GLC-2B General Lab Centrifuge. The lower organic phase was removed and 
transferred to a 50 ml Coming centrifuge tube. The entire process was
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repeated twice more after which the top aqueous phase was transferred to a 
50 ml centrifuge tube.
Nucleic acid precipitation
One-tenth volume of 5M sodium chloride and 2 (original) volumes of 
100% ethanol was added to the aqueous layer producing a stringy precipitate 
of DNA. The 5M sodium chloride was used to reduced the amount of RNA in 
the precipitated nucleic acid (6.14). Each tube was centrifuged for 10 minutes 
at 2800 rpm and the supernatant poured off. The DNA was washed 2 times in 
ethanol, dried, then resuspended in 4 ml of TE buffer by shaking overnight in a 
60°C water bath.
Twenty units (0.2ml) of RNase A was added to each sample then 
incubated for 60 min at 37°C to remove any residual RNA (6.11). The samples 
were again extracted 3 times with 1 volume of phenol.chloroform: isoamyl 
alcohol (25:24:1). DNA from the resulting aqueous layer was precipitated with 
2 volumes of ethanol. The samples were centrifuged and the supernatant 
removed. The DNA was washed 2 times in ethanol, dried under nitrogen, then 
resuspended in 2 ml of TE buffer by shaking overnight in a 608C water bath. 
DNA concentration was determined by absorbance using a Hitachi U-2000 
spectrophotometer. 200 pi of each sample was placed into a 6.5 ml liquid 
scintillation vial containing Hionic-Fluor™ scintillation cocktail then counted on 
a Packard 1900TR Liquid Scintillation Analyzer.
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Protein precipitation
Precipitation of cellular protein was accomplished by adding 1.5 
volumes of acetone to the combined organic phases. After centrifuging the 
tubes for 10 minutes at 2800 rpm, the supernatants were poured off. The 
protein pellets were washed 2 times in acetone, dried in a vacuum desiccator, 
weighed, then processed for liquid scintillation counting.
Tissue preparation for liquid scintillation counting
Because radiolabeled biological samples could not be analyzed 
directly using a liquid scintillation counter, sample preparation methods were 
vitally important for obtaining accurate counts. A homogenous mixture of the 
biological sample and the liquid scintillation cocktail was needed. Some 
tissues such as urine could be added directly to the cocktail, while others 
required extensive preparation (6.15).
Blood
To a 50 pi sample of blood was added 1 ml of a 50:50 mixture of 
isopropanol:Soluene-350. The mixture was incubated for 30 minutes at 50°C. 
To decolorize the sample, 500 pi of 30% hydrogen peroxide was added 
dropwise while swirling. The mixture was incubated for 60 minutes at 50°C. 
Finally 4.5 ml of Hionic-Fluor™ scintillation cocktail was added for counting. 
Urine
200 pi of urine was added directly to 5.5 ml of Hionic-Fluor™ Liquid 
scintillation cocktail.
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Methanol cage wash sample
200 pi of each methanol wash sample was added to 5.5 ml of Hionic- 
Fluor™ Liquid scintillation cocktail.
Feces
100-200 ml of the mixed fecal solution was added to 1 ml of Soluene- 
350, swirled till mixed, then incubated for 2 hours at 50°C. Isopropyl alcohol 
(0.5 ml) was added, the mixture vortexed, then again incubated for 2 hours at 
50°C. Hydrogen peroxide (300 pi of 30% solution), if needed, was added 
dropwise while swirling and the sample incubated for 60 minutes at 50°C. Four 
ml of Hionic-Fluor™ scintillation cocktail was then added for counting.
Tissue
One ml of Soluene-350 was added to all sample tissues. Each sample 
was incubated a minimum of 4 hours at 50°C. After digestion, 4.5 ml Hionic- 
Fluor™ scintillation cocktail was added for counting. Hydrogen peroxide (200 
pi of 30% solution), if needed, was added dropwise while swirling. The 
samples were then incubated for 60 minutes at 50°C.
Samples were dark adapted overnight then counted in a Packard Tri- 
Carb 1900 TR Liquid Scintillation Analyzer. Normalization and quench curves 
were conducted before samples were run. Each sample was counted for 10 
minutes.
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Results
The stability of tritiated Ethacure
There appeared to be no significant differences in peak areas, 
shapes, and retention times between the 3 chromatographs. There was no 
obvious breakdown or exchange of label of the tritiated Ethacure occurring 
under acidic, neutral, or basic conditions. This suggested that the tritiated 
material would be stable under physiological conditions as well as under DNA 
extraction protocols used in the isolation procedures.
Separation and purification of tritiated Ethacure
Final analysis depicted purity levels of 95% for the [3H]-2,6-DETDA 
isomer. The identity of the 2,6-DETDA isomer was confirmed by the graphic 
relationship of the UV chromatograph relative to the LS spectrometry (Figure 
6.2). The purity level was considered adequate for the ensuing distribution and 
excretion studies.
Distribution and excretion studies for 2.6-DETDA
Calculated values for the weights of the skin, stomach, small intestine, 
caecum and colon used in determining the percent of administered dose in the 
distribution and excretion studies are listed in Chapter 5 (Table 5.1). The 
average weight for the pancreas was determined to be 3.569 ± 0.438 mg/100 g 
of body weight. Percent of body weight values used for blood (6.16), fat (6.17), 
and muscle (6.18) were 7%, 7.6% and 50% respectively.
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Figure 6.2 Graphical confirmation of tritiated 2,6-DETDA (bottom) after 
separation of tritiated Ethacure’s (top) 2,4- and 2,6-DETDA 
isomers.
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Results of the tritiated 2,6-DETDA tissue distribution study presented 
as (jmol of 2,6-DETDA per gram of tissue were depicted in Table 6.1 and 
Figures 6.3, 6.4 and 6.5. The data revealed the highest levels of label 
occurred in the gastrointestinal system during the first 8 hours reflecting both 
absorbed and possibly unabsorbed 2,6-DETDA. Relatively high levels of 
radioactivity was present in the bladder for the first 8 hours presumably 
reflecting both distributed and excreted compound. The metabolic and 
excretory organs, liver and kidney, contained moderate levels of label in 
relatively equal amounts. Label in the thyroid and pancreas was much higher 
than expected, for non-excretory organs, with thyroid levels exceeding even 
that of liver tissue. The concentration of radioactivity in all tissues except the 
stomach, caecum, colon, thyroid, pancreas and spleen was greatest at 4 hours. 
With the exception of the stomach, thyroid, pancreas and spleen, tissues 
exhibited a classic biphasic model of distribution and excretion with the onset 
of the slow phase occurring after the 4 hour time point. As can be gleaned 
from the 24 and 48 hour time frames, DETDA was rapidly cleared from all 
tissues. Day 6 residual levels of label (Figure 6.5) was uniform in all tissues 
except the thyroid gland which was almost 4 fold higher than any other tissue.
The 2,6-DETDA tissue distribution results presented as percent of 
administered dose were depicted in Table 6.2 and Figures 6.6,6.7 and 6.8. 
Radioactivity in the gastrointestinal system followed the expected profile. 
Stomach values were highest in the first hour with declining amounts over time.

















Table 6.1 Summation of the tritiated 2,6-DETDA distribution study in the male Sprague Dawley rat. Values
represent pmol of 2,6-DETDA/g of tissue (n=4, n=3 for 1 hr. lung) and the standard deviation (S.D.) for 
each tissue and time point.
Tissue 1 hr 4 hr 8 hr 24  hr 48  hr
pm ol/gm S .D . pm ol/gm S .D . pm ol/gm S .D . pm ol/gm S .D . pm ol/gm S .D .
Stom ach 0 .3 7 5 7 0 .1741 0 .3 4 2 0 0 .1 4 3 6 0 .1 1 9 4 0 .0661 0 .0 0 62 0 .0 0 2 0 0 .0 0 2 9 0 .0 0 0 2
D uodenum 0 .1 8 5 4 0 .0 8 3 4 0 .2 1 1 5 0 .1 1 8 6 0 .0 6 9 0 0 .0 4 7 2 0 .0 0 4 7 0 .0 0 0 4 0 .0 0 2 9 0 .0 0 0 2
C aecum 0 .0 2 6 2 0 .0 1 4 0 0 .0 6 3 8 0 .0 4 7 3 0 .1 4 9 9 0 .0 6 4 2 0.0201 0 .0 1 0 5 0 .0 0 3 2 0 .0 0 1 5
B ladder 0 .0 6 0 9 0 .0 3 4 0 0 .0 6 7 8 0 .0 1 9 9 0 .0 6 2 2 0 .0 301 0 .0 1 1 5 0 .0 0 4 3 0 .0 0 3 8 0 .0 0 1 7
Colon 0 .0 2 6 8 0 .0 0 3 5 0 .0 3 0 0 0 .0 0 8 9 0 .0 4 3 3 0 .0 3 7 8 0.0091 0 .0 0 2 2 0 .0 0 2 7 0 .0 0 0 2
Thyroid 0 .1 6 7 8 0 .2 5 4 4 0 .0 8 5 7 0 .0 8 1 3 0 .0 5 5 3 0 .0 5 6 2 0 .0 1 3 4 0 .0 0 3 6 0 .0 1 04 0 .0 0 2 6
P ancreas 0 .0 9 2 4 0 .0 5 0 9 0 .0331 0 .0 151 0 .0 4 3 5 0 .0 5 8 0 0 .0 0 4 3 0 .0 0 0 2 0 .0 0 2 7 0 .0 0 0 2
Liver 0 .0 2 7 4 0 .0 1 2 0 0 .0 3 6 4 0 .0 1 5 6 0 .0 2 4 7 0 .0 0 2 5 0 .0 0 67 0 .0 0 0 5 0 .0 0 4 7 0 .0 0 0 6
K idney 0 .0 2 9 5 0 .0 1 5 7 0 .0 3 5 3 0 .0 0 5 8 0 .0 2 7 2 0 .0 0 5 9 0 .0 0 6 7 0 .0 0 0 8 0 .0 0 4 8 0 .0 0 0 4
Fat 0 .0 2 3 4 0 .0 1 6 4 0 .0 2 6 5 0 .0 0 6 6 0 .0 1 0 5 0 .0 0 3 2 0 .0 0 2 2 0 .0 0 1 3 0 .0011 0 .0 0 0 7
Lung 0 .0 1 5 7 0 .0101 0.0241 0 .0 1 0 8 0 .0121 0 .0 0 1 6 0 .0 0 4 6 0 .0 0 0 3 0 .0 0 3 0 0 .0 0 0 4
H eart 0 .0 1 0 2 0 .0 0 6 6 0 .0101 0 .0 0 1 0 0.0071 0 .0 0 0 6 0 .0 0 3 5 0 .0 0 0 5 0 .0 0 2 6 0 .0 0 0 4
Spleen 0 .0 5 6 2 0 .0 5 2 8 0.0211 0 .0 1 3 4 0 .0 1 6 0 0 .0 1 3 2 0 .0 0 3 9 0 .0 0 0 2 0 .0 02 8 0 .0 0 0 2
Blood 0 .0071 0 .0 0 3 7 0 .0 1 1 7 0 .0 0 1 2 0 .0 1 06 0 .0 0 0 7 0 .0 06 4 0 .0 0 0 6 0 .0 0 4 0 0 .0 0 0 3
Skin 0 .0 1 1 3 0 .0061 0 .0 1 6 6 0 .0 0 7 2 0 .0 0 9 9 0 .0 0 2 3 0.0051 0 .0 0 0 7 0 .0 0 3 2 0 .0 0 0 4
M uscle 0 .0 0 5 7 0 .0 0 2 9 0.0071 0 .0 0 1 4 0 .0 0 5 8 0 .0 0 0 7 0 .0 0 3 5 0 .0 0 0 4 0 .0 0 2 6 0.0001
Thym us 0 .0 0 5 9 0 .0 0 2 8 0 .0 0 8 0 0 .0011 0 .0 0 7 0 0 .0 0 0 9 0 .0 0 3 6 0 .0 0 0 6 0 .0 0 2 7 0.0001
Brain 0 .0 1 3 4 0 .0 091 0 .0 18 7 0 .0 1 2 2 0.0091 0 .0 0 1 8 0.0041 0 .0 0 0 3 0 .0 0 3 2 0.0001
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Graphical representation of the tritiated 2,6-DETDA study in the adult male Sprague Dawley rat. 
Values represent pmol of 2,6-DETDA/g of tissue (n=4, n=3 for 1 hr. lung). Higher and lower range of 



































Figure 6.4 Graphical representation of the tritiated 2,6-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent pmol of 2,6-DETDA/g of tissue (n=4, n=3 for 1 hr. lung). Higher and 


















































Figure 6.5 Results of the tritiated 2,6-DETDA tissue distribution study in the adult male Sprague Dawley rat. 

















Table 6.2 Summation of the tritiated 2,6-DETDA distribution study in the male Sprague Dawley rat. Values
represent the percent of administered dose (n=4, n=3 for 1 hr. lung) and the standard deviation (S.D.) 
for each tissue and time point.
Tissues 1 hr 4 hr 8 hr 24  hr 48  hr
% Dose S .D . % Dose S.D . % Dose S.D . % Dose S.D . % Dose S .D .
Feces 12 .213 12.271 8.808 1.791 14 .168 1.292 2 4 .3 3 9 1.239 2 9 .7 0 6 0 .6 38
Urine 2 .1 88 1.774 15.417 2 .3 0 6 33.511 6 .5 0 0 4 4 .4 06 5.102 4 4 .0 3 4 2 .5 96
Muscle 8.271 4 .2 2 5 10.228 2 .0 5 4 8.353 1.006 5.071 0 .632 3.841 0.191
Skin 4 .9 47 2 .6 6 9 7.231 3 .1 56 4 .3 0 7 0 .9 86 2 .2 0 9 0 .3 20 1.375 0 .1 74
Blood 1.443 0.747 2.371 0 .2 44 2 .1 6 0 0 .1 3 8 1.306 0.123 0 .8 09 0 .070
Fat 5 .1 64 3.617 5.851 1.465 2 .317 0 .7 0 5 0 .4 8 5 0 .2 87 0 .2 4 2 0 .1 47
Liver 3.151 1.195 4 .0 92 2 .0 98 2 .6 4 2 0 .3 73 0 .9 40 0 .095 0 .6 30 0 .0 99
C aecum 0.3 46 0 .185 0.842 0 .6 25 1.979 0 .8 47 0 .265 0.138 0 .0 42 0 .020
Stom ach 6 .3 3 3 2 .9 35 5.764 2 .4 2 0 2 .0 1 3 1.114 0.105 0.034 0 .0 4 8 0 .0 04
Sm . Intest. 8 .0 90 3.638 9.227 5.174 3 .0 12 2 .0 5 9 0 .2 0 5 0 .0 15 0 .1 27 0 .0 1 0
Kidney 0.721 0.415 0.871 0 .1 29 0.620 0 .1 45 0.161 0 .0 22 0 .1 1 9 0.012
Thym us 0.0 45 0.021 0 .0 57 0 .0 0 7 0.042 0 .0 0 7 0 .0 19 0 .0 03 0.013 0.001
Lung 0.201 0.132 0 .340 0.134 0 .145 0 .0 3 6 0 .0 6 2 0 .0 14 0.041 0.011
H eart 0 .114 0.072 0.111 0 .0 14 0 .0 79 0 .0 0 3 0 .0 3 9 0.008 0 .0 26 0 .0 0 2
Spleen 0 .4 5 9 0.471 0 .1 28 0 .0 75 0 .0 93 0 .0 8 9 0.021 0 .0 0 2 0 .0 18 0 .003
Pancreas 0 .9 57 0 .5 27 0 .3 43 0 .1 5 6 0.450 0 .6 0 0 0 .0 45 0 .0 02 0 .0 28 0 .0 03
Bladder 0 .0 54 0.027 0.061 0 .0 2 0 0 .0 60 0 .0 4 0 0 .0 0 9 0 .0 03 0 .0 04 0 .0 02
Thyroid 0 .0 4 0 0.058 0 .0 16 0 .0 19 0.011 0.011 0 .0 0 3 0.000 0.002 0 .0 00
Brain 0 .2 5 3 0 .2 16 0.363 0 .2 17 0.187 0.031 0 .0 85 0 .0 15 0 .0 6 0 0 .0 03
Colon 0.315 0.214 0.353 0.105 0.508 0 .4 45 0 .1 06 0 .0 2 6 0 .0 32 0.002















Graphical representation of the tritiated 2,6-DETDA distribution study in the adult male Sprague 
Dawley rat. Values represent the percent of administered dose (n=4, n=3 for 1 hr. lung). Higher and 



























Figure 6.7 Graphical representation of the tritiated 2,6-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent the percent of administered dose (n=4, n=3 for 1 hr. lung). Higher and 
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Figure 6.8 Results of the tritiated 2,6-DETDA tissue distribution study in the adult male Sprague Dawley rat.




The small intestine peaked at the 4-hour point then rapidly declined. Caecum 
and colon both peaked at the 8-hour time point reflecting label being absorbed 
as compound progressed down the intestinal tract. Large body mass tissues 
(muscle, skin and fat), as expected, contained relatively large amounts of label. 
Fecal and urinary values represented an accumulation of excreted label at 
each time point. By 8 hours, urinary excretion became the primary route of 
elimination. By 24 hours, over 68% of the labeled compound had been 
excreted and by 6 days (Table 6.3) only 3.4% of label remained in the tissues. 
As expected, at day 6, the majority of label was present in the large body mass 
organs. Elevated levels in liver and kidney were probably denotative of 
metabolism and excretion functions. Blood levels remained relatively constant 
up to 48 hours reflecting label diffusing out of body tissues prior to excretion.
Figure 6.9 plots the accumulated excretion profile for the 2,6-DETDA 
isomer over 6 days. Almost 72% of the administered dose of tritiated 2,6- 
DETDA was excreted in the first 24 hours. The urinary system proved to be the 
major route of elimination for the compound excreting 50% of the dose within 
24 hours compared to 22% in the feces (Table 6.4). Label excretion was 
nearly complete by 48 hours with only slight amounts excreted over the next 4 
days. Almost twice as much label was eliminated through the urinary system 
compared to fecal excretion. Recovery of label ranged between 85% and 96% 
with an average of 94%.
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Table 6.3 Summary for day 6 of the tritiated 2,6-DETDA distribution study in 
the adult male Sprague Dawley rat. Values represent either the 
percent of administered dose or the pmol of 2,6-DETDA in the 
tissue (n=5).
Tissue % of dose Stnd. Dev. Tissue pmol/g Stnd. Dev.
Blood 0.340 0.053 Blood 0.0017 0.0003
Fat 0.062 0.018 Fat 0.0003 0.0001
Skin 0.852 0.106 Skin 0.0020 0.0002
Muscle 1.649 0.523 Muscle 0.0011 0.0004
Thymus 0.006 0.002 Thymus 0.0013 0.0002
Lung 0.020 0.005 Lung 0.0014 0.0002
Heart 0.011 0.002 Heart 0.0011 0.0002
Spleen 0.011 0.002 Spleen 0.0017 0.0002
Pancreas 0.012 0.003 Pancreas 0.0012 0.0003
Bladder 0.001 0.000 Bladder 0.0013 0.0003
Kidney 0.057 0.012 Kidney 0.0024 0.0005
Liver 0.275 0.028 Liver 0.0020 0.0002
Stomach 0.013 0.004 Stomach 0.0008 0.0002
Sm. Intest. 0.047 0.017 Duodenum 0.0011 0.0004
Caecum 0.013 0.004 Caecum 0.0010 0.0003
Colon 0.012 0.001 Colon 0.0011 0.0001
Thyroid 0.002 0.000 Thyroid 0.0156 0.0042
Brain 0.029 0.009 Brain 0.0015 0.0004
Total 3.412
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Figure 6.9 Urinary and fecal excretion profile of tritiated 2,6-DETDA over 6 
days. Data points represent the percentage of administered dose 
of 2,6-DETDA (n=5) accumulated over time from urine and fecal 
samples.
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Table 6.4 Summary of the 6 day tritiated 2,6-DETDA excretion study in the 
adult male Sprague Dawley rat. Values represent the percent of 
administered dose of tritiated 2,6-DETDA excreted at each time 
point (n=5).
Urines Feces
Day % of Dose Stnd.Dev. % of Dose Stnd.Dev.
1 49.98 7.84 21.68 4.39
2 4.56 3.32 7.87 4.90
3 1.44 0.27 1.02 0.22
4 1.00 0.28 0.68 0.24
5 0.71 0.18 0.48 0.20
6 0.53 0.14 0.84 0.44
Total 58.23 32.56
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Covalent binding studies
Binding study results of DETDA to DNA and protein is compiled in 
Table 6.5. Relative to Ethacure (80.8% 2,4-DETDA, 19.2% 2,6-DETDA), 5 
pmol of 2,6-DETDA/|jmol of DNA was found covalently bound. For the 2,6- 
DETDA isomer, 38% of the label was bound to the protein fraction equating to 
31 nmol 2,6-DETDA per gram of liver protein. The 260/280 ratio for the 
samples was 1.9.
Discussion
It is obvious from the data that the 2,6-DETDA isomer was rapidly 
absorbed from the gastrointestinal system. The distribution profile suggests 
that the compound has both water and fat soluble properties. The relatively 
greater accumulation of label in the thyroid, pancreas, and liver tissue may 
reflect the possible toxic qualities encountered in the long term feeding study. 
The data also suggest that 2,6-DETDA was distributed to most, if not every 
tissue in the body. The excretion profile showed that the primary route of 
excretion for 2,6-DETDA was the urinary system with almost twice as much 
label being eliminated compared to fecal excretion. The majority of urinary and 
fecal elimination occurred during the first 24 hours of the study.
Cellular DNA is often the target of covalent addition. These DNA 
adducts can have serious ramifications because of the critical role that DNA 
plays in cellular functions and cell reproduction. The importance of persistent 
in vivo DNA-arylamine adducts can be seen in the devastating consequences 
of gene mutations and cancer (6.19-6.24).
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Table 6.5 Tritiated 2,6-DETDA covalent binding on rat liver DNA and 
protein.
Isomer pmol DETDA nmol DETDA % of label on 
per pmol DNA per g Protein protein
2,6-DETDA 5 31 38
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Furlong et al. conducted TDA in vitro binding studies on rat liver 
hepatocytes. Incubating hepatocytes with 100 pmol of 2,6-TDA for 24 hours 
resulted in approximately 51 pmol 2,6-TDA/pmol DNA (6.25). This compares to 
5 pmol 2,6-DETDA/(jmol DNA carried out at a concentration of about 30 pmol. 
Furlong’s study showed that 2,4-TDA binding to rat liver DNA was 
concentration dependent below 100 pmol. Binding at 30 pmol concentrations 
resulted in about 50% less binding. There were no concentration dependent 
study results reported for the 2,6-TDA isomer. Although this was an in vitro 
study, results suggest that compared to TDA, DETDA is less likely to be 
involved in covalent binding to DNA. DETDA does however, seem to have 
considerable affinity for protein. Consequences of DETDA protein binding, if 
any are unknown at the present time.
Ethacure has been used successfully for over 20 years as a 
replacement chemical for known toxic compounds. The results of this study 
showed that 2,6-DETDA, a significant component of Ethacure, cleared quickly 
after an orally administered dose such that by 24 hours, less than one-third of 
the label remained in the tissues. With the exception of the 2,6-isomer in the 
thyroid gland, there appeared to be very little accumulation in tissue 6 days 
after exposure.
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CHAPTER 7 
SUMMARY AND CONCLUSIONS
The pK, values of the 2 amine groups (2.5 and 4.6) and the absorption 
characteristics determined for Ethacure (2790 mM'1 cm'1) were used in HPLC 
method development providing information needed for HPLC and 
spectrophotometry analysis. A reverse-phase HPLC method using a Whatman 
C18 Partisphere 5pm 4.6x250mm column, 100 mmol dibutylamine phosphate 
buffer (pH 3.0) and a flow rate of 0.5 ml/min achieved the best separation and 
resolution for both the 2,4- and 2,6-DETDA isomers. The HPLC-UV and 
electrochemical detection methods developed allowed for detection of the 2,4- 
and 2,6-DETDA isomers but not the anticipated acetylated metabolites. Gas 
chromatography, using either FID or NP detection, proved to be the method of 
choice for analysis providing excellent detection and quantitation of 2,4- and
2.6-DETDA as well as the mono- and di-acetylated metabolites.
The Varian Bond Elut LRC® C-8 bonded phase extraction columns 
provided a clean, efficient and reproducible method for extracting 2,4- and 2,6- 
DETDA as well as monoacetylated and diacetylated metabolites from urine.
The use of bonded phase extraction columns would allow for large scale 
screening of urine samples using automation techniques.
The synthesis of both monoacetylated and diacetylated DETDA 
metabolites were successful and reproducible. The structures of the 2,4- and
2.6-DETDA isomers and the 2,4- and 2,6-monoacetylated DETDA metabolites
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
250
were confirmed by both NMR and GC/MS analysis. The 2,4- and 2,6- 
diacetylated metabolites were confirmed by GC/MS spectra.
Because acetylation is considered to be a major biotransformation 
reaction for aromatic amines compounds in most species, both monoacetylated 
and/or diacetylated DETDA metabolites were also expected to be produced in 
the biotransformation profile of DETDA. The total lack of acetylated 
metabolites in the urine of the Ethacure treated male Sprague-Dawley rats was 
unexpected. After oral administration of Ethacure, approximately 4% of the 
mixture in the form of 2,4- and 2,6-DETDA was recovered in the urine. The 
only structural difference between TDA and DETDA are the benzylic ethyl 
groups at the 3 and 5 position on the ring. Since TDA has been shown to 
undergo acetylation in the rat, one could conclude that the ethyl groups may be 
responsible for the lack of or decrease in acetylation of DETDA. The ethyl 
groups may possibly allow other biotransformation reactions to predominate in 
the metabolism of DETDA.
Distribution profiles of labeled DETDA indicates the compound has 
both water and fat soluble properties. There appears to be little difference in 
the pattern of distribution between the 2,4-DETDA and the 2,6-DETDA isomers 
with the possible exception of the thyroid gland. The thyroid and pancreatic 
tissue accumulation of label may reflect the possible toxic qualities 
encountered in the long term Ethacure feeding study.
Differences in the excretion profile between the 2,4- and 2,6-DETDA 
isomers seem to signify variations in the biotransformation of each compound.
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The greater urinary excretion of 2,6-DETDA (58%) compared to 2,4-DETDA 
(44%) suggests a more excretable, water soluble metabolite may have been 
produced. This could be accomplished by greater phase II conjugation 
reactions (glucuronidation, sulfation, glutathione) on the 2,6-isomer compared 
to the 2,4-isomer (7.1). Restricted enzymatic access due to the flanking of the 
4-position amino group by benzylic ethyl groups on the 2,4-isomer could effect 
these results.
Ethacure has been used successfully for over 20 years as a 
replacement chemical for known toxic compounds. The results of this study 
shows that DETDA clears quickly after an orally administered dose, such that 
by 24 hours, less than one-third of the label remains in the tissues. With the 
exception of higher levels of DETDA in the thyroid gland, there appears to be 
very little accumulation in tissue 6 days after exposure.
The data from this study should add confidence to the results from 
early short and long term toxicity studies which indicated that DETDA was a 
safer alternative to some of the products that it could replace. Future studies 
delineating biotransformation products and the effects of DETDA on the thyroid 
gland are recommended.
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APPENDIX A: BUFFERS AND SOLUTIONS
Dibutylamine: To distill, 200 ml of dibutylamine was mixed with 20 g of 
potassium hydroxide and stirred for 45 minutes. The dibutylamine was filtered 
through a ceramic filter and 10 g of barium oxide added. The solution was then 
distilled (dibutylamine boiling point is 159°C), placed in an amber bottle, and 
stored under argon.
EDTA 0.5M: Mix 18.61 grams of EDTA (disodium salt, dihydrate, mw 372.24) 
in 60 ml of HPLC-grade water. Adjust pH to 8.0 using concentrated NaOH. 
Pour into a 100 ml volumetric flask and fill to 100 ml with HPLC-grade water.. 
Guanidine lsothiocyanate-3M: Place 35.45 grams of guanidine isothiocyanate 
(FW118.16) into a small beaker. Add 60 ml of HPLC-grade water and stir until 
dissolved. Pour into a 100 ml volumetric flask and fill to 100 ml with HPLC- 
grade water.
Potassium Phosphate Buffer, pH 7.0 (1 Liter): Weigh out 13.61 g of KH2P04 
(MW 136.09). Place into a 1 liter volumetric flask. Dissolve the KH2P04 in 875 
ml of 18 MO -cm water. Raise the pH to 7.0 using 1M potassium hydroxide 
while continuously stirring. Add HPLC-grade water for a total volume of 1 liter. 
Store at 5°C and discard after 30 days.
RNase A: To prepare 20 units/ml, mix 1.6 mg of RNase A with 1.44 ml of 
HPLC-grade water. Add 200 pi to each DNA sample.
TE buffer: Place 5 ml of 2M Tris and 2 ml of 0.5M EDTA into a 1 liter volumetric 
flask. Fill flask to 1 liter with HPLC-grade water.
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Tris 2M: Add 17.76 grams of Trizma® HCL and 10.6 grams of Tris base to 60 
ml of HPLC-grade water in a 100 ml volumetric flask. Adjust pH to 8.0 using 
concentrated HCL. Fill flask to 100 ml with HPLC-grade water.
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Figure B1 Representative sample of HPLC-UV chromatogram. Conditions 
included a C18 Partisphere 5 pm 4.6x250 mm reverse phase 
column, Shimadzu LC-600 pump, Shimadzu SPD-10AV UV 
detector, and a 16.5% acetonitrile, 100 mM dibutylamine 
phosphate buffer (pH 3.0). Approximate retention times: 2,4- 
DETDA, 4.3; 2,6-DETDA, 5.0; 2,4-monoacetylated DETDA, 5.6-
5.8, 2,6-monoacetylated DETDA, 7.6; 2,4-diacetylated DETDA,
11.2; 2,6-diacetylated DETDA, 19.2. Note excessive peak tailing 
on the 2,4-monoacetylated metabolite.
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APPENDIX C: GC CHROMATOGRAMS
j- '
Figure C1 Representative chromatogram from Chapter 4 metabolism
experiment. Chromatogram is of normal rat urine spiked with 2,4- 
DETDA (5.96 min), 2,6-DETDA (6.28), 2,4-monoacetylated 
DETDA (9.52, 9.67), 2,6-monoacetyiated (10.12) 2,4-diacetylated 
DETDA (13.78), 2,6-diacetylated DETDA (14.35), and internal 
standard diazepam (16.43). Compare to Figure C2 (Control 
urine) and Figure C3 (8 hour urine sample from an Ethacure 
treated rat.
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Figure C2 Representative chromatogram from Chapter 4 metabolism
experiment. Chromatogram is a normal rat urine control sample. 
Note that there are no interfering peaks present when compared 
to a spiked urine sample (Figure C1).
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Figure C3 Representative chromatogram from Chapter 4 metabolism
experiment. Chromatogram is from a urine sample collected at an 
8 hour time point in a rat treated with Ethacure. Note that only 
2,4-DETDA (5.97 min.), 2,6-DETDA (6.28) and diazepam (16.43) 
were detected in the sample. None of the expected acetylated 
metabolites were observed at the limit of quantitation.
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